Skip to main content
Erschienen in: Clinical Drug Investigation 7/2017

01.07.2017 | Review Article

Acid-Suppressive Therapy and Risk of Infections: Pros and Cons

verfasst von: Leon Fisher, Alexander Fisher

Erschienen in: Clinical Drug Investigation | Ausgabe 7/2017

Einloggen, um Zugang zu erhalten

Abstract

This narrative review summarises the benefits, risks and appropriate use of acid-suppressing drugs (ASDs), proton pump inhibitors and histamine-2 receptor antagonists, advocating a rationale balanced and individualised approach aimed to minimise any serious adverse consequences. It focuses on current controversies on the potential of ASDs to contribute to infections—bacterial, parasitic, fungal, protozoan and viral, particularly in the elderly, comprehensively and critically discusses the growing body of observational literature linking ASD use to a variety of enteric, respiratory, skin and systemic infectious diseases and complications (Clostridium difficile diarrhoea, pneumonia, spontaneous bacterial peritonitis, septicaemia and other). The proposed pathogenic mechanisms of ASD-associated infections (related and unrelated to the inhibition of gastric acid secretion, alterations of the gut microbiome and immunity), and drug-drug interactions are also described. Both probiotics use and correcting vitamin D status may have a significant protective effect decreasing the incidence of ASD-associated infections, especially in the elderly. Despite the limitations of the existing data, the importance of individualised therapy and caution in long-term ASD use considering the balance of benefits and potential harms, factors that may predispose to and actions that may prevent/attenuate adverse effects is evident. A six-step practical algorithm for ASD therapy based on the best available evidence is presented.
Literatur
1.
Zurück zum Zitat Fisher L, Fisher A, Pavli P, Davis M. Perioperative acute upper gastrointestinal haemorrhage in older patients with hip fracture: incidence, risk factors and prevention. Aliment Pharmacol Ther. 2007;25(3):297–308.PubMedCrossRef Fisher L, Fisher A, Pavli P, Davis M. Perioperative acute upper gastrointestinal haemorrhage in older patients with hip fracture: incidence, risk factors and prevention. Aliment Pharmacol Ther. 2007;25(3):297–308.PubMedCrossRef
2.
Zurück zum Zitat Leontiadis GI, Sreedharan A, Dorward S, Barton P, Delaney B, Howden CW, et al. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol Assess. 2007;11(51):iii–iv, 1–164. Leontiadis GI, Sreedharan A, Dorward S, Barton P, Delaney B, Howden CW, et al. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol Assess. 2007;11(51):iii–iv, 1–164.
4.
Zurück zum Zitat Alhazzani W, Alenezi F, Jaeschke RZ, Moayyedi P, Cook DJ. Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis. Crit Care Med. 2013;41(3):693–705.PubMedCrossRef Alhazzani W, Alenezi F, Jaeschke RZ, Moayyedi P, Cook DJ. Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis. Crit Care Med. 2013;41(3):693–705.PubMedCrossRef
5.
Zurück zum Zitat Heidelbaugh JJ. Proton pump inhibitors and risk of vitamin and mineral deficiency: evidence and clinical implications. Ther Adv Drug Saf. 2013;4(3):125–33.PubMedPubMedCentral Heidelbaugh JJ. Proton pump inhibitors and risk of vitamin and mineral deficiency: evidence and clinical implications. Ther Adv Drug Saf. 2013;4(3):125–33.PubMedPubMedCentral
6.
Zurück zum Zitat Reimer C. Safety of long-term PPI therapy. Best Pract Res Clin Gastroenterol. 2013;27(3):443–54.PubMedCrossRef Reimer C. Safety of long-term PPI therapy. Best Pract Res Clin Gastroenterol. 2013;27(3):443–54.PubMedCrossRef
7.
Zurück zum Zitat Medlock S, Eslami S, Askari M, Taherzadeh Z, Opondo D, de Rooij SE, et al. Co-prescription of gastroprotective agents and their efficacy in elderly patients taking nonsteroidal anti-inflammatory drugs: a systematic review of observational studies. Clin Gastroenterol Hepatol. 2013;11(10):1259–69 e10. Medlock S, Eslami S, Askari M, Taherzadeh Z, Opondo D, de Rooij SE, et al. Co-prescription of gastroprotective agents and their efficacy in elderly patients taking nonsteroidal anti-inflammatory drugs: a systematic review of observational studies. Clin Gastroenterol Hepatol. 2013;11(10):1259–69 e10.
8.
Zurück zum Zitat Safavi M, Sabourian R, Foroumadi A. Treatment of Helicobacter pylori infection: current and future insights. World J Clin Cases. 2016;4(1):5–19.PubMedPubMedCentralCrossRef Safavi M, Sabourian R, Foroumadi A. Treatment of Helicobacter pylori infection: current and future insights. World J Clin Cases. 2016;4(1):5–19.PubMedPubMedCentralCrossRef
9.
Zurück zum Zitat Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst Rev. 2006;2:CD003840. Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst Rev. 2006;2:CD003840.
10.
Zurück zum Zitat Wallace JL. Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn’t the stomach digest itself? Physiol Rev. 2008;88(4):1547–65.PubMedCrossRef Wallace JL. Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn’t the stomach digest itself? Physiol Rev. 2008;88(4):1547–65.PubMedCrossRef
11.
Zurück zum Zitat Katz PO, Scheiman JM, Barkun AN. Review article: acid-related disease–what are the unmet clinical needs? Aliment Pharmacol Ther. 2006;23(Suppl 2):9–22.PubMedCrossRef Katz PO, Scheiman JM, Barkun AN. Review article: acid-related disease–what are the unmet clinical needs? Aliment Pharmacol Ther. 2006;23(Suppl 2):9–22.PubMedCrossRef
12.
Zurück zum Zitat Strand DS, Kim D, Peura DA. 25 years of proton pump inhibitors: a comprehensive review. Gut Liver. 2017;11(1):27–37.PubMedCrossRef Strand DS, Kim D, Peura DA. 25 years of proton pump inhibitors: a comprehensive review. Gut Liver. 2017;11(1):27–37.PubMedCrossRef
13.
Zurück zum Zitat Scarpignato C, Gatta L, Zullo A, Blandizzi C, Group S-A-F, Italian Society of Pharmacology tIAoHG, et al. Effective and safe proton pump inhibitor therapy in acid-related diseases—a position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14(1):179. Scarpignato C, Gatta L, Zullo A, Blandizzi C, Group S-A-F, Italian Society of Pharmacology tIAoHG, et al. Effective and safe proton pump inhibitor therapy in acid-related diseases—a position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14(1):179.
14.
Zurück zum Zitat Thomson AB, Sauve MD, Kassam N, Kamitakahara H. Safety of the long-term use of proton pump inhibitors. World J Gastroenterol. 2010;16(19):2323–30.PubMedPubMedCentralCrossRef Thomson AB, Sauve MD, Kassam N, Kamitakahara H. Safety of the long-term use of proton pump inhibitors. World J Gastroenterol. 2010;16(19):2323–30.PubMedPubMedCentralCrossRef
15.
Zurück zum Zitat Attwood SE, Ell C, Galmiche JP, Fiocca R, Hatlebakk JG, Hasselgren B, et al. Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies. Aliment Pharmacol Ther. 2015;41(11):1162–74.PubMedCrossRef Attwood SE, Ell C, Galmiche JP, Fiocca R, Hatlebakk JG, Hasselgren B, et al. Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies. Aliment Pharmacol Ther. 2015;41(11):1162–74.PubMedCrossRef
16.
Zurück zum Zitat Labenz J, Willmer C. Efficacy and safety of OTC omeprazole. MMW Fortschr Med. 2012;17(154 Suppl 4):110–4. Labenz J, Willmer C. Efficacy and safety of OTC omeprazole. MMW Fortschr Med. 2012;17(154 Suppl 4):110–4.
18.
Zurück zum Zitat Pea F. Antimicrobial treatment of bacterial infections in frail elderly patients: the difficult balance between efficacy, safety and tolerability. Curr Opin Pharmacol. 2015;24:18–22.PubMedCrossRef Pea F. Antimicrobial treatment of bacterial infections in frail elderly patients: the difficult balance between efficacy, safety and tolerability. Curr Opin Pharmacol. 2015;24:18–22.PubMedCrossRef
19.
Zurück zum Zitat Leibovici L, Paul M. Ethical dilemmas in antibiotic treatment: focus on the elderly. Clin Microbiol Infect. 2015;21(1):27–9.PubMedCrossRef Leibovici L, Paul M. Ethical dilemmas in antibiotic treatment: focus on the elderly. Clin Microbiol Infect. 2015;21(1):27–9.PubMedCrossRef
20.
Zurück zum Zitat Marcum ZA, Hanlon JT, Strotmeyer ES, Newman AB, Shorr RI, Simonsick EM, et al. Gastroprotective agent underuse in high-risk older daily nonsteroidal anti-inflammatory drug users over time. J Am Geriatr Soc. 2014;62(10):1923–7.PubMedPubMedCentralCrossRef Marcum ZA, Hanlon JT, Strotmeyer ES, Newman AB, Shorr RI, Simonsick EM, et al. Gastroprotective agent underuse in high-risk older daily nonsteroidal anti-inflammatory drug users over time. J Am Geriatr Soc. 2014;62(10):1923–7.PubMedPubMedCentralCrossRef
21.
Zurück zum Zitat Opondo D, Visscher S, Eslami S, Verheij RA, Korevaar JC, Abu-Hanna A. Quality of co-prescribing NSAID and gastroprotective medications for elders in the Netherlands and its association with the electronic medical record. PLoS One. 2015;10(6):e0129515.PubMedPubMedCentralCrossRef Opondo D, Visscher S, Eslami S, Verheij RA, Korevaar JC, Abu-Hanna A. Quality of co-prescribing NSAID and gastroprotective medications for elders in the Netherlands and its association with the electronic medical record. PLoS One. 2015;10(6):e0129515.PubMedPubMedCentralCrossRef
22.
Zurück zum Zitat Heidelbaugh JJ, Goldberg KL, Inadomi JM. Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk [corrected]. Am J Gastroenterol. 2009;104(Suppl 2):S27–32.PubMedCrossRef Heidelbaugh JJ, Goldberg KL, Inadomi JM. Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk [corrected]. Am J Gastroenterol. 2009;104(Suppl 2):S27–32.PubMedCrossRef
23.
Zurück zum Zitat Durand C, Willett KC, Desilets AR. Proton pump inhibitor use in hospitalized patients: is overutilization becoming a problem? Clin Med Insights Gastroenterol. 2012;5:65–76.PubMedPubMedCentral Durand C, Willett KC, Desilets AR. Proton pump inhibitor use in hospitalized patients: is overutilization becoming a problem? Clin Med Insights Gastroenterol. 2012;5:65–76.PubMedPubMedCentral
24.
Zurück zum Zitat Vakil N. Prescribing proton pump inhibitors: is it time to pause and rethink? Drugs. 2012;72(4):437–45.PubMedCrossRef Vakil N. Prescribing proton pump inhibitors: is it time to pause and rethink? Drugs. 2012;72(4):437–45.PubMedCrossRef
25.
Zurück zum Zitat Kelly OB, Dillane C, Patchett SE, Harewood GC, Murray FE. The inappropriate prescription of oral proton pump inhibitors in the hospital setting: a prospective cross-sectional study. Dig Dis Sci. 2015;60(8):2280–6.PubMedCrossRef Kelly OB, Dillane C, Patchett SE, Harewood GC, Murray FE. The inappropriate prescription of oral proton pump inhibitors in the hospital setting: a prospective cross-sectional study. Dig Dis Sci. 2015;60(8):2280–6.PubMedCrossRef
26.
Zurück zum Zitat Delcher A, Hily S, Boureau AS, Chapelet G, Berrut G, de Decker L. Multimorbidities and overprescription of proton pump inhibitors in older patients. PLoS One. 2015;10(11):e0141779.PubMedPubMedCentralCrossRef Delcher A, Hily S, Boureau AS, Chapelet G, Berrut G, de Decker L. Multimorbidities and overprescription of proton pump inhibitors in older patients. PLoS One. 2015;10(11):e0141779.PubMedPubMedCentralCrossRef
27.
Zurück zum Zitat Heidelbaugh JJ, Metz DC, Yang YX. Proton pump inhibitors: are they overutilised in clinical practice and do they pose significant risk? Int J Clin Pract. 2012;66(6):582–91.PubMedCrossRef Heidelbaugh JJ, Metz DC, Yang YX. Proton pump inhibitors: are they overutilised in clinical practice and do they pose significant risk? Int J Clin Pract. 2012;66(6):582–91.PubMedCrossRef
28.
Zurück zum Zitat Buckley MS, Park AS, Anderson CS, Barletta JF, Bikin DS, Gerkin RD, et al. Impact of a clinical pharmacist stress ulcer prophylaxis management program on inappropriate use in hospitalized patients. Am J Med. 2015;128(8):905–13.PubMedCrossRef Buckley MS, Park AS, Anderson CS, Barletta JF, Bikin DS, Gerkin RD, et al. Impact of a clinical pharmacist stress ulcer prophylaxis management program on inappropriate use in hospitalized patients. Am J Med. 2015;128(8):905–13.PubMedCrossRef
30.
Zurück zum Zitat Shamburek RD, Schubert ML. Pharmacology of gastric acid inhibition. Baillieres Clin Gastroenterol. 1993;7(1):23–54.PubMedCrossRef Shamburek RD, Schubert ML. Pharmacology of gastric acid inhibition. Baillieres Clin Gastroenterol. 1993;7(1):23–54.PubMedCrossRef
31.
Zurück zum Zitat Hirschowitz BI, Keeling D, Lewin M, Okabe S, Parsons M, Sewing K, et al. Pharmacological aspects of acid secretion. Dig Dis Sci. 1995;40(2 Suppl):3S–23S.PubMedCrossRef Hirschowitz BI, Keeling D, Lewin M, Okabe S, Parsons M, Sewing K, et al. Pharmacological aspects of acid secretion. Dig Dis Sci. 1995;40(2 Suppl):3S–23S.PubMedCrossRef
32.
Zurück zum Zitat Jain KS, Shah AK, Bariwal J, Shelke SM, Kale AP, Jagtap JR, et al. Recent advances in proton pump inhibitors and management of acid-peptic disorders. Bioorg Med Chem. 2007;15(3):1181–205.PubMedCrossRef Jain KS, Shah AK, Bariwal J, Shelke SM, Kale AP, Jagtap JR, et al. Recent advances in proton pump inhibitors and management of acid-peptic disorders. Bioorg Med Chem. 2007;15(3):1181–205.PubMedCrossRef
33.
Zurück zum Zitat Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Drugs. 2003;63(24):2739–54.PubMedCrossRef Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Drugs. 2003;63(24):2739–54.PubMedCrossRef
34.
Zurück zum Zitat Li XQ, Andersson TB, Ahlstrom M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32(8):821–7.PubMedCrossRef Li XQ, Andersson TB, Ahlstrom M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32(8):821–7.PubMedCrossRef
35.
Zurück zum Zitat Lim PW, Goh KL, Wong BC. CYP2C19 genotype and the PPIs—focus on rabeprazole. J Gastroenterol Hepatol. 2005;20(Suppl):S22–8.PubMedCrossRef Lim PW, Goh KL, Wong BC. CYP2C19 genotype and the PPIs—focus on rabeprazole. J Gastroenterol Hepatol. 2005;20(Suppl):S22–8.PubMedCrossRef
36.
Zurück zum Zitat Fock KM, Ang TL, Bee LC, Lee EJ. Proton pump inhibitors: do differences in pharmacokinetics translate into differences in clinical outcomes? Clin Pharmacokinet. 2008;47(1):1–6.PubMedCrossRef Fock KM, Ang TL, Bee LC, Lee EJ. Proton pump inhibitors: do differences in pharmacokinetics translate into differences in clinical outcomes? Clin Pharmacokinet. 2008;47(1):1–6.PubMedCrossRef
37.
Zurück zum Zitat Kuo CH, Wang SS, Hsu WH, Kuo FC, Weng BC, Li CJ, et al. Rabeprazole can overcome the impact of CYP2C19 polymorphism on quadruple therapy. Helicobacter. 2010;15(4):265–72.PubMedCrossRef Kuo CH, Wang SS, Hsu WH, Kuo FC, Weng BC, Li CJ, et al. Rabeprazole can overcome the impact of CYP2C19 polymorphism on quadruple therapy. Helicobacter. 2010;15(4):265–72.PubMedCrossRef
38.
Zurück zum Zitat Ogilvie BW, Yerino P, Kazmi F, Buckley DB, Rostami-Hodjegan A, Paris BL, et al. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel. Drug Metab Dispos. 2011;39(11):2020–33.PubMedCrossRef Ogilvie BW, Yerino P, Kazmi F, Buckley DB, Rostami-Hodjegan A, Paris BL, et al. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel. Drug Metab Dispos. 2011;39(11):2020–33.PubMedCrossRef
39.
Zurück zum Zitat Reynolds JC. The clinical importance of drug interactions with antiulcer therapy. J Clin Gastroenterol. 1990;12(Suppl 2):S54–63.PubMedCrossRef Reynolds JC. The clinical importance of drug interactions with antiulcer therapy. J Clin Gastroenterol. 1990;12(Suppl 2):S54–63.PubMedCrossRef
40.
41.
Zurück zum Zitat Aymard JP, Aymard B, Netter P, Bannwarth B, Trechot P, Streiff F. Haematological adverse effects of histamine H2-receptor antagonists. Med Toxicol Adverse Drug Exp. 1988;3(6):430–48.PubMed Aymard JP, Aymard B, Netter P, Bannwarth B, Trechot P, Streiff F. Haematological adverse effects of histamine H2-receptor antagonists. Med Toxicol Adverse Drug Exp. 1988;3(6):430–48.PubMed
42.
Zurück zum Zitat Fisher AA, Le Couteur DG. Nephrotoxicity and hepatotoxicity of histamine H2 receptor antagonists. Drug Saf. 2001;24(1):39–57.PubMedCrossRef Fisher AA, Le Couteur DG. Nephrotoxicity and hepatotoxicity of histamine H2 receptor antagonists. Drug Saf. 2001;24(1):39–57.PubMedCrossRef
43.
Zurück zum Zitat Powell JR, Donn KH. The pharmacokinetic basis for H2-antagonist drug interactions: concepts and implications. J Clin Gastroenterol. 1983;5(Suppl 1):95–113.PubMedCrossRef Powell JR, Donn KH. The pharmacokinetic basis for H2-antagonist drug interactions: concepts and implications. J Clin Gastroenterol. 1983;5(Suppl 1):95–113.PubMedCrossRef
44.
Zurück zum Zitat Penston J, Wormsley KG. Adverse reactions and interactions with H2-receptor antagonists. Med Toxicol. 1986;1(3):192–216.PubMedCrossRef Penston J, Wormsley KG. Adverse reactions and interactions with H2-receptor antagonists. Med Toxicol. 1986;1(3):192–216.PubMedCrossRef
45.
Zurück zum Zitat Hansten PD. Overview of the safety profile of the H2-receptor antagonists. DICP. 1990;24(11 Suppl):S38–41.PubMed Hansten PD. Overview of the safety profile of the H2-receptor antagonists. DICP. 1990;24(11 Suppl):S38–41.PubMed
46.
Zurück zum Zitat Chen Y, Liu BC, Glass K, Kirk MD. High incidence of hospitalisation due to infectious gastroenteritis in older people associated with poor self-rated health. BMJ Open. 2015;5(12):e010161.PubMedPubMedCentralCrossRef Chen Y, Liu BC, Glass K, Kirk MD. High incidence of hospitalisation due to infectious gastroenteritis in older people associated with poor self-rated health. BMJ Open. 2015;5(12):e010161.PubMedPubMedCentralCrossRef
47.
Zurück zum Zitat Leufkens H, Claessens A, Heerdink E, van Eijk J, Lamers CB. A prospective follow-up study of 5669 users of lansoprazole in daily practice. Aliment Pharmacol Ther. 1997;11(5):887–97.PubMedCrossRef Leufkens H, Claessens A, Heerdink E, van Eijk J, Lamers CB. A prospective follow-up study of 5669 users of lansoprazole in daily practice. Aliment Pharmacol Ther. 1997;11(5):887–97.PubMedCrossRef
48.
Zurück zum Zitat Martin RM, Dunn NR, Freemantle S, Shakir S. The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies. Br J Clin Pharmacol. 2000;50(4):366–72.PubMedPubMedCentralCrossRef Martin RM, Dunn NR, Freemantle S, Shakir S. The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies. Br J Clin Pharmacol. 2000;50(4):366–72.PubMedPubMedCentralCrossRef
49.
Zurück zum Zitat Claessens AA, Heerdink ER, van Eijk JT, Lamers CB, Leufkens HG. Characteristics of diarrhoea in 10,008 users of lansoprazole in daily practice: which co-factors contribute? Pharmacoepidemiol Drug Saf. 2002;11(8):703–8.PubMedCrossRef Claessens AA, Heerdink ER, van Eijk JT, Lamers CB, Leufkens HG. Characteristics of diarrhoea in 10,008 users of lansoprazole in daily practice: which co-factors contribute? Pharmacoepidemiol Drug Saf. 2002;11(8):703–8.PubMedCrossRef
50.
Zurück zum Zitat Wilton LV, Key C, Shakir SA. The pharmacovigilance of pantoprazole: the results of postmarketing surveillance on 11 541 patients in England. Drug Saf. 2003;26(2):121–32.PubMedCrossRef Wilton LV, Key C, Shakir SA. The pharmacovigilance of pantoprazole: the results of postmarketing surveillance on 11 541 patients in England. Drug Saf. 2003;26(2):121–32.PubMedCrossRef
51.
Zurück zum Zitat McFarland LV. Epidemiology, risk factors and treatments for antibiotic-associated diarrhea. Dig Dis. 1998;16(5):292–307.PubMedCrossRef McFarland LV. Epidemiology, risk factors and treatments for antibiotic-associated diarrhea. Dig Dis. 1998;16(5):292–307.PubMedCrossRef
52.
Zurück zum Zitat Jansen A, Stark K, Kunkel J, Schreier E, Ignatius R, Liesenfeld O, et al. Aetiology of community-acquired, acute gastroenteritis in hospitalised adults: a prospective cohort study. BMC Infect Dis. 2008;8:143.PubMedPubMedCentralCrossRef Jansen A, Stark K, Kunkel J, Schreier E, Ignatius R, Liesenfeld O, et al. Aetiology of community-acquired, acute gastroenteritis in hospitalised adults: a prospective cohort study. BMC Infect Dis. 2008;8:143.PubMedPubMedCentralCrossRef
53.
Zurück zum Zitat McFarland LV. Antibiotic-associated diarrhea: epidemiology, trends and treatment. Future Microbiol. 2008;3(5):563–78.PubMedCrossRef McFarland LV. Antibiotic-associated diarrhea: epidemiology, trends and treatment. Future Microbiol. 2008;3(5):563–78.PubMedCrossRef
54.
Zurück zum Zitat Chui KK, Jagai JS, Griffiths JK, Naumova EN. Hospitalization of the elderly in the United States for nonspecific gastrointestinal diseases: a search for etiological clues. Am J Public Health. 2011;101(11):2082–6.PubMedPubMedCentralCrossRef Chui KK, Jagai JS, Griffiths JK, Naumova EN. Hospitalization of the elderly in the United States for nonspecific gastrointestinal diseases: a search for etiological clues. Am J Public Health. 2011;101(11):2082–6.PubMedPubMedCentralCrossRef
55.
Zurück zum Zitat Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431–55.PubMedCrossRef Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431–55.PubMedCrossRef
56.
Zurück zum Zitat Polage CR, Solnick JV, Cohen SH. Nosocomial diarrhea: evaluation and treatment of causes other than Clostridium difficile. Clin Infect Dis. 2012;55(7):982–9.PubMedPubMedCentralCrossRef Polage CR, Solnick JV, Cohen SH. Nosocomial diarrhea: evaluation and treatment of causes other than Clostridium difficile. Clin Infect Dis. 2012;55(7):982–9.PubMedPubMedCentralCrossRef
57.
Zurück zum Zitat Viswanathan VK, Mallozzi MJ, Vedantam G. Clostridium difficile infection: an overview of the disease and its pathogenesis, epidemiology and interventions. Gut Microbes. 2010;1(4):234–42.PubMedPubMedCentralCrossRef Viswanathan VK, Mallozzi MJ, Vedantam G. Clostridium difficile infection: an overview of the disease and its pathogenesis, epidemiology and interventions. Gut Microbes. 2010;1(4):234–42.PubMedPubMedCentralCrossRef
58.
Zurück zum Zitat Pilotto A, Franceschi M, Vitale D, Zaninelli A, Di Mario F, Seripa D, et al. The prevalence of diarrhea and its association with drug use in elderly outpatients: a multicenter study. Am J Gastroenterol. 2008;103(11):2816–23.PubMedCrossRef Pilotto A, Franceschi M, Vitale D, Zaninelli A, Di Mario F, Seripa D, et al. The prevalence of diarrhea and its association with drug use in elderly outpatients: a multicenter study. Am J Gastroenterol. 2008;103(11):2816–23.PubMedCrossRef
59.
Zurück zum Zitat Laine L, Ahnen D, McClain C, Solcia E, Walsh JH. Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther. 2000;14(6):651–68.PubMedCrossRef Laine L, Ahnen D, McClain C, Solcia E, Walsh JH. Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther. 2000;14(6):651–68.PubMedCrossRef
60.
Zurück zum Zitat Magill SS, Edwards JR, Fridkin SK, Emerging Infections Program Healthcare-Associated I, Antimicrobial Use Prevalence Survey T. Survey of health care-associated infections. N Engl J Med. 2014;370(26):2542–3.PubMedCrossRef Magill SS, Edwards JR, Fridkin SK, Emerging Infections Program Healthcare-Associated I, Antimicrobial Use Prevalence Survey T. Survey of health care-associated infections. N Engl J Med. 2014;370(26):2542–3.PubMedCrossRef
61.
Zurück zum Zitat Dubberke E. Strategies for prevention of Clostridium difficile infection. J Hosp Med. 2012;7(Suppl 3):S14–7.PubMedCrossRef Dubberke E. Strategies for prevention of Clostridium difficile infection. J Hosp Med. 2012;7(Suppl 3):S14–7.PubMedCrossRef
62.
Zurück zum Zitat Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108(4):478–98 (quiz 99). Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108(4):478–98 (quiz 99).
64.
Zurück zum Zitat Shields K, Araujo-Castillo RV, Theethira TG, Alonso CD, Kelly CP. Recurrent Clostridium difficile infection: from colonization to cure. Anaerobe. 2015;34:59–73.PubMedPubMedCentralCrossRef Shields K, Araujo-Castillo RV, Theethira TG, Alonso CD, Kelly CP. Recurrent Clostridium difficile infection: from colonization to cure. Anaerobe. 2015;34:59–73.PubMedPubMedCentralCrossRef
65.
Zurück zum Zitat Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372(9):825–34.PubMedCrossRef Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372(9):825–34.PubMedCrossRef
66.
Zurück zum Zitat Goldstein EJ, Johnson S, Maziade PJ, McFarland LV, Trick W, Dresser L, et al. Pathway to prevention of nosocomial Clostridium difficile infection. Clin Infect Dis. 2015;15(60 Suppl 2):S148–58.CrossRef Goldstein EJ, Johnson S, Maziade PJ, McFarland LV, Trick W, Dresser L, et al. Pathway to prevention of nosocomial Clostridium difficile infection. Clin Infect Dis. 2015;15(60 Suppl 2):S148–58.CrossRef
67.
Zurück zum Zitat Gao T, He B, Pan Y, Deng Q, Sun H, Liu X, et al. Association of Clostridium difficile infection in hospital mortality: a systematic review and meta-analysis. Am J Infect Control. 2015;43(12):1316–20.PubMedCrossRef Gao T, He B, Pan Y, Deng Q, Sun H, Liu X, et al. Association of Clostridium difficile infection in hospital mortality: a systematic review and meta-analysis. Am J Infect Control. 2015;43(12):1316–20.PubMedCrossRef
68.
Zurück zum Zitat Ananthakrishnan AN. Clostridium difficile infection: epidemiology, risk factors and management. Nat Rev Gastroenterol Hepatol. 2011;8(1):17–26.PubMedCrossRef Ananthakrishnan AN. Clostridium difficile infection: epidemiology, risk factors and management. Nat Rev Gastroenterol Hepatol. 2011;8(1):17–26.PubMedCrossRef
69.
Zurück zum Zitat Halabi WJ, Nguyen VQ, Carmichael JC, Pigazzi A, Stamos MJ, Mills S. Clostridium difficile colitis in the United States: a decade of trends, outcomes, risk factors for colectomy, and mortality after colectomy. J Am Coll Surg. 2013;217(5):802–12.PubMedCrossRef Halabi WJ, Nguyen VQ, Carmichael JC, Pigazzi A, Stamos MJ, Mills S. Clostridium difficile colitis in the United States: a decade of trends, outcomes, risk factors for colectomy, and mortality after colectomy. J Am Coll Surg. 2013;217(5):802–12.PubMedCrossRef
70.
Zurück zum Zitat Schubert AM, Sinani H, Schloss PD. Antibiotic-induced alterations of the murine gut microbiota and subsequent effects on colonization resistance against Clostridium difficile. MBio. 2015;6(4):e00974.PubMedPubMedCentralCrossRef Schubert AM, Sinani H, Schloss PD. Antibiotic-induced alterations of the murine gut microbiota and subsequent effects on colonization resistance against Clostridium difficile. MBio. 2015;6(4):e00974.PubMedPubMedCentralCrossRef
71.
Zurück zum Zitat Martin JS, Monaghan TM, Wilcox MH. Clostridium difficile infection: epidemiology, diagnosis and understanding transmission. Nat Rev Gastroenterol Hepatol. 2016;13(4):206–16.PubMedCrossRef Martin JS, Monaghan TM, Wilcox MH. Clostridium difficile infection: epidemiology, diagnosis and understanding transmission. Nat Rev Gastroenterol Hepatol. 2016;13(4):206–16.PubMedCrossRef
72.
Zurück zum Zitat Gerding DN, Lessa FC. The epidemiology of Clostridium difficile infection inside and outside health care institutions. Infect Dis Clin N Am. 2015;29(1):37–50.CrossRef Gerding DN, Lessa FC. The epidemiology of Clostridium difficile infection inside and outside health care institutions. Infect Dis Clin N Am. 2015;29(1):37–50.CrossRef
73.
Zurück zum Zitat Hunter JC, Mu Y, Dumyati GK, Farley MM, Winston LG, Johnston HL, et al. Burden of nursing home-onset Clostridium difficile infection in the United States: estimates of incidence and patient outcomes. Open Forum Infect Dis. 2016;3(1):ofv196.PubMedPubMedCentralCrossRef Hunter JC, Mu Y, Dumyati GK, Farley MM, Winston LG, Johnston HL, et al. Burden of nursing home-onset Clostridium difficile infection in the United States: estimates of incidence and patient outcomes. Open Forum Infect Dis. 2016;3(1):ofv196.PubMedPubMedCentralCrossRef
74.
Zurück zum Zitat Chitnis AS, Holzbauer SM, Belflower RM, Winston LG, Bamberg WM, Lyons C, et al. Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011. JAMA Intern Med. 2013;173(14):1359–67.PubMedCrossRef Chitnis AS, Holzbauer SM, Belflower RM, Winston LG, Bamberg WM, Lyons C, et al. Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011. JAMA Intern Med. 2013;173(14):1359–67.PubMedCrossRef
75.
Zurück zum Zitat Claesson MJ, Cusack S, O’Sullivan O, Greene-Diniz R, de Weerd H, Flannery E, et al. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc Natl Acad Sci USA. 2011;15(108 Suppl 1):4586–91.CrossRef Claesson MJ, Cusack S, O’Sullivan O, Greene-Diniz R, de Weerd H, Flannery E, et al. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc Natl Acad Sci USA. 2011;15(108 Suppl 1):4586–91.CrossRef
77.
Zurück zum Zitat Keller JM, Surawicz CM. Clostridium difficile infection in the elderly. Clin Geriatr Med. 2014;30(1):79–93.PubMedCrossRef Keller JM, Surawicz CM. Clostridium difficile infection in the elderly. Clin Geriatr Med. 2014;30(1):79–93.PubMedCrossRef
78.
Zurück zum Zitat Rodriguez C, Korsak N, Taminiau B, Avesani V, Van Broeck J, Delmee M, et al. Clostridium difficile infection in elderly nursing home residents. Anaerobe. 2014;30:184–7.PubMedCrossRef Rodriguez C, Korsak N, Taminiau B, Avesani V, Van Broeck J, Delmee M, et al. Clostridium difficile infection in elderly nursing home residents. Anaerobe. 2014;30:184–7.PubMedCrossRef
79.
Zurück zum Zitat Pawar D, Tsay R, Nelson DS, Elumalai MK, Lessa FC, Clifford McDonald L, et al. Burden of Clostridium difficile infection in long-term care facilities in Monroe County, New York. Infect Control Hosp Epidemiol. 2012;33(11):1107–12.PubMedCrossRef Pawar D, Tsay R, Nelson DS, Elumalai MK, Lessa FC, Clifford McDonald L, et al. Burden of Clostridium difficile infection in long-term care facilities in Monroe County, New York. Infect Control Hosp Epidemiol. 2012;33(11):1107–12.PubMedCrossRef
80.
Zurück zum Zitat Laffan AM, Bellantoni MF, Greenough WB 3rd, Zenilman JM. Burden of Clostridium difficile-associated diarrhea in a long-term care facility. J Am Geriatr Soc. 2006;54(7):1068–73.PubMedCrossRef Laffan AM, Bellantoni MF, Greenough WB 3rd, Zenilman JM. Burden of Clostridium difficile-associated diarrhea in a long-term care facility. J Am Geriatr Soc. 2006;54(7):1068–73.PubMedCrossRef
81.
Zurück zum Zitat Simor AE. Diagnosis, management, and prevention of Clostridium difficile infection in long-term care facilities: a review. J Am Geriatr Soc. 2010;58(8):1556–64.PubMedCrossRef Simor AE. Diagnosis, management, and prevention of Clostridium difficile infection in long-term care facilities: a review. J Am Geriatr Soc. 2010;58(8):1556–64.PubMedCrossRef
82.
Zurück zum Zitat Zilberberg MD, Nathanson BH, Sadigov S, Higgins TL, Kollef MH, Shorr AF. Epidemiology and outcomes of Clostridium difficile-associated disease among patients on prolonged acute mechanical ventilation. Chest. 2009;136(3):752–8.PubMedCrossRef Zilberberg MD, Nathanson BH, Sadigov S, Higgins TL, Kollef MH, Shorr AF. Epidemiology and outcomes of Clostridium difficile-associated disease among patients on prolonged acute mechanical ventilation. Chest. 2009;136(3):752–8.PubMedCrossRef
83.
Zurück zum Zitat Morrison RH, Hall NS, Said M, Rice T, Groff H, Brodine SK, et al. Risk factors associated with complications and mortality in patients with Clostridium difficile infection. Clin Infect Dis. 2011;53(12):1173–8.PubMedCrossRef Morrison RH, Hall NS, Said M, Rice T, Groff H, Brodine SK, et al. Risk factors associated with complications and mortality in patients with Clostridium difficile infection. Clin Infect Dis. 2011;53(12):1173–8.PubMedCrossRef
84.
Zurück zum Zitat Vardakas KZ, Polyzos KA, Patouni K, Rafailidis PI, Samonis G, Falagas ME. Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence. Int J Antimicrob Agents. 2012;40(1):1–8.PubMedCrossRef Vardakas KZ, Polyzos KA, Patouni K, Rafailidis PI, Samonis G, Falagas ME. Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence. Int J Antimicrob Agents. 2012;40(1):1–8.PubMedCrossRef
85.
Zurück zum Zitat Mizusawa M, Doron S, Gorbach S. Clostridium difficile diarrhea in the elderly: current issues and management options. Drugs Aging. 2015;32(8):639–47.PubMedCrossRef Mizusawa M, Doron S, Gorbach S. Clostridium difficile diarrhea in the elderly: current issues and management options. Drugs Aging. 2015;32(8):639–47.PubMedCrossRef
86.
Zurück zum Zitat Drekonja DM, Amundson WH, Decarolis DD, Kuskowski MA, Lederle FA, Johnson JR. Antimicrobial use and risk for recurrent Clostridium difficile infection. Am J Med. 2011;124(11):1081 e1–. Drekonja DM, Amundson WH, Decarolis DD, Kuskowski MA, Lederle FA, Johnson JR. Antimicrobial use and risk for recurrent Clostridium difficile infection. Am J Med. 2011;124(11):1081 e1–.
87.
Zurück zum Zitat Garey KW, Dao-Tran TK, Jiang ZD, Price MP, Gentry LO, Dupont HL. A clinical risk index for Clostridium difficile infection in hospitalised patients receiving broad-spectrum antibiotics. J Hosp Infect. 2008;70(2):142–7.PubMedCrossRef Garey KW, Dao-Tran TK, Jiang ZD, Price MP, Gentry LO, Dupont HL. A clinical risk index for Clostridium difficile infection in hospitalised patients receiving broad-spectrum antibiotics. J Hosp Infect. 2008;70(2):142–7.PubMedCrossRef
88.
Zurück zum Zitat Furuya-Kanamori L, Stone JC, Clark J, McKenzie SJ, Yakob L, Paterson DL, et al. Comorbidities, exposure to medications, and the risk of community-acquired Clostridium difficile infection: a systematic review and meta-analysis. Infect Control Hosp Epidemiol. 2015;36(2):132–41.PubMedCrossRef Furuya-Kanamori L, Stone JC, Clark J, McKenzie SJ, Yakob L, Paterson DL, et al. Comorbidities, exposure to medications, and the risk of community-acquired Clostridium difficile infection: a systematic review and meta-analysis. Infect Control Hosp Epidemiol. 2015;36(2):132–41.PubMedCrossRef
89.
Zurück zum Zitat Lin HJ, Hung YP, Liu HC, Lee JC, Lee CI, Wu YH, et al. Risk factors for Clostridium difficile-associated diarrhea among hospitalized adults with fecal toxigenic C. difficile colonization. J Microbiol Immunol Infect. 2015;48(2):183–9.PubMedCrossRef Lin HJ, Hung YP, Liu HC, Lee JC, Lee CI, Wu YH, et al. Risk factors for Clostridium difficile-associated diarrhea among hospitalized adults with fecal toxigenic C. difficile colonization. J Microbiol Immunol Infect. 2015;48(2):183–9.PubMedCrossRef
90.
Zurück zum Zitat Johanesen PA, Mackin KE, Hutton ML, Awad MM, Larcombe S, Amy JM, et al. Disruption of the gut microbiome: Clostridium difficile infection and the threat of antibiotic resistance. Genes (Basel). 2015;6(4):1347–60. Johanesen PA, Mackin KE, Hutton ML, Awad MM, Larcombe S, Amy JM, et al. Disruption of the gut microbiome: Clostridium difficile infection and the threat of antibiotic resistance. Genes (Basel). 2015;6(4):1347–60.
91.
Zurück zum Zitat Bartlett JG, Gerding DN. Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis. 2008;15(46 Suppl 1):S12–8.CrossRef Bartlett JG, Gerding DN. Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis. 2008;15(46 Suppl 1):S12–8.CrossRef
92.
Zurück zum Zitat Johnson S. Recurrent Clostridium difficile infection: causality and therapeutic approaches. Int J Antimicrob Agents. 2009;33(Suppl 1):S33–6.PubMedCrossRef Johnson S. Recurrent Clostridium difficile infection: causality and therapeutic approaches. Int J Antimicrob Agents. 2009;33(Suppl 1):S33–6.PubMedCrossRef
93.
Zurück zum Zitat Leffler DA, Lamont JT. Clostridium difficile infection. N Engl J Med. 2015;372(16):1539–48.PubMedCrossRef Leffler DA, Lamont JT. Clostridium difficile infection. N Engl J Med. 2015;372(16):1539–48.PubMedCrossRef
94.
Zurück zum Zitat Al-Tureihi FI, Hassoun A, Wolf-Klein G, Isenberg H. Albumin, length of stay, and proton pump inhibitors: key factors in Clostridium difficile-associated disease in nursing home patients. J Am Med Dir Assoc. 2005;6(2):105–8.PubMedCrossRef Al-Tureihi FI, Hassoun A, Wolf-Klein G, Isenberg H. Albumin, length of stay, and proton pump inhibitors: key factors in Clostridium difficile-associated disease in nursing home patients. J Am Med Dir Assoc. 2005;6(2):105–8.PubMedCrossRef
95.
Zurück zum Zitat Jayatilaka S, Shakov R, Eddi R, Bakaj G, Baddoura WJ, DeBari VA. Clostridium difficile infection in an urban medical center: five-year analysis of infection rates among adult admissions and association with the use of proton pump inhibitors. Ann Clin Lab Sci. 2007;37(3):241–7.PubMed Jayatilaka S, Shakov R, Eddi R, Bakaj G, Baddoura WJ, DeBari VA. Clostridium difficile infection in an urban medical center: five-year analysis of infection rates among adult admissions and association with the use of proton pump inhibitors. Ann Clin Lab Sci. 2007;37(3):241–7.PubMed
96.
Zurück zum Zitat Cadle RM, Mansouri MD, Logan N, Kudva DR, Musher DM. Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis. Am J Health Syst Pharm. 2007;64(22):2359–63.PubMedCrossRef Cadle RM, Mansouri MD, Logan N, Kudva DR, Musher DM. Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis. Am J Health Syst Pharm. 2007;64(22):2359–63.PubMedCrossRef
97.
Zurück zum Zitat Aseeri M, Schroeder T, Kramer J, Zackula R. Gastric acid suppression by proton pump inhibitors as a risk factor for clostridium difficile-associated diarrhea in hospitalized patients. Am J Gastroenterol. 2008;103(9):2308–13.PubMedCrossRef Aseeri M, Schroeder T, Kramer J, Zackula R. Gastric acid suppression by proton pump inhibitors as a risk factor for clostridium difficile-associated diarrhea in hospitalized patients. Am J Gastroenterol. 2008;103(9):2308–13.PubMedCrossRef
98.
Zurück zum Zitat Cunningham R, Dial S. Is over-use of proton pump inhibitors fuelling the current epidemic of Clostridium difficile-associated diarrhoea? J Hosp Infect. 2008;70(1):1–6.PubMedCrossRef Cunningham R, Dial S. Is over-use of proton pump inhibitors fuelling the current epidemic of Clostridium difficile-associated diarrhoea? J Hosp Infect. 2008;70(1):1–6.PubMedCrossRef
99.
Zurück zum Zitat Pant C, Madonia P, Minocha A. Does PPI therapy predispose to Clostridium difficile infection? Nat Rev Gastroenterol Hepatol. 2009;6(9):555–7.PubMedCrossRef Pant C, Madonia P, Minocha A. Does PPI therapy predispose to Clostridium difficile infection? Nat Rev Gastroenterol Hepatol. 2009;6(9):555–7.PubMedCrossRef
100.
Zurück zum Zitat Linsky A, Gupta K, Lawler EV, Fonda JR, Hermos JA. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med. 2010;170(9):772–8.PubMedCrossRef Linsky A, Gupta K, Lawler EV, Fonda JR, Hermos JA. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med. 2010;170(9):772–8.PubMedCrossRef
101.
Zurück zum Zitat Bavishi C, Dupont HL. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther. 2011;34(11–12):1269–81.PubMedCrossRef Bavishi C, Dupont HL. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther. 2011;34(11–12):1269–81.PubMedCrossRef
102.
Zurück zum Zitat Stevens V, Dumyati G, Brown J, Wijngaarden E. Differential risk of Clostridium difficile infection with proton pump inhibitor use by level of antibiotic exposure. Pharmacoepidemiol Drug Saf. 2011;20(10):1035–42.PubMedCrossRef Stevens V, Dumyati G, Brown J, Wijngaarden E. Differential risk of Clostridium difficile infection with proton pump inhibitor use by level of antibiotic exposure. Pharmacoepidemiol Drug Saf. 2011;20(10):1035–42.PubMedCrossRef
103.
Zurück zum Zitat Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol. 2012;107(7):1011–9.PubMedCrossRef Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol. 2012;107(7):1011–9.PubMedCrossRef
104.
Zurück zum Zitat Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol. 2012;107(7):1001–10.PubMedCrossRef Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol. 2012;107(7):1001–10.PubMedCrossRef
105.
Zurück zum Zitat Pohl JF. Clostridium difficile infection and proton pump inhibitors. Curr Opin Pediatr. 2012;24(5):627–31.PubMedCrossRef Pohl JF. Clostridium difficile infection and proton pump inhibitors. Curr Opin Pediatr. 2012;24(5):627–31.PubMedCrossRef
106.
Zurück zum Zitat Deshpande A, Pant C, Pasupuleti V, Rolston DD, Jain A, Deshpande N, et al. Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. Clin Gastroenterol Hepatol. 2012;10(3):225–33.PubMedCrossRef Deshpande A, Pant C, Pasupuleti V, Rolston DD, Jain A, Deshpande N, et al. Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. Clin Gastroenterol Hepatol. 2012;10(3):225–33.PubMedCrossRef
107.
Zurück zum Zitat Tleyjeh IM, Abdulhak AB, Riaz M, Garbati MA, Al-Tannir M, Alasmari FA, et al. The association between histamine 2 receptor antagonist use and Clostridium difficile infection: a systematic review and meta-analysis. PLoS One. 2013;8(3):e56498.PubMedPubMedCentralCrossRef Tleyjeh IM, Abdulhak AB, Riaz M, Garbati MA, Al-Tannir M, Alasmari FA, et al. The association between histamine 2 receptor antagonist use and Clostridium difficile infection: a systematic review and meta-analysis. PLoS One. 2013;8(3):e56498.PubMedPubMedCentralCrossRef
108.
Zurück zum Zitat Tleyjeh IM, Bin Abdulhak AA, Riaz M, Alasmari FA, Garbati MA, AlGhamdi M, et al. Association between proton pump inhibitor therapy and Clostridium difficile infection: a contemporary systematic review and meta-analysis. PLoS One. 2012;7(12):e50836.PubMedPubMedCentralCrossRef Tleyjeh IM, Bin Abdulhak AA, Riaz M, Alasmari FA, Garbati MA, AlGhamdi M, et al. Association between proton pump inhibitor therapy and Clostridium difficile infection: a contemporary systematic review and meta-analysis. PLoS One. 2012;7(12):e50836.PubMedPubMedCentralCrossRef
109.
Zurück zum Zitat Vesteinsdottir I, Gudlaugsdottir S, Einarsdottir R, Kalaitzakis E, Sigurdardottir O, Bjornsson ES. Risk factors for Clostridium difficile toxin-positive diarrhea: a population-based prospective case–control study. Eur J Clin Microbiol Infect Dis. 2012;31(10):2601–10.PubMedCrossRef Vesteinsdottir I, Gudlaugsdottir S, Einarsdottir R, Kalaitzakis E, Sigurdardottir O, Bjornsson ES. Risk factors for Clostridium difficile toxin-positive diarrhea: a population-based prospective case–control study. Eur J Clin Microbiol Infect Dis. 2012;31(10):2601–10.PubMedCrossRef
110.
Zurück zum Zitat Shivashankar R, Khanna S, Kammer PP, Harmsen WS, Zinsmeister AR, Baddour LM, et al. Clinical factors associated with development of severe-complicated Clostridium difficile infection. Clin Gastroenterol Hepatol. 2013;11(11):1466–71.PubMedCrossRef Shivashankar R, Khanna S, Kammer PP, Harmsen WS, Zinsmeister AR, Baddour LM, et al. Clinical factors associated with development of severe-complicated Clostridium difficile infection. Clin Gastroenterol Hepatol. 2013;11(11):1466–71.PubMedCrossRef
111.
Zurück zum Zitat Barletta JF, El-Ibiary SY, Davis LE, Nguyen B, Raney CR. Proton pump inhibitors and the risk for hospital-acquired Clostridium difficile infection. Mayo Clin Proc. 2013;88(10):1085–90.PubMedCrossRef Barletta JF, El-Ibiary SY, Davis LE, Nguyen B, Raney CR. Proton pump inhibitors and the risk for hospital-acquired Clostridium difficile infection. Mayo Clin Proc. 2013;88(10):1085–90.PubMedCrossRef
112.
Zurück zum Zitat Freedberg DE, Salmasian H, Friedman C, Abrams JA. Proton pump inhibitors and risk for recurrent Clostridium difficile infection among inpatients. Am J Gastroenterol. 2013;108(11):1794–801.PubMedPubMedCentralCrossRef Freedberg DE, Salmasian H, Friedman C, Abrams JA. Proton pump inhibitors and risk for recurrent Clostridium difficile infection among inpatients. Am J Gastroenterol. 2013;108(11):1794–801.PubMedPubMedCentralCrossRef
113.
Zurück zum Zitat Biswal S. Proton pump inhibitors and risk for Clostridium difficile associated diarrhea. Biomed J. 2014;37(4):178–83.PubMedCrossRef Biswal S. Proton pump inhibitors and risk for Clostridium difficile associated diarrhea. Biomed J. 2014;37(4):178–83.PubMedCrossRef
114.
Zurück zum Zitat McDonald EG, Milligan J, Frenette C, Lee TC. Continuous proton pump inhibitor therapy and the associated risk of recurrent Clostridium difficile infection. JAMA Intern Med. 2015;175(5):784–91.PubMedCrossRef McDonald EG, Milligan J, Frenette C, Lee TC. Continuous proton pump inhibitor therapy and the associated risk of recurrent Clostridium difficile infection. JAMA Intern Med. 2015;175(5):784–91.PubMedCrossRef
115.
Zurück zum Zitat Ro Y, Eun CS, Kim HS, Kim JY, Byun YJ, Yoo KS, et al. Risk of Clostridium difficile infection with the use of a proton pump inhibitor for stress ulcer prophylaxis in critically ill patients. Gut Liver. 2016;10(4):581–6.PubMedPubMedCentralCrossRef Ro Y, Eun CS, Kim HS, Kim JY, Byun YJ, Yoo KS, et al. Risk of Clostridium difficile infection with the use of a proton pump inhibitor for stress ulcer prophylaxis in critically ill patients. Gut Liver. 2016;10(4):581–6.PubMedPubMedCentralCrossRef
116.
Zurück zum Zitat Cunningham R, Dale B, Undy B, Gaunt N. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect. 2003;54(3):243–5.PubMedCrossRef Cunningham R, Dale B, Undy B, Gaunt N. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect. 2003;54(3):243–5.PubMedCrossRef
117.
Zurück zum Zitat Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA. 2005;294(23):2989–95.PubMedCrossRef Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA. 2005;294(23):2989–95.PubMedCrossRef
118.
Zurück zum Zitat Yearsley KA, Gilby LJ, Ramadas AV, Kubiak EM, Fone DL, Allison MC. Proton pump inhibitor therapy is a risk factor for Clostridium difficile-associated diarrhoea. Aliment Pharmacol Ther. 2006;24(4):613–9.PubMedCrossRef Yearsley KA, Gilby LJ, Ramadas AV, Kubiak EM, Fone DL, Allison MC. Proton pump inhibitor therapy is a risk factor for Clostridium difficile-associated diarrhoea. Aliment Pharmacol Ther. 2006;24(4):613–9.PubMedCrossRef
119.
Zurück zum Zitat Howell MD, Novack V, Grgurich P, Soulliard D, Novack L, Pencina M, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med. 2010;170(9):784–90.PubMedCrossRef Howell MD, Novack V, Grgurich P, Soulliard D, Novack L, Pencina M, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med. 2010;170(9):784–90.PubMedCrossRef
120.
Zurück zum Zitat Loo VG, Bourgault AM, Poirier L, Lamothe F, Michaud S, Turgeon N, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med. 2011;365(18):1693–703.PubMedCrossRef Loo VG, Bourgault AM, Poirier L, Lamothe F, Michaud S, Turgeon N, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med. 2011;365(18):1693–703.PubMedCrossRef
121.
Zurück zum Zitat Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007;102(9):2047–56 (quiz 57). Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007;102(9):2047–56 (quiz 57).
122.
Zurück zum Zitat Wilhelm SM, Rjater RG, Kale-Pradhan PB. Perils and pitfalls of long-term effects of proton pump inhibitors. Expert Rev Clin Pharmacol. 2013;6(4):443–51.PubMedCrossRef Wilhelm SM, Rjater RG, Kale-Pradhan PB. Perils and pitfalls of long-term effects of proton pump inhibitors. Expert Rev Clin Pharmacol. 2013;6(4):443–51.PubMedCrossRef
123.
Zurück zum Zitat Kwok CS, Yeong JK, Loke YK. Meta-analysis: risk of fractures with acid-suppressing medication. Bone. 2011;48(4):768–76.PubMedCrossRef Kwok CS, Yeong JK, Loke YK. Meta-analysis: risk of fractures with acid-suppressing medication. Bone. 2011;48(4):768–76.PubMedCrossRef
124.
Zurück zum Zitat Brown KE, Knoderer CA, Nichols KR, Crumby AS. Acid-suppressing agents and risk for Clostridium difficile infection in pediatric patients. Clin Pediatr (Phila). 2015;54(11):1102–6.CrossRef Brown KE, Knoderer CA, Nichols KR, Crumby AS. Acid-suppressing agents and risk for Clostridium difficile infection in pediatric patients. Clin Pediatr (Phila). 2015;54(11):1102–6.CrossRef
125.
Zurück zum Zitat Buendgens L, Bruensing J, Matthes M, Duckers H, Luedde T, Trautwein C, et al. Administration of proton pump inhibitors in critically ill medical patients is associated with increased risk of developing Clostridium difficile-associated diarrhea. J Crit Care. 2014;29(4):696 e11–5. Buendgens L, Bruensing J, Matthes M, Duckers H, Luedde T, Trautwein C, et al. Administration of proton pump inhibitors in critically ill medical patients is associated with increased risk of developing Clostridium difficile-associated diarrhea. J Crit Care. 2014;29(4):696 e11–5.
126.
Zurück zum Zitat Gupta A, Khanna S. Community-acquired Clostridium difficile infection: an increasing public health threat. Infect Drug Resist. 2014;7:63–72.PubMedPubMedCentral Gupta A, Khanna S. Community-acquired Clostridium difficile infection: an increasing public health threat. Infect Drug Resist. 2014;7:63–72.PubMedPubMedCentral
128.
Zurück zum Zitat Weiss K, Louie T, Miller MA, Mullane K, Crook DW, Gorbach SL. Effects of proton pump inhibitors and histamine-2 receptor antagonists on response to fidaxomicin or vancomycin in patients with Clostridium difficile-associated diarrhoea. BMJ Open Gastroenterol. 2015;2(1):e000028.PubMedPubMedCentralCrossRef Weiss K, Louie T, Miller MA, Mullane K, Crook DW, Gorbach SL. Effects of proton pump inhibitors and histamine-2 receptor antagonists on response to fidaxomicin or vancomycin in patients with Clostridium difficile-associated diarrhoea. BMJ Open Gastroenterol. 2015;2(1):e000028.PubMedPubMedCentralCrossRef
129.
Zurück zum Zitat Freedberg DE, Toussaint NC, Chen SP, Ratner AJ, Whittier S, Wang TC, et al. Proton pump inhibitors alter specific taxa in the human gastrointestinal microbiome: a crossover trial. Gastroenterology. 2015;149(4):883–5 e9. Freedberg DE, Toussaint NC, Chen SP, Ratner AJ, Whittier S, Wang TC, et al. Proton pump inhibitors alter specific taxa in the human gastrointestinal microbiome: a crossover trial. Gastroenterology. 2015;149(4):883–5 e9.
130.
Zurück zum Zitat Bajaj JS, Cox IJ, Betrapally NS, Heuman DM, Schubert ML, Ratneswaran M, et al. Systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gut microbiota composition and function. Am J Physiol Gastrointest Liver Physiol. 2014;307(10):G951–7.PubMedPubMedCentralCrossRef Bajaj JS, Cox IJ, Betrapally NS, Heuman DM, Schubert ML, Ratneswaran M, et al. Systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gut microbiota composition and function. Am J Physiol Gastrointest Liver Physiol. 2014;307(10):G951–7.PubMedPubMedCentralCrossRef
131.
Zurück zum Zitat Yoo DH, Kim IS, Van Le TK, Jung IH, Yoo HH, Kim DH. Gut microbiota-mediated drug interactions between lovastatin and antibiotics. Drug Metab Dispos. 2014;42(9):1508–13.PubMedCrossRef Yoo DH, Kim IS, Van Le TK, Jung IH, Yoo HH, Kim DH. Gut microbiota-mediated drug interactions between lovastatin and antibiotics. Drug Metab Dispos. 2014;42(9):1508–13.PubMedCrossRef
132.
Zurück zum Zitat Shah S, Lewis A, Leopold D, Dunstan F, Woodhouse K. Gastric acid suppression does not promote clostridial diarrhoea in the elderly. QJM. 2000;93(3):175–81.PubMedCrossRef Shah S, Lewis A, Leopold D, Dunstan F, Woodhouse K. Gastric acid suppression does not promote clostridial diarrhoea in the elderly. QJM. 2000;93(3):175–81.PubMedCrossRef
133.
Zurück zum Zitat Pepin J, Saheb N, Coulombe MA, Alary ME, Corriveau MP, Authier S, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005;41(9):1254–60.PubMedCrossRef Pepin J, Saheb N, Coulombe MA, Alary ME, Corriveau MP, Authier S, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005;41(9):1254–60.PubMedCrossRef
134.
Zurück zum Zitat Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005;353(23):2442–9.PubMedCrossRef Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005;353(23):2442–9.PubMedCrossRef
135.
Zurück zum Zitat Lowe DO, Mamdani MM, Kopp A, Low DE, Juurlink DN. Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: a population-based study. Clin Infect Dis. 2006;43(10):1272–6.PubMedCrossRef Lowe DO, Mamdani MM, Kopp A, Low DE, Juurlink DN. Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: a population-based study. Clin Infect Dis. 2006;43(10):1272–6.PubMedCrossRef
136.
Zurück zum Zitat Naggie S, Miller BA, Zuzak KB, Pence BW, Mayo AJ, Nicholson BP, et al. A case–control study of community-associated Clostridium difficile infection: no role for proton pump inhibitors. Am J Med. 2011;124(3):276 e1–7. Naggie S, Miller BA, Zuzak KB, Pence BW, Mayo AJ, Nicholson BP, et al. A case–control study of community-associated Clostridium difficile infection: no role for proton pump inhibitors. Am J Med. 2011;124(3):276 e1–7.
137.
Zurück zum Zitat Novack L, Kogan S, Gimpelevich L, Howell M, Borer A, Kelly CP, et al. Acid suppression therapy does not predispose to Clostridium difficile infection: the case of the potential bias. PLoS One. 2014;9(10):e110790.PubMedPubMedCentralCrossRef Novack L, Kogan S, Gimpelevich L, Howell M, Borer A, Kelly CP, et al. Acid suppression therapy does not predispose to Clostridium difficile infection: the case of the potential bias. PLoS One. 2014;9(10):e110790.PubMedPubMedCentralCrossRef
138.
Zurück zum Zitat Fujimori S. What are the effects of proton pump inhibitors on the small intestine? World J Gastroenterol. 2015;21(22):6817–9.PubMedPubMedCentral Fujimori S. What are the effects of proton pump inhibitors on the small intestine? World J Gastroenterol. 2015;21(22):6817–9.PubMedPubMedCentral
139.
Zurück zum Zitat Kyne L, Sougioultzis S, McFarland LV, Kelly CP. Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea. Infect Control Hosp Epidemiol. 2002;23(11):653–9.PubMedCrossRef Kyne L, Sougioultzis S, McFarland LV, Kelly CP. Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea. Infect Control Hosp Epidemiol. 2002;23(11):653–9.PubMedCrossRef
140.
Zurück zum Zitat Khanna S, Aronson SL, Kammer PP, Baddour LM, Pardi DS. Gastric acid suppression and outcomes in Clostridium difficile infection: a population-based study. Mayo Clin Proc. 2012;87(7):636–42.PubMedPubMedCentralCrossRef Khanna S, Aronson SL, Kammer PP, Baddour LM, Pardi DS. Gastric acid suppression and outcomes in Clostridium difficile infection: a population-based study. Mayo Clin Proc. 2012;87(7):636–42.PubMedPubMedCentralCrossRef
141.
Zurück zum Zitat Faleck DM, Salmasian H, Furuya EY, Larson EL, Abrams JA, Freedberg DE. Proton pump inhibitors do not increase risk for Clostridium difficile infection in the intensive care unit. Am J Gastroenterol. 2016;111(11):1641–8.PubMedPubMedCentralCrossRef Faleck DM, Salmasian H, Furuya EY, Larson EL, Abrams JA, Freedberg DE. Proton pump inhibitors do not increase risk for Clostridium difficile infection in the intensive care unit. Am J Gastroenterol. 2016;111(11):1641–8.PubMedPubMedCentralCrossRef
142.
Zurück zum Zitat de la Coba Ortiz C, Arguelles Arias F, de Argila Martin, de Prados C, Judez Gutierrez J, Linares Rodriguez A, Ortega Alonso A, et al. Proton-pump inhibitors adverse effects: a review of the evidence and position statement by the Sociedad Espanola de Patologia Digestiva. Rev Esp Enferm Dig. 2016;108(4):207–24. de la Coba Ortiz C, Arguelles Arias F, de Argila Martin, de Prados C, Judez Gutierrez J, Linares Rodriguez A, Ortega Alonso A, et al. Proton-pump inhibitors adverse effects: a review of the evidence and position statement by the Sociedad Espanola de Patologia Digestiva. Rev Esp Enferm Dig. 2016;108(4):207–24.
143.
144.
145.
Zurück zum Zitat Neal KR, Scott HM, Slack RC, Logan RF. Omeprazole as a risk factor for campylobacter gastroenteritis: case–control study. BMJ. 1996;312(7028):414–5.PubMedPubMedCentralCrossRef Neal KR, Scott HM, Slack RC, Logan RF. Omeprazole as a risk factor for campylobacter gastroenteritis: case–control study. BMJ. 1996;312(7028):414–5.PubMedPubMedCentralCrossRef
146.
Zurück zum Zitat Garcia Rodriguez LA, Ruigomez A, Panes J. Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. Clin Gastroenterol Hepatol. 2007;5(12):1418–23.PubMedCrossRef Garcia Rodriguez LA, Ruigomez A, Panes J. Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. Clin Gastroenterol Hepatol. 2007;5(12):1418–23.PubMedCrossRef
147.
Zurück zum Zitat Wu HH, Chen YT, Shih CJ, Lee YT, Kuo SC, Chen TL. Association between recent use of proton pump inhibitors and nontyphoid salmonellosis: a nested case–control study. Clin Infect Dis. 2014;59(11):1554–8.PubMedPubMedCentralCrossRef Wu HH, Chen YT, Shih CJ, Lee YT, Kuo SC, Chen TL. Association between recent use of proton pump inhibitors and nontyphoid salmonellosis: a nested case–control study. Clin Infect Dis. 2014;59(11):1554–8.PubMedPubMedCentralCrossRef
148.
Zurück zum Zitat Bouwknegt M, van Pelt W, Kubbinga ME, Weda M, Havelaar AH. Potential association between the recent increase in campylobacteriosis incidence in the Netherlands and proton-pump inhibitor use—an ecological study. Euro Surveillance. 2014;19(32). Bouwknegt M, van Pelt W, Kubbinga ME, Weda M, Havelaar AH. Potential association between the recent increase in campylobacteriosis incidence in the Netherlands and proton-pump inhibitor use—an ecological study. Euro Surveillance. 2014;19(32).
149.
Zurück zum Zitat Garcia Rodriguez LA, Ruigomez A. Gastric acid, acid-suppressing drugs, and bacterial gastroenteritis: how much of a risk? Epidemiology. 1997;8(5):571–4.PubMedCrossRef Garcia Rodriguez LA, Ruigomez A. Gastric acid, acid-suppressing drugs, and bacterial gastroenteritis: how much of a risk? Epidemiology. 1997;8(5):571–4.PubMedCrossRef
150.
Zurück zum Zitat Doorduyn Y, Van Pelt W, Siezen CL, Van Der Horst F, Van Duynhoven YT, Hoebee B, et al. Novel insight in the association between salmonellosis or campylobacteriosis and chronic illness, and the role of host genetics in susceptibility to these diseases. Epidemiol Infect. 2008;136(9):1225–34.PubMedCrossRef Doorduyn Y, Van Pelt W, Siezen CL, Van Der Horst F, Van Duynhoven YT, Hoebee B, et al. Novel insight in the association between salmonellosis or campylobacteriosis and chronic illness, and the role of host genetics in susceptibility to these diseases. Epidemiol Infect. 2008;136(9):1225–34.PubMedCrossRef
151.
Zurück zum Zitat Neal KR, Briji SO, Slack RC, Hawkey CJ, Logan RF. Recent treatment with H2 antagonists and antibiotics and gastric surgery as risk factors for Salmonella infection. BMJ. 1994;308(6922):176.PubMedPubMedCentralCrossRef Neal KR, Briji SO, Slack RC, Hawkey CJ, Logan RF. Recent treatment with H2 antagonists and antibiotics and gastric surgery as risk factors for Salmonella infection. BMJ. 1994;308(6922):176.PubMedPubMedCentralCrossRef
152.
Zurück zum Zitat Doorduyn Y, Van Den Brandhof WE, Van Duynhoven YT, Wannet WJ, Van Pelt W. Risk factors for Salmonella Enteritidis and Typhimurium (DT104 and non-DT104) infections in The Netherlands: predominant roles for raw eggs in Enteritidis and sandboxes in Typhimurium infections. Epidemiol Infect. 2006;134(3):617–26.PubMedCrossRef Doorduyn Y, Van Den Brandhof WE, Van Duynhoven YT, Wannet WJ, Van Pelt W. Risk factors for Salmonella Enteritidis and Typhimurium (DT104 and non-DT104) infections in The Netherlands: predominant roles for raw eggs in Enteritidis and sandboxes in Typhimurium infections. Epidemiol Infect. 2006;134(3):617–26.PubMedCrossRef
153.
Zurück zum Zitat Bowen A, Newman A, Estivariz C, Gilbertson N, Archer J, Srinivasan A, et al. Role of acid-suppressing medications during a sustained outbreak of Salmonella enteritidis infection in a long-term care facility. Infect Control Hosp Epidemiol. 2007;28(10):1202–5.PubMedCrossRef Bowen A, Newman A, Estivariz C, Gilbertson N, Archer J, Srinivasan A, et al. Role of acid-suppressing medications during a sustained outbreak of Salmonella enteritidis infection in a long-term care facility. Infect Control Hosp Epidemiol. 2007;28(10):1202–5.PubMedCrossRef
154.
Zurück zum Zitat Giannella RA, Broitman SA, Zamcheck N. Salmonella enteritis. I. Role of reduced gastric secretion in pathogenesis. Am J Dig Dis. 1971;16(11):1000–6.PubMedCrossRef Giannella RA, Broitman SA, Zamcheck N. Salmonella enteritis. I. Role of reduced gastric secretion in pathogenesis. Am J Dig Dis. 1971;16(11):1000–6.PubMedCrossRef
155.
Zurück zum Zitat Gray JA, Trueman AM. Severe salmonella gastroenteritis associated with hypochlorhydria. Scott Med J. 1971;16(5):255–8.PubMedCrossRef Gray JA, Trueman AM. Severe salmonella gastroenteritis associated with hypochlorhydria. Scott Med J. 1971;16(5):255–8.PubMedCrossRef
156.
Zurück zum Zitat Martinsen TC, Bergh K, Waldum HL. Gastric juice: a barrier against infectious diseases. Basic Clin Pharmacol Toxicol. 2005;96(2):94–102.PubMedCrossRef Martinsen TC, Bergh K, Waldum HL. Gastric juice: a barrier against infectious diseases. Basic Clin Pharmacol Toxicol. 2005;96(2):94–102.PubMedCrossRef
157.
Zurück zum Zitat Kunz LJ, Waddell WR. Association of Salmonella enteritis with operations on the stomach. N Engl J Med. 1956;255(12):555–9.PubMedCrossRef Kunz LJ, Waddell WR. Association of Salmonella enteritis with operations on the stomach. N Engl J Med. 1956;255(12):555–9.PubMedCrossRef
158.
Zurück zum Zitat Close AS, Smith MB, Koch ML, Ellison EH. An analysis of ten cases of Salmonella infection on a general surgical service. Arch Surg. 1960;80:972–6.PubMedCrossRef Close AS, Smith MB, Koch ML, Ellison EH. An analysis of ten cases of Salmonella infection on a general surgical service. Arch Surg. 1960;80:972–6.PubMedCrossRef
159.
Zurück zum Zitat Sokol EM. Salmonella derby infections after gastrointestinal surgery. J Mt Sinai Hosp N Y. 1965;32:36–41.PubMed Sokol EM. Salmonella derby infections after gastrointestinal surgery. J Mt Sinai Hosp N Y. 1965;32:36–41.PubMed
160.
Zurück zum Zitat Buchin PJ, Andriole VT, Spiro HM. Salmonella infections and hypochlorhydria. J Clin Gastroenterol. 1980;2(2):133–8.PubMedCrossRef Buchin PJ, Andriole VT, Spiro HM. Salmonella infections and hypochlorhydria. J Clin Gastroenterol. 1980;2(2):133–8.PubMedCrossRef
161.
162.
Zurück zum Zitat Black RE, Levine MM, Clements ML, Hughes TP, Blaser MJ. Experimental Campylobacter jejuni infection in humans. J Infect Dis. 1988;157(3):472–9.PubMedCrossRef Black RE, Levine MM, Clements ML, Hughes TP, Blaser MJ. Experimental Campylobacter jejuni infection in humans. J Infect Dis. 1988;157(3):472–9.PubMedCrossRef
163.
Zurück zum Zitat Brophy S, Jones KH, Rahman MA, Zhou SM, John A, Atkinson MD, et al. Incidence of Campylobacter and Salmonella infections following first prescription for PPI: a cohort study using routine data. Am J Gastroenterol. 2013;108(7):1094–100.PubMedCrossRef Brophy S, Jones KH, Rahman MA, Zhou SM, John A, Atkinson MD, et al. Incidence of Campylobacter and Salmonella infections following first prescription for PPI: a cohort study using routine data. Am J Gastroenterol. 2013;108(7):1094–100.PubMedCrossRef
164.
Zurück zum Zitat Fujita T. Risk factors of community-acquired enteric infection. Am J Gastroenterol. 2014;109(1):137–8.PubMedCrossRef Fujita T. Risk factors of community-acquired enteric infection. Am J Gastroenterol. 2014;109(1):137–8.PubMedCrossRef
165.
Zurück zum Zitat Ramaswamy V, Cresence VM, Rejitha JS, Lekshmi MU, Dharsana KS, Prasad SP, et al. Listeria—review of epidemiology and pathogenesis. J Microbiol Immunol Infect. 2007;40(1):4–13.PubMed Ramaswamy V, Cresence VM, Rejitha JS, Lekshmi MU, Dharsana KS, Prasad SP, et al. Listeria—review of epidemiology and pathogenesis. J Microbiol Immunol Infect. 2007;40(1):4–13.PubMed
166.
Zurück zum Zitat Swaminathan B, Gerner-Smidt P. The epidemiology of human listeriosis. Microbes Infect. 2007;9(10):1236–43.PubMedCrossRef Swaminathan B, Gerner-Smidt P. The epidemiology of human listeriosis. Microbes Infect. 2007;9(10):1236–43.PubMedCrossRef
167.
Zurück zum Zitat White SJ, McClung DM, Wilson JG, Roberts BN, Donaldson JR. Influence of pH on bile sensitivity amongst various strains of Listeria monocytogenes under aerobic and anaerobic conditions. J Med Microbiol. 2015;64(11):1287–96.PubMedPubMedCentralCrossRef White SJ, McClung DM, Wilson JG, Roberts BN, Donaldson JR. Influence of pH on bile sensitivity amongst various strains of Listeria monocytogenes under aerobic and anaerobic conditions. J Med Microbiol. 2015;64(11):1287–96.PubMedPubMedCentralCrossRef
169.
Zurück zum Zitat Gillespie IA, McLauchlin J, Little CL, Penman C, Mook P, Grant K, et al. Disease presentation in relation to infection foci for non-pregnancy-associated human listeriosis in England and Wales, 2001 to 2007. J Clin Microbiol. 2009;47(10):3301–7.PubMedPubMedCentralCrossRef Gillespie IA, McLauchlin J, Little CL, Penman C, Mook P, Grant K, et al. Disease presentation in relation to infection foci for non-pregnancy-associated human listeriosis in England and Wales, 2001 to 2007. J Clin Microbiol. 2009;47(10):3301–7.PubMedPubMedCentralCrossRef
170.
Zurück zum Zitat Kasper S, Huhulescu S, Auer B, Heller I, Karner F, Wurzner R, et al. Epidemiology of listeriosis in Austria. Wien Klin Wochenschr. 2009;121(3–4):113–9.PubMedCrossRef Kasper S, Huhulescu S, Auer B, Heller I, Karner F, Wurzner R, et al. Epidemiology of listeriosis in Austria. Wien Klin Wochenschr. 2009;121(3–4):113–9.PubMedCrossRef
171.
Zurück zum Zitat Gerner-Smidt P, Ethelberg S, Schiellerup P, Christensen JJ, Engberg J, Fussing V, et al. Invasive listeriosis in Denmark 1994–2003: a review of 299 cases with special emphasis on risk factors for mortality. Clin Microbiol Infect. 2005;11(8):618–24.PubMedCrossRef Gerner-Smidt P, Ethelberg S, Schiellerup P, Christensen JJ, Engberg J, Fussing V, et al. Invasive listeriosis in Denmark 1994–2003: a review of 299 cases with special emphasis on risk factors for mortality. Clin Microbiol Infect. 2005;11(8):618–24.PubMedCrossRef
172.
Zurück zum Zitat Preussel K, Milde-Busch A, Schmich P, Wetzstein M, Stark K, Werber D. Risk factors for sporadic non-pregnancy associated listeriosis in Germany-immunocompromised patients and frequently consumed ready-to-eat products. PLoS One. 2015;10(11):e0142986.PubMedPubMedCentralCrossRef Preussel K, Milde-Busch A, Schmich P, Wetzstein M, Stark K, Werber D. Risk factors for sporadic non-pregnancy associated listeriosis in Germany-immunocompromised patients and frequently consumed ready-to-eat products. PLoS One. 2015;10(11):e0142986.PubMedPubMedCentralCrossRef
173.
Zurück zum Zitat Huang YT, Ko WC, Chan YJ, Lu JJ, Tsai HY, Liao CH, et al. Disease burden of invasive listeriosis and molecular characterization of clinical isolates in Taiwan, 2000–2013. PLoS One. 2015;10(11):e0141241.PubMedPubMedCentralCrossRef Huang YT, Ko WC, Chan YJ, Lu JJ, Tsai HY, Liao CH, et al. Disease burden of invasive listeriosis and molecular characterization of clinical isolates in Taiwan, 2000–2013. PLoS One. 2015;10(11):e0141241.PubMedPubMedCentralCrossRef
174.
Zurück zum Zitat Ho JL, Shands KN, Friedland G, Eckind P, Fraser DW. An outbreak of type 4b Listeria monocytogenes infection involving patients from eight Boston hospitals. Arch Intern Med. 1986;146(3):520–4.PubMedCrossRef Ho JL, Shands KN, Friedland G, Eckind P, Fraser DW. An outbreak of type 4b Listeria monocytogenes infection involving patients from eight Boston hospitals. Arch Intern Med. 1986;146(3):520–4.PubMedCrossRef
175.
Zurück zum Zitat Kader SA, Mansour AM, Mohran Z, el-Taoil A, Abdalla KF. A study on the relation between proton pump inhibitor and gastric giardiasis. J Egypt Soc Parasitol. 1998;28(1):149–57.PubMed Kader SA, Mansour AM, Mohran Z, el-Taoil A, Abdalla KF. A study on the relation between proton pump inhibitor and gastric giardiasis. J Egypt Soc Parasitol. 1998;28(1):149–57.PubMed
176.
Zurück zum Zitat Cobb CA, Curtis GD, Bansi DS, Slade E, Mehal W, Mitchell RG, et al. Increased prevalence of Listeria monocytogenes in the faeces of patients receiving long-term H2-antagonists. Eur J Gastroenterol Hepatol. 1996;8(11):1071–4.PubMedCrossRef Cobb CA, Curtis GD, Bansi DS, Slade E, Mehal W, Mitchell RG, et al. Increased prevalence of Listeria monocytogenes in the faeces of patients receiving long-term H2-antagonists. Eur J Gastroenterol Hepatol. 1996;8(11):1071–4.PubMedCrossRef
177.
Zurück zum Zitat Schlech WF 3rd, Chase DP, Badley A. A model of food-borne Listeria monocytogenes infection in the Sprague–Dawley rat using gastric inoculation: development and effect of gastric acidity on infective dose. Int J Food Microbiol. 1993;18(1):15–24.PubMedCrossRef Schlech WF 3rd, Chase DP, Badley A. A model of food-borne Listeria monocytogenes infection in the Sprague–Dawley rat using gastric inoculation: development and effect of gastric acidity on infective dose. Int J Food Microbiol. 1993;18(1):15–24.PubMedCrossRef
178.
Zurück zum Zitat Ferreira A, Sue D, O’Byrne CP, Boor KJ. Role of Listeria monocytogenes sigma(B) in survival of lethal acidic conditions and in the acquired acid tolerance response. Appl Environ Microbiol. 2003;69(5):2692–8.PubMedPubMedCentralCrossRef Ferreira A, Sue D, O’Byrne CP, Boor KJ. Role of Listeria monocytogenes sigma(B) in survival of lethal acidic conditions and in the acquired acid tolerance response. Appl Environ Microbiol. 2003;69(5):2692–8.PubMedPubMedCentralCrossRef
179.
Zurück zum Zitat Sleator RD, Watson D, Hill C, Gahan CG. The interaction between Listeria monocytogenes and the host gastrointestinal tract. Microbiology. 2009;155(Pt 8):2463–75.PubMedCrossRef Sleator RD, Watson D, Hill C, Gahan CG. The interaction between Listeria monocytogenes and the host gastrointestinal tract. Microbiology. 2009;155(Pt 8):2463–75.PubMedCrossRef
180.
181.
Zurück zum Zitat Smith JL, Liu Y, Paoli GC. How does Listeria monocytogenes combat acid conditions? Can J Microbiol. 2013;59(3):141–52.PubMedCrossRef Smith JL, Liu Y, Paoli GC. How does Listeria monocytogenes combat acid conditions? Can J Microbiol. 2013;59(3):141–52.PubMedCrossRef
182.
Zurück zum Zitat Cristiano P, Paradisi F. Can cimetidine facilitate infections by oral route. Lancet. 1982;2(8288):45.PubMedCrossRef Cristiano P, Paradisi F. Can cimetidine facilitate infections by oral route. Lancet. 1982;2(8288):45.PubMedCrossRef
183.
Zurück zum Zitat Steffen R. Antacids—a risk factor in travellers brucellosis? Scand J Infect Dis. 1977;9(4):311–2.PubMedCrossRef Steffen R. Antacids—a risk factor in travellers brucellosis? Scand J Infect Dis. 1977;9(4):311–2.PubMedCrossRef
184.
Zurück zum Zitat Antacids and brucellosis. Br Med J. 1978;1(6115):739–40. Antacids and brucellosis. Br Med J. 1978;1(6115):739–40.
185.
Zurück zum Zitat Osband ME, Cohen EB, Miller BR, Shen YJ, Cohen L, Flescher L, et al. Biochemical analysis of specific histamine HI and H2 receptors on lymphocytes. Blood. 1981;58(1):87–90.PubMed Osband ME, Cohen EB, Miller BR, Shen YJ, Cohen L, Flescher L, et al. Biochemical analysis of specific histamine HI and H2 receptors on lymphocytes. Blood. 1981;58(1):87–90.PubMed
187.
Zurück zum Zitat Fakir M, Saison C, Wong T, Matta B, Hardin JM. Septicemia due to Yersinia enterocolitica in a hemodialyzed, iron-depleted patient receiving omeprazole and oral iron supplementation. Am J Kidney Dis. 1992;19(3):282–4.PubMedCrossRef Fakir M, Saison C, Wong T, Matta B, Hardin JM. Septicemia due to Yersinia enterocolitica in a hemodialyzed, iron-depleted patient receiving omeprazole and oral iron supplementation. Am J Kidney Dis. 1992;19(3):282–4.PubMedCrossRef
188.
Zurück zum Zitat Peterson WL, Mackowiak PA, Barnett CC, Marling-Cason M, Haley ML. The human gastric bactericidal barrier: mechanisms of action, relative antibacterial activity, and dietary influences. J Infect Dis. 1989;159(5):979–83.PubMedCrossRef Peterson WL, Mackowiak PA, Barnett CC, Marling-Cason M, Haley ML. The human gastric bactericidal barrier: mechanisms of action, relative antibacterial activity, and dietary influences. J Infect Dis. 1989;159(5):979–83.PubMedCrossRef
189.
Zurück zum Zitat Evans CA, Gilman RH, Rabbani GH, Salazar G, Ali A. Gastric acid secretion and enteric infection in Bangladesh. Trans R Soc Trop Med Hyg. 1997;91(6):681–5.PubMedPubMedCentralCrossRef Evans CA, Gilman RH, Rabbani GH, Salazar G, Ali A. Gastric acid secretion and enteric infection in Bangladesh. Trans R Soc Trop Med Hyg. 1997;91(6):681–5.PubMedPubMedCentralCrossRef
190.
Zurück zum Zitat DuPont HL, Hornick RB, Snyder MJ, Libonati JP, Formal SB, Gangarosa EJ. Immunity in shigellosis. I. Response of man to attenuated strains of Shigella. J Infect Dis. 1972;125(1):5–11.PubMedCrossRef DuPont HL, Hornick RB, Snyder MJ, Libonati JP, Formal SB, Gangarosa EJ. Immunity in shigellosis. I. Response of man to attenuated strains of Shigella. J Infect Dis. 1972;125(1):5–11.PubMedCrossRef
191.
Zurück zum Zitat Ruddell WS, Axon AT, Findlay JM, Bartholomew BA, Hill MJ. Effect of cimetidine on the gastric bacterial flora. Lancet. 1980;1(8170):672–4.PubMedCrossRef Ruddell WS, Axon AT, Findlay JM, Bartholomew BA, Hill MJ. Effect of cimetidine on the gastric bacterial flora. Lancet. 1980;1(8170):672–4.PubMedCrossRef
192.
Zurück zum Zitat Muscroft TJ, Keighley MR. Cimetidine, gastric pH, and nitrosation. Lancet. 1981;1(8227):1002.PubMedCrossRef Muscroft TJ, Keighley MR. Cimetidine, gastric pH, and nitrosation. Lancet. 1981;1(8227):1002.PubMedCrossRef
193.
Zurück zum Zitat Reed PI, Haines K, Smith PL, Walters CL, House FR. Intragastric acidity, bacteria, nitrite, and N-nitroso compounds before, during, and after cimetidine treatment. Lancet. 1982;2(8288):39.PubMedCrossRef Reed PI, Haines K, Smith PL, Walters CL, House FR. Intragastric acidity, bacteria, nitrite, and N-nitroso compounds before, during, and after cimetidine treatment. Lancet. 1982;2(8288):39.PubMedCrossRef
194.
Zurück zum Zitat Stockbrugger RW, Cotton PB, Eugenides N, Bartholomew BA, Hill MJ, Walters CL. Intragastric nitrites, nitrosamines, and bacterial overgrowth during cimetidine treatment. Gut. 1982;23(12):1048–54.PubMedPubMedCentralCrossRef Stockbrugger RW, Cotton PB, Eugenides N, Bartholomew BA, Hill MJ, Walters CL. Intragastric nitrites, nitrosamines, and bacterial overgrowth during cimetidine treatment. Gut. 1982;23(12):1048–54.PubMedPubMedCentralCrossRef
195.
Zurück zum Zitat Stockbruegger RW. Bacterial overgrowth as a consequence of reduced gastric acidity. Scand J Gastroenterol Suppl. 1985;111:7–16.PubMedCrossRef Stockbruegger RW. Bacterial overgrowth as a consequence of reduced gastric acidity. Scand J Gastroenterol Suppl. 1985;111:7–16.PubMedCrossRef
196.
Zurück zum Zitat Sharma BK, Santana IA, Wood EC, Walt RP, Pereira M, Noone P, et al. Intragastric bacterial activity and nitrosation before, during, and after treatment with omeprazole. Br Med J (Clin Res Ed). 1984;289(6447):717–9.CrossRef Sharma BK, Santana IA, Wood EC, Walt RP, Pereira M, Noone P, et al. Intragastric bacterial activity and nitrosation before, during, and after treatment with omeprazole. Br Med J (Clin Res Ed). 1984;289(6447):717–9.CrossRef
197.
Zurück zum Zitat Verdu E, Viani F, Armstrong D, Fraser R, Siegrist HH, Pignatelli B, et al. Effect of omeprazole on intragastric bacterial counts, nitrates, nitrites, and N-nitroso compounds. Gut. 1994;35(4):455–60.PubMedPubMedCentralCrossRef Verdu E, Viani F, Armstrong D, Fraser R, Siegrist HH, Pignatelli B, et al. Effect of omeprazole on intragastric bacterial counts, nitrates, nitrites, and N-nitroso compounds. Gut. 1994;35(4):455–60.PubMedPubMedCentralCrossRef
198.
Zurück zum Zitat Theisen J, Nehra D, Citron D, Johansson J, Hagen JA, Crookes PF, et al. Suppression of gastric acid secretion in patients with gastroesophageal reflux disease results in gastric bacterial overgrowth and deconjugation of bile acids. J Gastrointest Surg. 2000;4(1):50–4.PubMedCrossRef Theisen J, Nehra D, Citron D, Johansson J, Hagen JA, Crookes PF, et al. Suppression of gastric acid secretion in patients with gastroesophageal reflux disease results in gastric bacterial overgrowth and deconjugation of bile acids. J Gastrointest Surg. 2000;4(1):50–4.PubMedCrossRef
199.
Zurück zum Zitat Williams C. Occurrence and significance of gastric colonization during acid-inhibitory therapy. Best Pract Res Clin Gastroenterol. 2001;15(3):511–21.PubMedCrossRef Williams C. Occurrence and significance of gastric colonization during acid-inhibitory therapy. Best Pract Res Clin Gastroenterol. 2001;15(3):511–21.PubMedCrossRef
200.
Zurück zum Zitat Sanduleanu S, Jonkers D, De Bruine A, Hameeteman W, Stockbrugger RW. Non-Helicobacter pylori bacterial flora during acid-suppressive therapy: differential findings in gastric juice and gastric mucosa. Aliment Pharmacol Ther. 2001;15(3):379–88.PubMedCrossRef Sanduleanu S, Jonkers D, De Bruine A, Hameeteman W, Stockbrugger RW. Non-Helicobacter pylori bacterial flora during acid-suppressive therapy: differential findings in gastric juice and gastric mucosa. Aliment Pharmacol Ther. 2001;15(3):379–88.PubMedCrossRef
201.
Zurück zum Zitat Gray JD, Shiner M. Influence of gastric pH on gastric and jejunal flora. Gut. 1967;8(6):574–81.PubMedCrossRef Gray JD, Shiner M. Influence of gastric pH on gastric and jejunal flora. Gut. 1967;8(6):574–81.PubMedCrossRef
202.
Zurück zum Zitat Shindo K, Machida M, Koide K, Fukumura M, Yamazaki R. Deconjugation ability of bacteria isolated from the jejunal fluid of patients with progressive systemic sclerosis and its gastric pH. Hepatogastroenterology. 1998;45(23):1643–50.PubMed Shindo K, Machida M, Koide K, Fukumura M, Yamazaki R. Deconjugation ability of bacteria isolated from the jejunal fluid of patients with progressive systemic sclerosis and its gastric pH. Hepatogastroenterology. 1998;45(23):1643–50.PubMed
203.
Zurück zum Zitat Nehra D, Howell P, Williams CP, Pye JK, Beynon J. Toxic bile acids in gastro-oesophageal reflux disease: influence of gastric acidity. Gut. 1999;44(5):598–602.PubMedPubMedCentralCrossRef Nehra D, Howell P, Williams CP, Pye JK, Beynon J. Toxic bile acids in gastro-oesophageal reflux disease: influence of gastric acidity. Gut. 1999;44(5):598–602.PubMedPubMedCentralCrossRef
204.
Zurück zum Zitat Mowat C, Williams C, Gillen D, Hossack M, Gilmour D, Carswell A, et al. Omeprazole, Helicobacter pylori status, and alterations in the intragastric milieu facilitating bacterial N-nitrosation. Gastroenterology. 2000;119(2):339–47.PubMedCrossRef Mowat C, Williams C, Gillen D, Hossack M, Gilmour D, Carswell A, et al. Omeprazole, Helicobacter pylori status, and alterations in the intragastric milieu facilitating bacterial N-nitrosation. Gastroenterology. 2000;119(2):339–47.PubMedCrossRef
205.
Zurück zum Zitat Sanduleanu S, Jonkers D, De Bruine A, Hameeteman W, Stockbrugger RW. Double gastric infection with Helicobacter pylori and non-Helicobacter pylori bacteria during acid-suppressive therapy: increase of pro-inflammatory cytokines and development of atrophic gastritis. Aliment Pharmacol Ther. 2001;15(8):1163–75.PubMedCrossRef Sanduleanu S, Jonkers D, De Bruine A, Hameeteman W, Stockbrugger RW. Double gastric infection with Helicobacter pylori and non-Helicobacter pylori bacteria during acid-suppressive therapy: increase of pro-inflammatory cytokines and development of atrophic gastritis. Aliment Pharmacol Ther. 2001;15(8):1163–75.PubMedCrossRef
206.
Zurück zum Zitat Milton-Thompson GJ, Lightfoot NF, Ahmet Z, Hunt RH, Barnard J, Bavin PM, et al. Intragastric acidity, bacteria, nitrite, and N-nitroso compounds before, during, and after cimetidine treatment. Lancet. 1982;1(8281):1091–5.PubMedCrossRef Milton-Thompson GJ, Lightfoot NF, Ahmet Z, Hunt RH, Barnard J, Bavin PM, et al. Intragastric acidity, bacteria, nitrite, and N-nitroso compounds before, during, and after cimetidine treatment. Lancet. 1982;1(8281):1091–5.PubMedCrossRef
207.
Zurück zum Zitat Viani F, Siegrist HH, Pignatelli B, Cederberg C, Idstrom JP, Verdu EF, et al. The effect of intra-gastric acidity and flora on the concentration of N-nitroso compounds in the stomach. Eur J Gastroenterol Hepatol. 2000;12(2):165–73.PubMedCrossRef Viani F, Siegrist HH, Pignatelli B, Cederberg C, Idstrom JP, Verdu EF, et al. The effect of intra-gastric acidity and flora on the concentration of N-nitroso compounds in the stomach. Eur J Gastroenterol Hepatol. 2000;12(2):165–73.PubMedCrossRef
208.
Zurück zum Zitat Pereira SP, Gainsborough N, Dowling RH. Drug-induced hypochlorhydria causes high duodenal bacterial counts in the elderly. Aliment Pharmacol Ther. 1998;12(1):99–104.PubMedCrossRef Pereira SP, Gainsborough N, Dowling RH. Drug-induced hypochlorhydria causes high duodenal bacterial counts in the elderly. Aliment Pharmacol Ther. 1998;12(1):99–104.PubMedCrossRef
209.
Zurück zum Zitat Bauer TM, Steinbruckner B, Brinkmann FE, Ditzen AK, Schwacha H, Aponte JJ, et al. Small intestinal bacterial overgrowth in patients with cirrhosis: prevalence and relation with spontaneous bacterial peritonitis. Am J Gastroenterol. 2001;96(10):2962–7.PubMedCrossRef Bauer TM, Steinbruckner B, Brinkmann FE, Ditzen AK, Schwacha H, Aponte JJ, et al. Small intestinal bacterial overgrowth in patients with cirrhosis: prevalence and relation with spontaneous bacterial peritonitis. Am J Gastroenterol. 2001;96(10):2962–7.PubMedCrossRef
210.
Zurück zum Zitat Fried M, Siegrist H, Frei R, Froehlich F, Duroux P, Thorens J, et al. Duodenal bacterial overgrowth during treatment in outpatients with omeprazole. Gut. 1994;35(1):23–6.PubMedPubMedCentralCrossRef Fried M, Siegrist H, Frei R, Froehlich F, Duroux P, Thorens J, et al. Duodenal bacterial overgrowth during treatment in outpatients with omeprazole. Gut. 1994;35(1):23–6.PubMedPubMedCentralCrossRef
211.
Zurück zum Zitat Saltzman JR, Kowdley KV, Pedrosa MC, Sepe T, Golner B, Perrone G, et al. Bacterial overgrowth without clinical malabsorption in elderly hypochlorhydric subjects. Gastroenterology. 1994;106(3):615–23.PubMedCrossRef Saltzman JR, Kowdley KV, Pedrosa MC, Sepe T, Golner B, Perrone G, et al. Bacterial overgrowth without clinical malabsorption in elderly hypochlorhydric subjects. Gastroenterology. 1994;106(3):615–23.PubMedCrossRef
212.
Zurück zum Zitat Gough A, Andrews D, Bacon PA, Emery P. Evidence of omeprazole-induced small bowel bacterial overgrowth in patients with scleroderma. Br J Rheumatol. 1995;34(10):976–7.PubMedCrossRef Gough A, Andrews D, Bacon PA, Emery P. Evidence of omeprazole-induced small bowel bacterial overgrowth in patients with scleroderma. Br J Rheumatol. 1995;34(10):976–7.PubMedCrossRef
213.
Zurück zum Zitat Lewis SJ, Franco S, Young G, O’Keefe SJ. Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole. Aliment Pharmacol Ther. 1996;10(4):557–61.PubMedCrossRef Lewis SJ, Franco S, Young G, O’Keefe SJ. Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole. Aliment Pharmacol Ther. 1996;10(4):557–61.PubMedCrossRef
214.
Zurück zum Zitat Dukowicz AC, Lacy BE, Levine GM. Small intestinal bacterial overgrowth: a comprehensive review. Gastroenterol Hepatol (N Y). 2007;3(2):112–22. Dukowicz AC, Lacy BE, Levine GM. Small intestinal bacterial overgrowth: a comprehensive review. Gastroenterol Hepatol (N Y). 2007;3(2):112–22.
215.
Zurück zum Zitat Lombardo L, Foti M, Ruggia O, Chiecchio A. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol. 2010;8(6):504–8.PubMedCrossRef Lombardo L, Foti M, Ruggia O, Chiecchio A. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol. 2010;8(6):504–8.PubMedCrossRef
216.
Zurück zum Zitat van Vlerken LG, Huisman EJ, van Hoek B, Renooij W, de Rooij FW, Siersema PD, et al. Bacterial infections in cirrhosis: role of proton pump inhibitors and intestinal permeability. Eur J Clin Invest. 2012;42(7):760–7.PubMedCrossRef van Vlerken LG, Huisman EJ, van Hoek B, Renooij W, de Rooij FW, Siersema PD, et al. Bacterial infections in cirrhosis: role of proton pump inhibitors and intestinal permeability. Eur J Clin Invest. 2012;42(7):760–7.PubMedCrossRef
217.
Zurück zum Zitat Jacobs C, Coss Adame E, Attaluri A, Valestin J, Rao SS. Dysmotility and proton pump inhibitor use are independent risk factors for small intestinal bacterial and/or fungal overgrowth. Aliment Pharmacol Ther. 2013;37(11):1103–11.PubMedPubMedCentralCrossRef Jacobs C, Coss Adame E, Attaluri A, Valestin J, Rao SS. Dysmotility and proton pump inhibitor use are independent risk factors for small intestinal bacterial and/or fungal overgrowth. Aliment Pharmacol Ther. 2013;37(11):1103–11.PubMedPubMedCentralCrossRef
218.
Zurück zum Zitat Freedberg DE, Lebwohl B, Abrams JA. The impact of proton pump inhibitors on the human gastrointestinal microbiome. Clin Lab Med. 2014;34(4):771–85.PubMedPubMedCentralCrossRef Freedberg DE, Lebwohl B, Abrams JA. The impact of proton pump inhibitors on the human gastrointestinal microbiome. Clin Lab Med. 2014;34(4):771–85.PubMedPubMedCentralCrossRef
219.
Zurück zum Zitat Franco DL, Disbrow MB, Kahn A, Koepke LM, Harris LA, Harrison ME, et al. Duodenal aspirates for small intestine bacterial overgrowth: yield, PPIs, and outcomes after treatment at a tertiary academic medical center. Gastroenterol Res Pract. 2015;2015:971582.PubMedPubMedCentralCrossRef Franco DL, Disbrow MB, Kahn A, Koepke LM, Harris LA, Harrison ME, et al. Duodenal aspirates for small intestine bacterial overgrowth: yield, PPIs, and outcomes after treatment at a tertiary academic medical center. Gastroenterol Res Pract. 2015;2015:971582.PubMedPubMedCentralCrossRef
220.
Zurück zum Zitat Spiegel BM, Chey WD, Chang L. Bacterial overgrowth and irritable bowel syndrome: unifying hypothesis or a spurious consequence of proton pump inhibitors? Am J Gastroenterol. 2008;103(12):2972–6.PubMedPubMedCentralCrossRef Spiegel BM, Chey WD, Chang L. Bacterial overgrowth and irritable bowel syndrome: unifying hypothesis or a spurious consequence of proton pump inhibitors? Am J Gastroenterol. 2008;103(12):2972–6.PubMedPubMedCentralCrossRef
221.
Zurück zum Zitat Altman KW, Chhaya V, Hammer ND, Pavlova S, Vesper BJ, Tao L, et al. Effect of proton pump inhibitor pantoprazole on growth and morphology of oral Lactobacillus strains. Laryngoscope. 2008;118(4):599–604.PubMedCrossRef Altman KW, Chhaya V, Hammer ND, Pavlova S, Vesper BJ, Tao L, et al. Effect of proton pump inhibitor pantoprazole on growth and morphology of oral Lactobacillus strains. Laryngoscope. 2008;118(4):599–604.PubMedCrossRef
222.
Zurück zum Zitat Lo WK, Chan WW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol. 2013;11(5):483–90.PubMedCrossRef Lo WK, Chan WW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol. 2013;11(5):483–90.PubMedCrossRef
223.
Zurück zum Zitat Thorens J, Froehlich F, Schwizer W, Saraga E, Bille J, Gyr K, et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut. 1996;39(1):54–9.PubMedPubMedCentralCrossRef Thorens J, Froehlich F, Schwizer W, Saraga E, Bille J, Gyr K, et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut. 1996;39(1):54–9.PubMedPubMedCentralCrossRef
224.
Zurück zum Zitat Iivonen MK, Ahola TO, Matikainen MJ. Bacterial overgrowth, intestinal transit, and nutrition after total gastrectomy. Comparison of a jejunal pouch with Roux-en-Y reconstruction in a prospective random study. Scand J Gastroenterol. 1998;33(1):63–70.PubMedCrossRef Iivonen MK, Ahola TO, Matikainen MJ. Bacterial overgrowth, intestinal transit, and nutrition after total gastrectomy. Comparison of a jejunal pouch with Roux-en-Y reconstruction in a prospective random study. Scand J Gastroenterol. 1998;33(1):63–70.PubMedCrossRef
225.
Zurück zum Zitat Paik CN, Choi MG, Lim CH, Park JM, Chung WC, Lee KM, et al. The role of small intestinal bacterial overgrowth in postgastrectomy patients. Neurogastroenterol Motil. 2011;23(5):e191–6.PubMedCrossRef Paik CN, Choi MG, Lim CH, Park JM, Chung WC, Lee KM, et al. The role of small intestinal bacterial overgrowth in postgastrectomy patients. Neurogastroenterol Motil. 2011;23(5):e191–6.PubMedCrossRef
226.
Zurück zum Zitat Schiller LR. Evaluation of small bowel bacterial overgrowth. Curr Gastroenterol Rep. 2007;9(5):373–7.PubMedCrossRef Schiller LR. Evaluation of small bowel bacterial overgrowth. Curr Gastroenterol Rep. 2007;9(5):373–7.PubMedCrossRef
227.
Zurück zum Zitat Corazza GR, Menozzi MG, Strocchi A, Rasciti L, Vaira D, Lecchini R, et al. The diagnosis of small bowel bacterial overgrowth. Reliability of jejunal culture and inadequacy of breath hydrogen testing. Gastroenterology. 1990;98(2):302–9.PubMedCrossRef Corazza GR, Menozzi MG, Strocchi A, Rasciti L, Vaira D, Lecchini R, et al. The diagnosis of small bowel bacterial overgrowth. Reliability of jejunal culture and inadequacy of breath hydrogen testing. Gastroenterology. 1990;98(2):302–9.PubMedCrossRef
228.
Zurück zum Zitat Ratuapli SK, Ellington TG, O’Neill MT, Umar SB, Harris LA, Foxx-Orenstein AE, et al. Proton pump inhibitor therapy use does not predispose to small intestinal bacterial overgrowth. Am J Gastroenterol. 2012;107(5):730–5.PubMedCrossRef Ratuapli SK, Ellington TG, O’Neill MT, Umar SB, Harris LA, Foxx-Orenstein AE, et al. Proton pump inhibitor therapy use does not predispose to small intestinal bacterial overgrowth. Am J Gastroenterol. 2012;107(5):730–5.PubMedCrossRef
229.
Zurück zum Zitat Schatz RA, Zhang Q, Lodhia N, Shuster J, Toskes PP, Moshiree B. Predisposing factors for positive d-xylose breath test for evaluation of small intestinal bacterial overgrowth: a retrospective study of 932 patients. World J Gastroenterol. 2015;21(15):4574–82.PubMedPubMedCentral Schatz RA, Zhang Q, Lodhia N, Shuster J, Toskes PP, Moshiree B. Predisposing factors for positive d-xylose breath test for evaluation of small intestinal bacterial overgrowth: a retrospective study of 932 patients. World J Gastroenterol. 2015;21(15):4574–82.PubMedPubMedCentral
230.
Zurück zum Zitat Fujiwara Y, Watanabe T, Muraki M, Yamagami H, Tanigawa T, Shiba M, et al. Association between chronic use of proton pump inhibitors and small-intestinal bacterial overgrowth assessed using lactulose hydrogen breath tests. Hepatogastroenterology. 2015;62(138):268–72.PubMed Fujiwara Y, Watanabe T, Muraki M, Yamagami H, Tanigawa T, Shiba M, et al. Association between chronic use of proton pump inhibitors and small-intestinal bacterial overgrowth assessed using lactulose hydrogen breath tests. Hepatogastroenterology. 2015;62(138):268–72.PubMed
231.
Zurück zum Zitat Brechmann T, Sperlbaum A, Schmiegel W. Levothyroxine therapy and impaired clearance are the strongest contributors to small intestinal bacterial overgrowth: results of a retrospective cohort study. World J Gastroenterol. 2017;23(5):842–52.PubMedPubMedCentralCrossRef Brechmann T, Sperlbaum A, Schmiegel W. Levothyroxine therapy and impaired clearance are the strongest contributors to small intestinal bacterial overgrowth: results of a retrospective cohort study. World J Gastroenterol. 2017;23(5):842–52.PubMedPubMedCentralCrossRef
232.
Zurück zum Zitat Cares K, Al-Ansari N, Macha S, Zoubi N, Zaghloul H, Thomas R, et al. Risk of small intestinal bacterial overgrowth with chronic use of proton pump inhibitors in children. Eur J Gastroenterol Hepatol. 2017;29(4):396–9.PubMedCrossRef Cares K, Al-Ansari N, Macha S, Zoubi N, Zaghloul H, Thomas R, et al. Risk of small intestinal bacterial overgrowth with chronic use of proton pump inhibitors in children. Eur J Gastroenterol Hepatol. 2017;29(4):396–9.PubMedCrossRef
233.
Zurück zum Zitat Bohm M, Siwiec RM, Wo JM. Diagnosis and management of small intestinal bacterial overgrowth. Nutr Clin Pract. 2013;28(3):289–99.PubMedCrossRef Bohm M, Siwiec RM, Wo JM. Diagnosis and management of small intestinal bacterial overgrowth. Nutr Clin Pract. 2013;28(3):289–99.PubMedCrossRef
234.
Zurück zum Zitat Tilg H, Shapiro L, Vannier E, Poutsiaka DD, Trehu E, Atkins MB, et al. Induction of circulating antagonists to IL-1 and TNF by IL-2 administration and their effects on IL-2 induced cytokine production in vitro. J Immunol. 1994;152(6):3189–98.PubMed Tilg H, Shapiro L, Vannier E, Poutsiaka DD, Trehu E, Atkins MB, et al. Induction of circulating antagonists to IL-1 and TNF by IL-2 administration and their effects on IL-2 induced cytokine production in vitro. J Immunol. 1994;152(6):3189–98.PubMed
235.
Zurück zum Zitat Wong VW, Tse CH, Lam TT, Wong GL, Chim AM, Chu WC, et al. Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis—a longitudinal study. PLoS One. 2013;8(4):e62885.PubMedPubMedCentralCrossRef Wong VW, Tse CH, Lam TT, Wong GL, Chim AM, Chu WC, et al. Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis—a longitudinal study. PLoS One. 2013;8(4):e62885.PubMedPubMedCentralCrossRef
236.
Zurück zum Zitat Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012;482(7384):179–85.PubMedPubMedCentral Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012;482(7384):179–85.PubMedPubMedCentral
237.
Zurück zum Zitat Strid H, Simren M, Stotzer PO, Ringstrom G, Abrahamsson H, Bjornsson ES. Patients with chronic renal failure have abnormal small intestinal motility and a high prevalence of small intestinal bacterial overgrowth. Digestion. 2003;67(3):129–37.PubMedCrossRef Strid H, Simren M, Stotzer PO, Ringstrom G, Abrahamsson H, Bjornsson ES. Patients with chronic renal failure have abnormal small intestinal motility and a high prevalence of small intestinal bacterial overgrowth. Digestion. 2003;67(3):129–37.PubMedCrossRef
239.
Zurück zum Zitat McLean MH, Dieguez D Jr, Miller LM, Young HA. Does the microbiota play a role in the pathogenesis of autoimmune diseases? Gut. 2015;64(2):332–41.PubMedCrossRef McLean MH, Dieguez D Jr, Miller LM, Young HA. Does the microbiota play a role in the pathogenesis of autoimmune diseases? Gut. 2015;64(2):332–41.PubMedCrossRef
240.
Zurück zum Zitat Vanner S. The small intestinal bacterial overgrowth. Irritable bowel syndrome hypothesis: implications for treatment. Gut. 2008;57(9):1315–21.PubMedCrossRef Vanner S. The small intestinal bacterial overgrowth. Irritable bowel syndrome hypothesis: implications for treatment. Gut. 2008;57(9):1315–21.PubMedCrossRef
241.
Zurück zum Zitat Carrara M, Desideri S, Azzurro M, Bulighin GM, Di Piramo D, Lomonaco L, et al. Small intestine bacterial overgrowth in patients with irritable bowel syndrome. Eur Rev Med Pharmacol Sci. 2008;12(3):197–202.PubMed Carrara M, Desideri S, Azzurro M, Bulighin GM, Di Piramo D, Lomonaco L, et al. Small intestine bacterial overgrowth in patients with irritable bowel syndrome. Eur Rev Med Pharmacol Sci. 2008;12(3):197–202.PubMed
242.
Zurück zum Zitat Andalib I, Shah H, Bal BS, Shope TR, Finelli FC, Koch TR. Breath hydrogen as a biomarker for glucose malabsorption after Roux-en-Y gastric bypass surgery. Dis Markers. 2015;2015:102760.PubMedPubMedCentralCrossRef Andalib I, Shah H, Bal BS, Shope TR, Finelli FC, Koch TR. Breath hydrogen as a biomarker for glucose malabsorption after Roux-en-Y gastric bypass surgery. Dis Markers. 2015;2015:102760.PubMedPubMedCentralCrossRef
243.
Zurück zum Zitat Sung HJ, Paik CN, Chung WC, Lee KM, Yang JM, Choi MG. Small intestinal bacterial overgrowth diagnosed by glucose hydrogen breath test in post-cholecystectomy patients. J Neurogastroenterol Motil. 2015;21(4):545–51.PubMedPubMedCentralCrossRef Sung HJ, Paik CN, Chung WC, Lee KM, Yang JM, Choi MG. Small intestinal bacterial overgrowth diagnosed by glucose hydrogen breath test in post-cholecystectomy patients. J Neurogastroenterol Motil. 2015;21(4):545–51.PubMedPubMedCentralCrossRef
244.
Zurück zum Zitat Capurso G, Signoretti M, Archibugi L, Stigliano S, Delle Fave G. Systematic review and meta-analysis: small intestinal bacterial overgrowth in chronic pancreatitis. United Eur Gastroenterol J. 2016;4(5):697–705.CrossRef Capurso G, Signoretti M, Archibugi L, Stigliano S, Delle Fave G. Systematic review and meta-analysis: small intestinal bacterial overgrowth in chronic pancreatitis. United Eur Gastroenterol J. 2016;4(5):697–705.CrossRef
245.
Zurück zum Zitat Therrien A, Bouchard S, Sidani S, Bouin M. Prevalence of small intestinal bacterial overgrowth among chronic pancreatitis patients: a case–control study. Can J Gastroenterol Hepatol. 2016;2016:7424831.PubMedPubMedCentral Therrien A, Bouchard S, Sidani S, Bouin M. Prevalence of small intestinal bacterial overgrowth among chronic pancreatitis patients: a case–control study. Can J Gastroenterol Hepatol. 2016;2016:7424831.PubMedPubMedCentral
246.
Zurück zum Zitat Lutz P, Nischalke HD, Strassburg CP, Spengler U. Spontaneous bacterial peritonitis: the clinical challenge of a leaky gut and a cirrhotic liver. World J Hepatol. 2015;7(3):304–14.PubMedPubMedCentralCrossRef Lutz P, Nischalke HD, Strassburg CP, Spengler U. Spontaneous bacterial peritonitis: the clinical challenge of a leaky gut and a cirrhotic liver. World J Hepatol. 2015;7(3):304–14.PubMedPubMedCentralCrossRef
247.
Zurück zum Zitat Bunchorntavakul C, Chamroonkul N, Chavalitdhamrong D. Bacterial infections in cirrhosis: a critical review and practical guidance. World J Hepatol. 2016;8(6):307–21.PubMedPubMedCentralCrossRef Bunchorntavakul C, Chamroonkul N, Chavalitdhamrong D. Bacterial infections in cirrhosis: a critical review and practical guidance. World J Hepatol. 2016;8(6):307–21.PubMedPubMedCentralCrossRef
248.
Zurück zum Zitat Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis. 2008;28(1):26–42.PubMedCrossRef Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis. 2008;28(1):26–42.PubMedCrossRef
249.
Zurück zum Zitat Fernandez J, Gustot T. Management of bacterial infections in cirrhosis. J Hepatol. 2012;56(Suppl 1):S1–12.PubMedCrossRef Fernandez J, Gustot T. Management of bacterial infections in cirrhosis. J Hepatol. 2012;56(Suppl 1):S1–12.PubMedCrossRef
250.
Zurück zum Zitat Luo JC, Leu HB, Hou MC, Huang CC, Lin HC, Lee FY, et al. Cirrhotic patients at increased risk of peptic ulcer bleeding: a nationwide population-based cohort study. Aliment Pharmacol Ther. 2012;36(6):542–50.PubMedCrossRef Luo JC, Leu HB, Hou MC, Huang CC, Lin HC, Lee FY, et al. Cirrhotic patients at increased risk of peptic ulcer bleeding: a nationwide population-based cohort study. Aliment Pharmacol Ther. 2012;36(6):542–50.PubMedCrossRef
251.
Zurück zum Zitat Kuo MT, Yang SC, Lu LS, Hsu CN, Kuo YH, Kuo CH, et al. Predicting risk factors for rebleeding, infections, mortality following peptic ulcer bleeding in patients with cirrhosis and the impact of antibiotics prophylaxis at different clinical stages of the disease. BMC Gastroenterol. 2015;15:61.PubMedPubMedCentralCrossRef Kuo MT, Yang SC, Lu LS, Hsu CN, Kuo YH, Kuo CH, et al. Predicting risk factors for rebleeding, infections, mortality following peptic ulcer bleeding in patients with cirrhosis and the impact of antibiotics prophylaxis at different clinical stages of the disease. BMC Gastroenterol. 2015;15:61.PubMedPubMedCentralCrossRef
252.
Zurück zum Zitat Venkatesh PG, Parasa S, Njei B, Sanaka MR, Navaneethan U. Increased mortality with peptic ulcer bleeding in patients with both compensated and decompensated cirrhosis. Gastrointest Endosc. 2014;79(4):605–14 e3. Venkatesh PG, Parasa S, Njei B, Sanaka MR, Navaneethan U. Increased mortality with peptic ulcer bleeding in patients with both compensated and decompensated cirrhosis. Gastrointest Endosc. 2014;79(4):605–14 e3.
253.
Zurück zum Zitat Lodato F, Azzaroli F, Di Girolamo M, Feletti V, Cecinato P, Lisotti A, et al. Proton pump inhibitors in cirrhosis: tradition or evidence based practice? World J Gastroenterol. 2008;14(19):2980–5.PubMedPubMedCentralCrossRef Lodato F, Azzaroli F, Di Girolamo M, Feletti V, Cecinato P, Lisotti A, et al. Proton pump inhibitors in cirrhosis: tradition or evidence based practice? World J Gastroenterol. 2008;14(19):2980–5.PubMedPubMedCentralCrossRef
254.
Zurück zum Zitat Bajaj JS, Zadvornova Y, Heuman DM, Hafeezullah M, Hoffmann RG, Sanyal AJ, et al. Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites. Am J Gastroenterol. 2009;104(5):1130–4.PubMedCrossRef Bajaj JS, Zadvornova Y, Heuman DM, Hafeezullah M, Hoffmann RG, Sanyal AJ, et al. Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites. Am J Gastroenterol. 2009;104(5):1130–4.PubMedCrossRef
255.
Zurück zum Zitat Siple JF, Morey JM, Gutman TE, Weinberg KL, Collins PD. Proton pump inhibitor use and association with spontaneous bacterial peritonitis in patients with cirrhosis and ascites. Ann Pharmacother. 2012;46(10):1413–8.PubMedCrossRef Siple JF, Morey JM, Gutman TE, Weinberg KL, Collins PD. Proton pump inhibitor use and association with spontaneous bacterial peritonitis in patients with cirrhosis and ascites. Ann Pharmacother. 2012;46(10):1413–8.PubMedCrossRef
256.
Zurück zum Zitat Goel GA, Deshpande A, Lopez R, Hall GS, van Duin D, Carey WD. Increased rate of spontaneous bacterial peritonitis among cirrhotic patients receiving pharmacologic acid suppression. Clin Gastroenterol Hepatol. 2012;10(4):422–7.PubMedCrossRef Goel GA, Deshpande A, Lopez R, Hall GS, van Duin D, Carey WD. Increased rate of spontaneous bacterial peritonitis among cirrhotic patients receiving pharmacologic acid suppression. Clin Gastroenterol Hepatol. 2012;10(4):422–7.PubMedCrossRef
257.
Zurück zum Zitat Ratelle M, Perreault S, Villeneuve JP, Tremblay L. Association between proton pump inhibitor use and spontaneous bacterial peritonitis in cirrhotic patients with ascites. Can J Gastroenterol Hepatol. 2014;28(6):330–4.PubMedPubMedCentralCrossRef Ratelle M, Perreault S, Villeneuve JP, Tremblay L. Association between proton pump inhibitor use and spontaneous bacterial peritonitis in cirrhotic patients with ascites. Can J Gastroenterol Hepatol. 2014;28(6):330–4.PubMedPubMedCentralCrossRef
258.
Zurück zum Zitat Min YW, Lim KS, Min BH, Gwak GY, Paik YH, Choi MS, et al. Proton pump inhibitor use significantly increases the risk of spontaneous bacterial peritonitis in 1965 patients with cirrhosis and ascites: a propensity score matched cohort study. Aliment Pharmacol Ther. 2014;40(6):695–704.PubMedCrossRef Min YW, Lim KS, Min BH, Gwak GY, Paik YH, Choi MS, et al. Proton pump inhibitor use significantly increases the risk of spontaneous bacterial peritonitis in 1965 patients with cirrhosis and ascites: a propensity score matched cohort study. Aliment Pharmacol Ther. 2014;40(6):695–704.PubMedCrossRef
259.
Zurück zum Zitat Chang SS, Lai CC, Lee MT, Lee YC, Tsai YW, Hsu WT, et al. Risk of spontaneous bacterial peritonitis associated with gastric acid suppression. Medicine (Baltimore). 2015;94(22):e944.CrossRef Chang SS, Lai CC, Lee MT, Lee YC, Tsai YW, Hsu WT, et al. Risk of spontaneous bacterial peritonitis associated with gastric acid suppression. Medicine (Baltimore). 2015;94(22):e944.CrossRef
260.
Zurück zum Zitat Sargenti K, Prytz H, Strand A, Nilsson E, Kalaitzakis E. Healthcare-associated and nosocomial bacterial infections in cirrhosis: predictors and impact on outcome. Liver Int. 2015;35(2):391–400.PubMedCrossRef Sargenti K, Prytz H, Strand A, Nilsson E, Kalaitzakis E. Healthcare-associated and nosocomial bacterial infections in cirrhosis: predictors and impact on outcome. Liver Int. 2015;35(2):391–400.PubMedCrossRef
261.
Zurück zum Zitat Merli M, Lucidi C, Di Gregorio V, Giannelli V, Giusto M, Ceccarelli G, et al. The chronic use of beta-blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis. Liver Int. 2015;35(2):362–9.PubMedCrossRef Merli M, Lucidi C, Di Gregorio V, Giannelli V, Giusto M, Ceccarelli G, et al. The chronic use of beta-blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis. Liver Int. 2015;35(2):362–9.PubMedCrossRef
262.
Zurück zum Zitat O’Leary JG, Reddy KR, Wong F, Kamath PS, Patton HM, Biggins SW, et al. Long-term use of antibiotics and proton pump inhibitors predict development of infections in patients with cirrhosis. Clin Gastroenterol Hepatol. 2015;13(4):753–9 e1–2. O’Leary JG, Reddy KR, Wong F, Kamath PS, Patton HM, Biggins SW, et al. Long-term use of antibiotics and proton pump inhibitors predict development of infections in patients with cirrhosis. Clin Gastroenterol Hepatol. 2015;13(4):753–9 e1–2.
263.
Zurück zum Zitat Choi EJ, Lee HJ, Kim KO, Lee SH, Eun JR, Jang BI, et al. Association between acid suppressive therapy and spontaneous bacterial peritonitis in cirrhotic patients with ascites. Scand J Gastroenterol. 2011;46(5):616–20.PubMedCrossRef Choi EJ, Lee HJ, Kim KO, Lee SH, Eun JR, Jang BI, et al. Association between acid suppressive therapy and spontaneous bacterial peritonitis in cirrhotic patients with ascites. Scand J Gastroenterol. 2011;46(5):616–20.PubMedCrossRef
264.
Zurück zum Zitat Dultz G, Piiper A, Zeuzem S, Kronenberger B, Waidmann O. Proton pump inhibitor treatment is associated with the severity of liver disease and increased mortality in patients with cirrhosis. Aliment Pharmacol Ther. 2015;41(5):459–66.PubMedCrossRef Dultz G, Piiper A, Zeuzem S, Kronenberger B, Waidmann O. Proton pump inhibitor treatment is associated with the severity of liver disease and increased mortality in patients with cirrhosis. Aliment Pharmacol Ther. 2015;41(5):459–66.PubMedCrossRef
265.
Zurück zum Zitat Dam G, Vilstrup H, Watson H, Jepsen P. Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites. Hepatology. 2016;64(4):1265–72.PubMedCrossRef Dam G, Vilstrup H, Watson H, Jepsen P. Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites. Hepatology. 2016;64(4):1265–72.PubMedCrossRef
266.
Zurück zum Zitat Yu T, Tang Y, Jiang L, Zheng Y, Xiong W, Lin L. Proton pump inhibitor therapy and its association with spontaneous bacterial peritonitis incidence and mortality: a meta-analysis. Dig Liver Dis. 2016;48(4):353–9.PubMedCrossRef Yu T, Tang Y, Jiang L, Zheng Y, Xiong W, Lin L. Proton pump inhibitor therapy and its association with spontaneous bacterial peritonitis incidence and mortality: a meta-analysis. Dig Liver Dis. 2016;48(4):353–9.PubMedCrossRef
267.
Zurück zum Zitat Xu HB, Wang HD, Li CH, Ye S, Dong MS, Xia QJ, et al. Proton pump inhibitor use and risk of spontaneous bacterial peritonitis in cirrhotic patients: a systematic review and meta-analysis. Genet Mol Res. 2015;14(3):7490–501.PubMedCrossRef Xu HB, Wang HD, Li CH, Ye S, Dong MS, Xia QJ, et al. Proton pump inhibitor use and risk of spontaneous bacterial peritonitis in cirrhotic patients: a systematic review and meta-analysis. Genet Mol Res. 2015;14(3):7490–501.PubMedCrossRef
268.
Zurück zum Zitat Trikudanathan G, Israel J, Cappa J, O’Sullivan DM. Association between proton pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patients—a systematic review and meta-analysis. Int J Clin Pract. 2011;65(6):674–8.PubMedCrossRef Trikudanathan G, Israel J, Cappa J, O’Sullivan DM. Association between proton pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patients—a systematic review and meta-analysis. Int J Clin Pract. 2011;65(6):674–8.PubMedCrossRef
269.
Zurück zum Zitat Deshpande A, Pasupuleti V, Thota P, Pant C, Mapara S, Hassan S, et al. Acid-suppressive therapy is associated with spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. J Gastroenterol Hepatol. 2013;28(2):235–42.PubMedCrossRef Deshpande A, Pasupuleti V, Thota P, Pant C, Mapara S, Hassan S, et al. Acid-suppressive therapy is associated with spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. J Gastroenterol Hepatol. 2013;28(2):235–42.PubMedCrossRef
270.
Zurück zum Zitat Huang KW, Kuan YC, Luo JC, Lin CL, Liang JA, Kao CH. Impact of long-term gastric acid suppression on spontaneous bacterial peritonitis in patients with advanced decompensated liver cirrhosis. Eur J Intern Med. 2016;32:91–5.PubMedCrossRef Huang KW, Kuan YC, Luo JC, Lin CL, Liang JA, Kao CH. Impact of long-term gastric acid suppression on spontaneous bacterial peritonitis in patients with advanced decompensated liver cirrhosis. Eur J Intern Med. 2016;32:91–5.PubMedCrossRef
271.
Zurück zum Zitat Tsai CF, Chen MH, Wang YP, Chu CJ, Huang YH, Lin HC, et al. Proton pump inhibitors increase risk for hepatic encephalopathy in patients with cirrhosis in population study. Gastroenterology. 2017;152(1):134–41.PubMedCrossRef Tsai CF, Chen MH, Wang YP, Chu CJ, Huang YH, Lin HC, et al. Proton pump inhibitors increase risk for hepatic encephalopathy in patients with cirrhosis in population study. Gastroenterology. 2017;152(1):134–41.PubMedCrossRef
272.
Zurück zum Zitat Miozzo SA, Tovo CV, John JA, de Mattos AA. Proton pump inhibitor use and spontaneous bacterial peritonitis in cirrhosis: an undesirable association? J Hepatol. 2015;63(2):529–30.PubMedCrossRef Miozzo SA, Tovo CV, John JA, de Mattos AA. Proton pump inhibitor use and spontaneous bacterial peritonitis in cirrhosis: an undesirable association? J Hepatol. 2015;63(2):529–30.PubMedCrossRef
273.
Zurück zum Zitat Terg R, Casciato P, Garbe C, Cartier M, Stieben T, Mendizabal M, et al. Proton pump inhibitor therapy does not increase the incidence of spontaneous bacterial peritonitis in cirrhosis: a multicenter prospective study. J Hepatol. 2015;62(5):1056–60.PubMedCrossRef Terg R, Casciato P, Garbe C, Cartier M, Stieben T, Mendizabal M, et al. Proton pump inhibitor therapy does not increase the incidence of spontaneous bacterial peritonitis in cirrhosis: a multicenter prospective study. J Hepatol. 2015;62(5):1056–60.PubMedCrossRef
274.
Zurück zum Zitat de Vos M, De Vroey B, Garcia BG, Roy C, Kidd F, Henrion J, et al. Role of proton pump inhibitors in the occurrence and the prognosis of spontaneous bacterial peritonitis in cirrhotic patients with ascites. Liver Int. 2013;33(9):1316–23.PubMedCrossRef de Vos M, De Vroey B, Garcia BG, Roy C, Kidd F, Henrion J, et al. Role of proton pump inhibitors in the occurrence and the prognosis of spontaneous bacterial peritonitis in cirrhotic patients with ascites. Liver Int. 2013;33(9):1316–23.PubMedCrossRef
275.
Zurück zum Zitat Mandorfer M, Bota S, Schwabl P, Bucsics T, Pfisterer N, Summereder C, et al. Proton pump inhibitor intake neither predisposes to spontaneous bacterial peritonitis or other infections nor increases mortality in patients with cirrhosis and ascites. PLoS One. 2014;9(11):e110503.PubMedPubMedCentralCrossRef Mandorfer M, Bota S, Schwabl P, Bucsics T, Pfisterer N, Summereder C, et al. Proton pump inhibitor intake neither predisposes to spontaneous bacterial peritonitis or other infections nor increases mortality in patients with cirrhosis and ascites. PLoS One. 2014;9(11):e110503.PubMedPubMedCentralCrossRef
276.
Zurück zum Zitat Lo EA, Wilby KJ, Ensom MH. Use of proton pump inhibitors in the management of gastroesophageal varices: a systematic review. Ann Pharmacother. 2015;49(2):207–19.PubMedCrossRef Lo EA, Wilby KJ, Ensom MH. Use of proton pump inhibitors in the management of gastroesophageal varices: a systematic review. Ann Pharmacother. 2015;49(2):207–19.PubMedCrossRef
277.
Zurück zum Zitat Picardi A, Vespasiani-Gentilucci U. Proton pump inhibitor prescription abuse and sepsis in cirrhosis. World J Gastrointest Pharmacol Ther. 2016;7(1):1–4.PubMedPubMedCentralCrossRef Picardi A, Vespasiani-Gentilucci U. Proton pump inhibitor prescription abuse and sepsis in cirrhosis. World J Gastrointest Pharmacol Ther. 2016;7(1):1–4.PubMedPubMedCentralCrossRef
278.
Zurück zum Zitat Garcia-Saenz-de-Sicilia M, Sanchez-Avila F, Chavez-Tapia NC, Lopez-Arce G, Garcia-Osogobio S, Ruiz-Cordero R, et al. PPIs are not associated with a lower incidence of portal-hypertension-related bleeding in cirrhosis. World J Gastroenterol. 2010;16(46):5869–73.PubMedPubMedCentralCrossRef Garcia-Saenz-de-Sicilia M, Sanchez-Avila F, Chavez-Tapia NC, Lopez-Arce G, Garcia-Osogobio S, Ruiz-Cordero R, et al. PPIs are not associated with a lower incidence of portal-hypertension-related bleeding in cirrhosis. World J Gastroenterol. 2010;16(46):5869–73.PubMedPubMedCentralCrossRef
279.
Zurück zum Zitat Tripathi D, Stanley AJ, Hayes PC, Patch D, Millson C, Mehrzad H, et al. U.K. guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut. 2015;64(11):1680–704.PubMedPubMedCentralCrossRef Tripathi D, Stanley AJ, Hayes PC, Patch D, Millson C, Mehrzad H, et al. U.K. guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut. 2015;64(11):1680–704.PubMedPubMedCentralCrossRef
280.
Zurück zum Zitat Meli M, Raffa MP, Malta R, Morreale I, Aprea L, D’Alessandro N. The use of proton pump inhibitors in an Italian hospital: focus on oncologic and critical non-ICU patients. Int J Clin Pharm. 2015;37(6):1152–61.PubMedCrossRef Meli M, Raffa MP, Malta R, Morreale I, Aprea L, D’Alessandro N. The use of proton pump inhibitors in an Italian hospital: focus on oncologic and critical non-ICU patients. Int J Clin Pharm. 2015;37(6):1152–61.PubMedCrossRef
281.
Zurück zum Zitat Lucena MI, Andrade RJ, Tognoni G, Hidalgo R, La De, Cuesta FS, Spanish Collaborative Study Group On Therapeutic Management In Liver D. Multicenter hospital study on prescribing patterns for prophylaxis and treatment of complications of cirrhosis. Eur J Clin Pharmacol. 2002;58(6):435–40.PubMedCrossRef Lucena MI, Andrade RJ, Tognoni G, Hidalgo R, La De, Cuesta FS, Spanish Collaborative Study Group On Therapeutic Management In Liver D. Multicenter hospital study on prescribing patterns for prophylaxis and treatment of complications of cirrhosis. Eur J Clin Pharmacol. 2002;58(6):435–40.PubMedCrossRef
282.
Zurück zum Zitat Chavez-Tapia NC, Tellez-Avila FI, Garcia-Leiva J, Valdovinos MA. Use and overuse of proton pump inhibitors in cirrhotic patients. Med Sci Monit. 2008;14(9):CR468–72.PubMed Chavez-Tapia NC, Tellez-Avila FI, Garcia-Leiva J, Valdovinos MA. Use and overuse of proton pump inhibitors in cirrhotic patients. Med Sci Monit. 2008;14(9):CR468–72.PubMed
283.
Zurück zum Zitat Perez-Fontan M, Machado Lopes D, Garcia Enriquez A, Lopez-Calvino B, Lopez-Muniz A, Garcia Falcon T, et al. Inhibition of gastric acid secretion by H2 receptor antagonists associates a definite risk of enteric peritonitis and infectious mortality in patients treated with peritoneal dialysis. PLoS One. 2016;11(2):e0148806.PubMedPubMedCentralCrossRef Perez-Fontan M, Machado Lopes D, Garcia Enriquez A, Lopez-Calvino B, Lopez-Muniz A, Garcia Falcon T, et al. Inhibition of gastric acid secretion by H2 receptor antagonists associates a definite risk of enteric peritonitis and infectious mortality in patients treated with peritoneal dialysis. PLoS One. 2016;11(2):e0148806.PubMedPubMedCentralCrossRef
284.
Zurück zum Zitat Wang YP, Liu CJ, Chen TJ, Lin YT, Fung CP. Proton pump inhibitor use significantly increases the risk of cryptogenic liver abscess: a population-based study. Aliment Pharmacol Ther. 2015;41(11):1175–81.PubMedCrossRef Wang YP, Liu CJ, Chen TJ, Lin YT, Fung CP. Proton pump inhibitor use significantly increases the risk of cryptogenic liver abscess: a population-based study. Aliment Pharmacol Ther. 2015;41(11):1175–81.PubMedCrossRef
285.
Zurück zum Zitat Schneider J, Weidner W, Hapfelmeier A, Wantia N, Feihl S, Schmid RM, et al. The use of proton pump inhibitors and the spectrum and number of biliary pathogens in patients with acute cholangitis. Aliment Pharmacol Ther. 2014;39(10):1194–203.PubMedCrossRef Schneider J, Weidner W, Hapfelmeier A, Wantia N, Feihl S, Schmid RM, et al. The use of proton pump inhibitors and the spectrum and number of biliary pathogens in patients with acute cholangitis. Aliment Pharmacol Ther. 2014;39(10):1194–203.PubMedCrossRef
286.
Zurück zum Zitat Yardley JH, Bayless TM. Giardiasis. Gastroenterology. 1967;52(2):301–4.PubMed Yardley JH, Bayless TM. Giardiasis. Gastroenterology. 1967;52(2):301–4.PubMed
288.
289.
Zurück zum Zitat Lane S, Lloyd D. Current trends in research into the waterborne parasite Giardia. Crit Rev Microbiol. 2002;28(2):123–47.PubMedCrossRef Lane S, Lloyd D. Current trends in research into the waterborne parasite Giardia. Crit Rev Microbiol. 2002;28(2):123–47.PubMedCrossRef
290.
Zurück zum Zitat Haas J, Bucken EW. On the pathogenicity of the lamblia infections. Dtsch Med Wochenschr. 1967;92(41):1869–71.PubMedCrossRef Haas J, Bucken EW. On the pathogenicity of the lamblia infections. Dtsch Med Wochenschr. 1967;92(41):1869–71.PubMedCrossRef
291.
Zurück zum Zitat Cook GC. Infective gastroenteritis and its relationship to reduced gastric acidity. Scand J Gastroenterol Suppl. 1985;111:17–23.PubMedCrossRef Cook GC. Infective gastroenteritis and its relationship to reduced gastric acidity. Scand J Gastroenterol Suppl. 1985;111:17–23.PubMedCrossRef
293.
Zurück zum Zitat Misra V, Misra SP, Dwivedi M, Singh PA. Giardia lamblia trophozoites in gastric biopsies. Indian J Pathol Microbiol. 2006;49(4):519–23.PubMed Misra V, Misra SP, Dwivedi M, Singh PA. Giardia lamblia trophozoites in gastric biopsies. Indian J Pathol Microbiol. 2006;49(4):519–23.PubMed
294.
Zurück zum Zitat Sheen E, Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci. 2011;56(4):931–50.PubMedCrossRef Sheen E, Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci. 2011;56(4):931–50.PubMedCrossRef
295.
Zurück zum Zitat Reynaert H, Fernandes E, Bourgain C, Smekens L, Devis G. Proton-pump inhibition and gastric giardiasis: a causal or casual association? J Gastroenterol. 1995;30(6):775–8.PubMedCrossRef Reynaert H, Fernandes E, Bourgain C, Smekens L, Devis G. Proton-pump inhibition and gastric giardiasis: a causal or casual association? J Gastroenterol. 1995;30(6):775–8.PubMedCrossRef
296.
Zurück zum Zitat Mukherjee S. Asymptomatic giardiasis—an association with proton pump inhibitors? Am J Gastroenterol. 2000;95(12):3666–7.PubMed Mukherjee S. Asymptomatic giardiasis—an association with proton pump inhibitors? Am J Gastroenterol. 2000;95(12):3666–7.PubMed
297.
Zurück zum Zitat Francois M, Levy-Bohbot N, Caron J, Durlach V. Chronic use of proton-pump inhibitors associated with giardiasis: a rare cause of hypomagnesemic hypoparathyroidism? Ann Endocrinol (Paris). 2008;69(5):446–8.CrossRef Francois M, Levy-Bohbot N, Caron J, Durlach V. Chronic use of proton-pump inhibitors associated with giardiasis: a rare cause of hypomagnesemic hypoparathyroidism? Ann Endocrinol (Paris). 2008;69(5):446–8.CrossRef
298.
Zurück zum Zitat Khatami SS, Mukunda B, Ravakhah K. Coinfection with Giardia lamblia and Clostridium difficile after use of ranitidine. Am J Med Sci. 2004;327(2):91–3.PubMedCrossRef Khatami SS, Mukunda B, Ravakhah K. Coinfection with Giardia lamblia and Clostridium difficile after use of ranitidine. Am J Med Sci. 2004;327(2):91–3.PubMedCrossRef
299.
Zurück zum Zitat Slonim JM, Ireton HJ, Smallwood RA. Giardiasis following gastric surgery. Aust N Z J Med. 1976;6(5):479–80.PubMedCrossRef Slonim JM, Ireton HJ, Smallwood RA. Giardiasis following gastric surgery. Aust N Z J Med. 1976;6(5):479–80.PubMedCrossRef
300.
Zurück zum Zitat Reyes-Vivas H, de la mora-de la Mora I, Castillo-Villanueva A, Yepez-Mulia L, Hernandez-Alcantara G, Figueroa-Salazar R, et al. Giardial triosephosphate isomerase as possible target of the cytotoxic effect of omeprazole in Giardia lamblia. Antimicrob Agents Chemother. 2014;58(12):7072–82.PubMedPubMedCentralCrossRef Reyes-Vivas H, de la mora-de la Mora I, Castillo-Villanueva A, Yepez-Mulia L, Hernandez-Alcantara G, Figueroa-Salazar R, et al. Giardial triosephosphate isomerase as possible target of the cytotoxic effect of omeprazole in Giardia lamblia. Antimicrob Agents Chemother. 2014;58(12):7072–82.PubMedPubMedCentralCrossRef
302.
Zurück zum Zitat Johnston FH, Morris PS, Speare R, McCarthy J, Currie B, Ewald D, et al. Strongyloidiasis: a review of the evidence for Australian practitioners. Aust J Rural Health. 2005;13(4):247–54.PubMedCrossRef Johnston FH, Morris PS, Speare R, McCarthy J, Currie B, Ewald D, et al. Strongyloidiasis: a review of the evidence for Australian practitioners. Aust J Rural Health. 2005;13(4):247–54.PubMedCrossRef
303.
Zurück zum Zitat Puthiyakunnon S, Boddu S, Li Y, Zhou X, Wang C, Li J, et al. Strongyloidiasis—an insight into its global prevalence and management. PLoS Negl Trop Dis. 2014;8(8):e3018.PubMedPubMedCentralCrossRef Puthiyakunnon S, Boddu S, Li Y, Zhou X, Wang C, Li J, et al. Strongyloidiasis—an insight into its global prevalence and management. PLoS Negl Trop Dis. 2014;8(8):e3018.PubMedPubMedCentralCrossRef
304.
Zurück zum Zitat Concha R, Harrington W Jr, Rogers AI. Intestinal strongyloidiasis: recognition, management, and determinants of outcome. J Clin Gastroenterol. 2005;39(3):203–11.PubMedCrossRef Concha R, Harrington W Jr, Rogers AI. Intestinal strongyloidiasis: recognition, management, and determinants of outcome. J Clin Gastroenterol. 2005;39(3):203–11.PubMedCrossRef
305.
Zurück zum Zitat Rivasi F, Pampiglione S, Boldorini R, Cardinale L. Histopathology of gastric and duodenal Strongyloides stercoralis locations in fifteen immunocompromised subjects. Arch Pathol Lab Med. 2006;130(12):1792–8.PubMed Rivasi F, Pampiglione S, Boldorini R, Cardinale L. Histopathology of gastric and duodenal Strongyloides stercoralis locations in fifteen immunocompromised subjects. Arch Pathol Lab Med. 2006;130(12):1792–8.PubMed
306.
Zurück zum Zitat Buonfrate D, Requena-Mendez A, Angheben A, Munoz J, Gobbi F, Van Den Ende J, et al. Severe strongyloidiasis: a systematic review of case reports. BMC Infect Dis. 2013;13:78.PubMedPubMedCentralCrossRef Buonfrate D, Requena-Mendez A, Angheben A, Munoz J, Gobbi F, Van Den Ende J, et al. Severe strongyloidiasis: a systematic review of case reports. BMC Infect Dis. 2013;13:78.PubMedPubMedCentralCrossRef
307.
Zurück zum Zitat Giannella RA, Broitman SA, Zamcheck N. Influence of gastric acidity on bacterial and parasitic enteric infections. A perspective. Ann Intern Med. 1973;78(2):271–6.PubMedCrossRef Giannella RA, Broitman SA, Zamcheck N. Influence of gastric acidity on bacterial and parasitic enteric infections. A perspective. Ann Intern Med. 1973;78(2):271–6.PubMedCrossRef
308.
Zurück zum Zitat Ainley CC, Clarke DG, Timothy AR, Thompson RP. Strongyloides stercoralis hyperinfection associated with cimetidine in an immunosuppressed patient: diagnosis by endoscopic biopsy. Gut. 1986;27(3):337–8.PubMedPubMedCentralCrossRef Ainley CC, Clarke DG, Timothy AR, Thompson RP. Strongyloides stercoralis hyperinfection associated with cimetidine in an immunosuppressed patient: diagnosis by endoscopic biopsy. Gut. 1986;27(3):337–8.PubMedPubMedCentralCrossRef
309.
310.
Zurück zum Zitat Cadranel JF, Eugene C. Another example of Strongyloides stercoralis infection associated with cimetidine in an immunosuppressed patient. Gut. 1986;27(10):1229.PubMedPubMedCentralCrossRef Cadranel JF, Eugene C. Another example of Strongyloides stercoralis infection associated with cimetidine in an immunosuppressed patient. Gut. 1986;27(10):1229.PubMedPubMedCentralCrossRef
311.
Zurück zum Zitat Wurtz R, Mirot M, Fronda G, Peters C, Kocka F. Short report: gastric infection by Strongyloides stercoralis. Am J Trop Med Hyg. 1994;51(3):339–40.PubMedCrossRef Wurtz R, Mirot M, Fronda G, Peters C, Kocka F. Short report: gastric infection by Strongyloides stercoralis. Am J Trop Med Hyg. 1994;51(3):339–40.PubMedCrossRef
312.
Zurück zum Zitat Owen DG. Attempts at oral infection of rats and mice with trophozoites of Entamoeba histolytica. Trans R Soc Trop Med Hyg. 1984;78(2):160–4.PubMedCrossRef Owen DG. Attempts at oral infection of rats and mice with trophozoites of Entamoeba histolytica. Trans R Soc Trop Med Hyg. 1984;78(2):160–4.PubMedCrossRef
313.
Zurück zum Zitat Makioka A, Kumagai M, Kobayashi S, Takeuchi T. Effect of artificial gastrointestinal fluids on the excystation and metacystic development of Entamoeba invadens. Parasitol Res. 2006;98(5):443–6.PubMedCrossRef Makioka A, Kumagai M, Kobayashi S, Takeuchi T. Effect of artificial gastrointestinal fluids on the excystation and metacystic development of Entamoeba invadens. Parasitol Res. 2006;98(5):443–6.PubMedCrossRef
314.
Zurück zum Zitat Lambrecht E, Bare J, Chavatte N, Bert W, Sabbe K, Houf K. Protozoan cysts act as a survival niche and protective shelter for foodborne pathogenic bacteria. Appl Environ Microbiol. 2015;81(16):5604–12.PubMedPubMedCentralCrossRef Lambrecht E, Bare J, Chavatte N, Bert W, Sabbe K, Houf K. Protozoan cysts act as a survival niche and protective shelter for foodborne pathogenic bacteria. Appl Environ Microbiol. 2015;81(16):5604–12.PubMedPubMedCentralCrossRef
315.
Zurück zum Zitat Lambrecht E, Bare J, Van Damme I, Bert W, Sabbe K, Houf K. Behavior of Yersinia enterocolitica in the presence of the bacterivorous Acanthamoeba castellanii. Appl Environ Microbiol. 2013;79(20):6407–13.PubMedPubMedCentralCrossRef Lambrecht E, Bare J, Van Damme I, Bert W, Sabbe K, Houf K. Behavior of Yersinia enterocolitica in the presence of the bacterivorous Acanthamoeba castellanii. Appl Environ Microbiol. 2013;79(20):6407–13.PubMedPubMedCentralCrossRef
316.
Zurück zum Zitat Axelsson-Olsson D, Svensson L, Olofsson J, Salomon P, Waldenstrom J, Ellstrom P, et al. Increase in acid tolerance of Campylobacter jejuni through coincubation with amoebae. Appl Environ Microbiol. 2010;76(13):4194–200.PubMedPubMedCentralCrossRef Axelsson-Olsson D, Svensson L, Olofsson J, Salomon P, Waldenstrom J, Ellstrom P, et al. Increase in acid tolerance of Campylobacter jejuni through coincubation with amoebae. Appl Environ Microbiol. 2010;76(13):4194–200.PubMedPubMedCentralCrossRef
317.
Zurück zum Zitat Gutierrez F, Masia M. Improving outcomes of elderly patients with community-acquired pneumonia. Drugs Aging. 2008;25(7):585–610.PubMedCrossRef Gutierrez F, Masia M. Improving outcomes of elderly patients with community-acquired pneumonia. Drugs Aging. 2008;25(7):585–610.PubMedCrossRef
318.
Zurück zum Zitat Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, et al. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med. 2015;373(5):415–27.PubMedPubMedCentralCrossRef Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, et al. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med. 2015;373(5):415–27.PubMedPubMedCentralCrossRef
319.
Zurück zum Zitat Dhawan N, Pandya N, Khalili M, Bautista M, Duggal A, Bahl J, et al. Predictors of mortality for nursing home-acquired pneumonia: a systematic review. Biomed Res Int. 2015;2015:285983.PubMedPubMedCentralCrossRef Dhawan N, Pandya N, Khalili M, Bautista M, Duggal A, Bahl J, et al. Predictors of mortality for nursing home-acquired pneumonia: a systematic review. Biomed Res Int. 2015;2015:285983.PubMedPubMedCentralCrossRef
320.
Zurück zum Zitat Feldman C, Anderson R. Community-acquired pneumonia: pathogenesis of acute cardiac events and potential adjunctive therapies. Chest. 2015;148(2):523–32.PubMedCrossRef Feldman C, Anderson R. Community-acquired pneumonia: pathogenesis of acute cardiac events and potential adjunctive therapies. Chest. 2015;148(2):523–32.PubMedCrossRef
321.
Zurück zum Zitat Teramoto S, Yoshida K, Hizawa N. Update on the pathogenesis and management of pneumonia in the elderly-roles of aspiration pneumonia. Respir Investig. 2015;53(5):178–84.PubMedCrossRef Teramoto S, Yoshida K, Hizawa N. Update on the pathogenesis and management of pneumonia in the elderly-roles of aspiration pneumonia. Respir Investig. 2015;53(5):178–84.PubMedCrossRef
322.
Zurück zum Zitat Ebihara S, Sekiya H, Miyagi M, Ebihara T, Okazaki T. Dysphagia, dystussia, and aspiration pneumonia in elderly people. J Thorac Dis. 2016;8(3):632–9.PubMedPubMedCentralCrossRef Ebihara S, Sekiya H, Miyagi M, Ebihara T, Okazaki T. Dysphagia, dystussia, and aspiration pneumonia in elderly people. J Thorac Dis. 2016;8(3):632–9.PubMedPubMedCentralCrossRef
323.
Zurück zum Zitat Wirth R, Dziewas R, Beck AM, Clave P, Hamdy S, Heppner HJ, et al. Oropharyngeal dysphagia in older persons—from pathophysiology to adequate intervention: a review and summary of an international expert meeting. Clin Interv Aging. 2016;11:189–208.PubMedPubMedCentralCrossRef Wirth R, Dziewas R, Beck AM, Clave P, Hamdy S, Heppner HJ, et al. Oropharyngeal dysphagia in older persons—from pathophysiology to adequate intervention: a review and summary of an international expert meeting. Clin Interv Aging. 2016;11:189–208.PubMedPubMedCentralCrossRef
324.
Zurück zum Zitat Steel HC, Cockeran R, Anderson R, Feldman C. Overview of community-acquired pneumonia and the role of inflammatory mechanisms in the immunopathogenesis of severe pneumococcal disease. Mediators Inflamm. 2013;2013:490346.PubMedPubMedCentralCrossRef Steel HC, Cockeran R, Anderson R, Feldman C. Overview of community-acquired pneumonia and the role of inflammatory mechanisms in the immunopathogenesis of severe pneumococcal disease. Mediators Inflamm. 2013;2013:490346.PubMedPubMedCentralCrossRef
325.
Zurück zum Zitat Komiya K, Ishii H, Kadota J. Healthcare-associated pneumonia and aspiration pneumonia. Aging Dis. 2015;6(1):27–37.PubMedCrossRef Komiya K, Ishii H, Kadota J. Healthcare-associated pneumonia and aspiration pneumonia. Aging Dis. 2015;6(1):27–37.PubMedCrossRef
326.
Zurück zum Zitat Laheij RJ, Van Ijzendoorn MC, Janssen MJ, Jansen JB. Gastric acid-suppressive therapy and community-acquired respiratory infections. Aliment Pharmacol Ther. 2003;18(8):847–51.PubMedCrossRef Laheij RJ, Van Ijzendoorn MC, Janssen MJ, Jansen JB. Gastric acid-suppressive therapy and community-acquired respiratory infections. Aliment Pharmacol Ther. 2003;18(8):847–51.PubMedCrossRef
327.
Zurück zum Zitat Eom CS, Jeon CY, Lim JW, Cho EG, Park SM, Lee KS. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ. 2011;183(3):310–9.PubMedPubMedCentralCrossRef Eom CS, Jeon CY, Lim JW, Cho EG, Park SM, Lee KS. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ. 2011;183(3):310–9.PubMedPubMedCentralCrossRef
328.
Zurück zum Zitat Herzig SJ, Howell MD, Ngo LH, Marcantonio ER. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA. 2009;301(20):2120–8.PubMedCrossRef Herzig SJ, Howell MD, Ngo LH, Marcantonio ER. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA. 2009;301(20):2120–8.PubMedCrossRef
329.
Zurück zum Zitat Gulmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case–control study. Arch Intern Med. 2007;167(9):950–5.PubMedCrossRef Gulmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case–control study. Arch Intern Med. 2007;167(9):950–5.PubMedCrossRef
330.
Zurück zum Zitat Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004;292(16):1955–60.PubMedCrossRef Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004;292(16):1955–60.PubMedCrossRef
331.
Zurück zum Zitat Eom CS, Park SM, Myung SK, Yun JM, Ahn JS. Use of acid-suppressive drugs and risk of fracture: a meta-analysis of observational studies. Ann Fam Med. 2011;9(3):257–67.PubMedPubMedCentralCrossRef Eom CS, Park SM, Myung SK, Yun JM, Ahn JS. Use of acid-suppressive drugs and risk of fracture: a meta-analysis of observational studies. Ann Fam Med. 2011;9(3):257–67.PubMedPubMedCentralCrossRef
332.
Zurück zum Zitat O’Keefe GE, Gentilello LM, Maier RV. Incidence of infectious complications associated with the use of histamine2-receptor antagonists in critically ill trauma patients. Ann Surg. 1998;227(1):120–5.PubMedPubMedCentralCrossRef O’Keefe GE, Gentilello LM, Maier RV. Incidence of infectious complications associated with the use of histamine2-receptor antagonists in critically ill trauma patients. Ann Surg. 1998;227(1):120–5.PubMedPubMedCentralCrossRef
333.
Zurück zum Zitat Lambert AA, Lam JO, Paik JJ, Ugarte-Gil C, Drummond MB, Crowell TA. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS One. 2015;10(6):e0128004.PubMedPubMedCentralCrossRef Lambert AA, Lam JO, Paik JJ, Ugarte-Gil C, Drummond MB, Crowell TA. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS One. 2015;10(6):e0128004.PubMedPubMedCentralCrossRef
334.
Zurück zum Zitat Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med. 2008;149(6):391–8.PubMedCrossRef Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med. 2008;149(6):391–8.PubMedCrossRef
335.
Zurück zum Zitat Lee SW, Lin CH, Lien HC, Lee TY, Yeh HZ, Chang CS. Proton pump inhibitors did not increase risk of pneumonia in patients with chronic obstructive pulmonary disease. J Clin Med Res. 2015;7(11):880–3.PubMedPubMedCentralCrossRef Lee SW, Lin CH, Lien HC, Lee TY, Yeh HZ, Chang CS. Proton pump inhibitors did not increase risk of pneumonia in patients with chronic obstructive pulmonary disease. J Clin Med Res. 2015;7(11):880–3.PubMedPubMedCentralCrossRef
336.
Zurück zum Zitat Chen CH, Lin HC, Lin HL, Lin YT, Chou JM, Hsu SP, et al. Proton pump inhibitor usage and the associated risk of pneumonia in patients with chronic kidney disease. J Microbiol Immunol Infect. 2015;48(4):390–6.PubMedCrossRef Chen CH, Lin HC, Lin HL, Lin YT, Chou JM, Hsu SP, et al. Proton pump inhibitor usage and the associated risk of pneumonia in patients with chronic kidney disease. J Microbiol Immunol Infect. 2015;48(4):390–6.PubMedCrossRef
337.
Zurück zum Zitat Ran L, Khatibi NH, Qin X, Zhang JH. Proton pump inhibitor prophylaxis increases the risk of nosocomial pneumonia in patients with an intracerebral hemorrhagic stroke. Acta Neurochir Suppl. 2011;111:435–9.PubMedCrossRef Ran L, Khatibi NH, Qin X, Zhang JH. Proton pump inhibitor prophylaxis increases the risk of nosocomial pneumonia in patients with an intracerebral hemorrhagic stroke. Acta Neurochir Suppl. 2011;111:435–9.PubMedCrossRef
338.
Zurück zum Zitat Ho SW, Hsieh MJ, Yang SF, Yeh YT, Wang YH, Yeh CB. Risk of stroke-associated pneumonia with acid-suppressive drugs: a population-based cohort study. Medicine (Baltimore). 2015;94(29):e1227.CrossRef Ho SW, Hsieh MJ, Yang SF, Yeh YT, Wang YH, Yeh CB. Risk of stroke-associated pneumonia with acid-suppressive drugs: a population-based cohort study. Medicine (Baltimore). 2015;94(29):e1227.CrossRef
339.
Zurück zum Zitat Arai N, Nakamizo T, Ihara H, Koide T, Nakamura A, Tabuse M, et al. Histamine H2-blocker and proton pump inhibitor use and the risk of pneumonia in acute stroke: a retrospective analysis on susceptible patients. PLoS One. 2017;12(1):e0169300.PubMedPubMedCentralCrossRef Arai N, Nakamizo T, Ihara H, Koide T, Nakamura A, Tabuse M, et al. Histamine H2-blocker and proton pump inhibitor use and the risk of pneumonia in acute stroke: a retrospective analysis on susceptible patients. PLoS One. 2017;12(1):e0169300.PubMedPubMedCentralCrossRef
340.
Zurück zum Zitat Herzig SJ, Doughty C, Lahoti S, Marchina S, Sanan N, Feng W, et al. Acid-suppressive medication use in acute stroke and hospital-acquired pneumonia. Ann Neurol. 2014;76(5):712–8.PubMedPubMedCentralCrossRef Herzig SJ, Doughty C, Lahoti S, Marchina S, Sanan N, Feng W, et al. Acid-suppressive medication use in acute stroke and hospital-acquired pneumonia. Ann Neurol. 2014;76(5):712–8.PubMedPubMedCentralCrossRef
341.
Zurück zum Zitat Sultan N, Nazareno J, Gregor J. Association between proton pump inhibitors and respiratory infections: a systematic review and meta-analysis of clinical trials. Can J Gastroenterol. 2008;22(9):761–6.PubMedPubMedCentralCrossRef Sultan N, Nazareno J, Gregor J. Association between proton pump inhibitors and respiratory infections: a systematic review and meta-analysis of clinical trials. Can J Gastroenterol. 2008;22(9):761–6.PubMedPubMedCentralCrossRef
342.
Zurück zum Zitat Estborn L, Joelson S. Occurrence of community-acquired respiratory tract infection in patients receiving esomeprazole: retrospective analysis of adverse events in 31 clinical trials. Drug Saf. 2008;31(7):627–36.PubMedCrossRef Estborn L, Joelson S. Occurrence of community-acquired respiratory tract infection in patients receiving esomeprazole: retrospective analysis of adverse events in 31 clinical trials. Drug Saf. 2008;31(7):627–36.PubMedCrossRef
343.
Zurück zum Zitat Estborn L, Joelson S. Frequency and time to onset of community-acquired respiratory tract infections in patients receiving esomeprazole: a retrospective analysis of patient-level data in placebo-controlled studies. Aliment Pharmacol Ther. 2015;42(5):607–13.PubMedCrossRef Estborn L, Joelson S. Frequency and time to onset of community-acquired respiratory tract infections in patients receiving esomeprazole: a retrospective analysis of patient-level data in placebo-controlled studies. Aliment Pharmacol Ther. 2015;42(5):607–13.PubMedCrossRef
344.
Zurück zum Zitat Eurich DT, Sadowski CA, Simpson SH, Marrie TJ, Majumdar SR. Recurrent community-acquired pneumonia in patients starting acid-suppressing drugs. Am J Med. 2010;123(1):47–53.PubMedCrossRef Eurich DT, Sadowski CA, Simpson SH, Marrie TJ, Majumdar SR. Recurrent community-acquired pneumonia in patients starting acid-suppressing drugs. Am J Med. 2010;123(1):47–53.PubMedCrossRef
345.
Zurück zum Zitat Dublin S, Walker RL, Jackson ML, Nelson JC, Weiss NS, Jackson LA. Use of proton pump inhibitors and H2 blockers and risk of pneumonia in older adults: a population-based case–control study. Pharmacoepidemiol Drug Saf. 2010;19(8):792–802.PubMedPubMedCentralCrossRef Dublin S, Walker RL, Jackson ML, Nelson JC, Weiss NS, Jackson LA. Use of proton pump inhibitors and H2 blockers and risk of pneumonia in older adults: a population-based case–control study. Pharmacoepidemiol Drug Saf. 2010;19(8):792–802.PubMedPubMedCentralCrossRef
346.
Zurück zum Zitat Momosaki R, Yasunaga H, Matsui H, Fushimi K, Abo M. Proton pump inhibitors versus histamine-2 receptor antagonists and risk of pneumonia in patients with acute stroke. J Stroke Cerebrovasc Dis. 2016;25(5):1035–40.PubMedCrossRef Momosaki R, Yasunaga H, Matsui H, Fushimi K, Abo M. Proton pump inhibitors versus histamine-2 receptor antagonists and risk of pneumonia in patients with acute stroke. J Stroke Cerebrovasc Dis. 2016;25(5):1035–40.PubMedCrossRef
347.
Zurück zum Zitat Yamanaka Y, Mammoto T, Kita T, Kishi Y. A study of 13 patients with gastric tube in place after esophageal resection: use of omeprazole to decrease gastric acidity and volume. J Clin Anesth. 2001;13(5):370–3.PubMedCrossRef Yamanaka Y, Mammoto T, Kita T, Kishi Y. A study of 13 patients with gastric tube in place after esophageal resection: use of omeprazole to decrease gastric acidity and volume. J Clin Anesth. 2001;13(5):370–3.PubMedCrossRef
348.
Zurück zum Zitat Kiljander TO. The role of proton pump inhibitors in the management of gastroesophageal reflux disease-related asthma and chronic cough. Am J Med. 2003;18(115 Suppl 3A):65S–71S.CrossRef Kiljander TO. The role of proton pump inhibitors in the management of gastroesophageal reflux disease-related asthma and chronic cough. Am J Med. 2003;18(115 Suppl 3A):65S–71S.CrossRef
349.
Zurück zum Zitat Shaheen NJ, Crockett SD, Bright SD, Madanick RD, Buckmire R, Couch M, et al. Randomised clinical trial: high-dose acid suppression for chronic cough—a double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2011;33(2):225–34.PubMedCrossRef Shaheen NJ, Crockett SD, Bright SD, Madanick RD, Buckmire R, Couch M, et al. Randomised clinical trial: high-dose acid suppression for chronic cough—a double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2011;33(2):225–34.PubMedCrossRef
350.
Zurück zum Zitat Campagnolo AM, Priston J, Thoen RH, Medeiros T, Assuncao AR. Laryngopharyngeal reflux: diagnosis, treatment, and latest research. Int Arch Otorhinolaryngol. 2014;18(2):184–91.PubMed Campagnolo AM, Priston J, Thoen RH, Medeiros T, Assuncao AR. Laryngopharyngeal reflux: diagnosis, treatment, and latest research. Int Arch Otorhinolaryngol. 2014;18(2):184–91.PubMed
351.
Zurück zum Zitat Xu X, Lv H, Yu L, Chen Q, Liang S, Qiu Z. A stepwise protocol for the treatment of refractory gastroesophageal reflux-induced chronic cough. J Thorac Dis. 2016;8(1):178–85.PubMedPubMedCentral Xu X, Lv H, Yu L, Chen Q, Liang S, Qiu Z. A stepwise protocol for the treatment of refractory gastroesophageal reflux-induced chronic cough. J Thorac Dis. 2016;8(1):178–85.PubMedPubMedCentral
352.
Zurück zum Zitat Committee CAGCA. Community-acquired pneumonia and acid-suppressive drugs: position statement. Can J Gastroenterol. 2006;20(2):119–21, 23–5. Committee CAGCA. Community-acquired pneumonia and acid-suppressive drugs: position statement. Can J Gastroenterol. 2006;20(2):119–21, 23–5.
353.
Zurück zum Zitat Cook DJ. Stress ulcer prophylaxis: gastrointestinal bleeding and nosocomial pneumonia. Best evidence synthesis. Scand J Gastroenterol Suppl. 1995;210:48–52.PubMedCrossRef Cook DJ. Stress ulcer prophylaxis: gastrointestinal bleeding and nosocomial pneumonia. Best evidence synthesis. Scand J Gastroenterol Suppl. 1995;210:48–52.PubMedCrossRef
354.
Zurück zum Zitat Cook DJ, Reeve BK, Guyatt GH, Heyland DK, Griffith LE, Buckingham L, et al. Stress ulcer prophylaxis in critically ill patients. Resolving discordant meta-analyses. JAMA. 1996;275(4):308–14.PubMedCrossRef Cook DJ, Reeve BK, Guyatt GH, Heyland DK, Griffith LE, Buckingham L, et al. Stress ulcer prophylaxis in critically ill patients. Resolving discordant meta-analyses. JAMA. 1996;275(4):308–14.PubMedCrossRef
355.
Zurück zum Zitat Bardou M, Quenot JP, Barkun A. Stress-related mucosal disease in the critically ill patient. Nat Rev Gastroenterol Hepatol. 2015;12(2):98–107.PubMedCrossRef Bardou M, Quenot JP, Barkun A. Stress-related mucosal disease in the critically ill patient. Nat Rev Gastroenterol Hepatol. 2015;12(2):98–107.PubMedCrossRef
356.
Zurück zum Zitat Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin MH, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA. 1995;274(8):639–44.PubMedCrossRef Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin MH, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA. 1995;274(8):639–44.PubMedCrossRef
357.
Zurück zum Zitat Driks MR, Craven DE, Celli BR, Manning M, Burke RA, Garvin GM, et al. Nosocomial pneumonia in intubated patients given sucralfate as compared with antacids or histamine type 2 blockers. The role of gastric colonization. N Engl J Med. 1987;317(22):1376–82.PubMedCrossRef Driks MR, Craven DE, Celli BR, Manning M, Burke RA, Garvin GM, et al. Nosocomial pneumonia in intubated patients given sucralfate as compared with antacids or histamine type 2 blockers. The role of gastric colonization. N Engl J Med. 1987;317(22):1376–82.PubMedCrossRef
358.
Zurück zum Zitat Maier RV, Mitchell D, Gentilello L. Optimal therapy for stress gastritis. Ann Surg. 1994;220(3):353–60 (discussion 60–3). Maier RV, Mitchell D, Gentilello L. Optimal therapy for stress gastritis. Ann Surg. 1994;220(3):353–60 (discussion 60–3).
359.
Zurück zum Zitat Messori A, Trippoli S, Vaiani M, Gorini M, Corrado A. Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: meta-analysis of randomised controlled trials. BMJ. 2000;321(7269):1103–6.PubMedPubMedCentralCrossRef Messori A, Trippoli S, Vaiani M, Gorini M, Corrado A. Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: meta-analysis of randomised controlled trials. BMJ. 2000;321(7269):1103–6.PubMedPubMedCentralCrossRef
360.
Zurück zum Zitat Cook D, Guyatt G, Marshall J, Leasa D, Fuller H, Hall R, et al. A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. N Engl J Med. 1998;338(12):791–7.PubMedCrossRef Cook D, Guyatt G, Marshall J, Leasa D, Fuller H, Hall R, et al. A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. N Engl J Med. 1998;338(12):791–7.PubMedCrossRef
361.
Zurück zum Zitat Khorvash F, Abbasi S, Meidani M, Dehdashti F, Ataei B. The comparison between proton pump inhibitors and sucralfate in incidence of ventilator associated pneumonia in critically ill patients. Adv Biomed Res. 2014;3:52.PubMedPubMedCentralCrossRef Khorvash F, Abbasi S, Meidani M, Dehdashti F, Ataei B. The comparison between proton pump inhibitors and sucralfate in incidence of ventilator associated pneumonia in critically ill patients. Adv Biomed Res. 2014;3:52.PubMedPubMedCentralCrossRef
362.
Zurück zum Zitat Barletta JF. Histamine-2-receptor antagonist administration and gastrointestinal bleeding when used for stress ulcer prophylaxis in patients with severe sepsis or septic shock. Ann Pharmacother. 2014;48(10):1276–81.PubMedCrossRef Barletta JF. Histamine-2-receptor antagonist administration and gastrointestinal bleeding when used for stress ulcer prophylaxis in patients with severe sepsis or septic shock. Ann Pharmacother. 2014;48(10):1276–81.PubMedCrossRef
363.
Zurück zum Zitat Barkun AN, Bardou M, Pham CQ, Martel M. Proton pump inhibitors vs. histamine 2 receptor antagonists for stress-related mucosal bleeding prophylaxis in critically ill patients: a meta-analysis. Am J Gastroenterol. 2012;107(4):507–20 (quiz 21). Barkun AN, Bardou M, Pham CQ, Martel M. Proton pump inhibitors vs. histamine 2 receptor antagonists for stress-related mucosal bleeding prophylaxis in critically ill patients: a meta-analysis. Am J Gastroenterol. 2012;107(4):507–20 (quiz 21).
364.
Zurück zum Zitat Alshamsi F, Belley-Cote E, Cook D, Almenawer SA, Alqahtani Z, Perri D, et al. Efficacy and safety of proton pump inhibitors for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis of randomized trials. Crit Care. 2016;20(1):120.PubMedPubMedCentralCrossRef Alshamsi F, Belley-Cote E, Cook D, Almenawer SA, Alqahtani Z, Perri D, et al. Efficacy and safety of proton pump inhibitors for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis of randomized trials. Crit Care. 2016;20(1):120.PubMedPubMedCentralCrossRef
366.
Zurück zum Zitat Yahav D, Eliakim-Raz N, Leibovici L, Paul M. Bloodstream infections in older patients. Virulence. 2016;7(3):341–52.PubMedCrossRef Yahav D, Eliakim-Raz N, Leibovici L, Paul M. Bloodstream infections in older patients. Virulence. 2016;7(3):341–52.PubMedCrossRef
368.
Zurück zum Zitat Rantala A, Ovaska J. Association between medically induced achlorhydria of the stomach and a severe postoperative infection? A report of two cases. Ann Chir Gynaecol. 1994;83(3):268–70.PubMed Rantala A, Ovaska J. Association between medically induced achlorhydria of the stomach and a severe postoperative infection? A report of two cases. Ann Chir Gynaecol. 1994;83(3):268–70.PubMed
369.
Zurück zum Zitat Krag M, Perner A, Wetterslev J, Wise MP, Borthwick M, Bendel S, et al. Stress ulcer prophylaxis in the intensive care unit: an international survey of 97 units in 11 countries. Acta Anaesthesiol Scand. 2015;59(5):576–85.PubMedCrossRef Krag M, Perner A, Wetterslev J, Wise MP, Borthwick M, Bendel S, et al. Stress ulcer prophylaxis in the intensive care unit: an international survey of 97 units in 11 countries. Acta Anaesthesiol Scand. 2015;59(5):576–85.PubMedCrossRef
370.
Zurück zum Zitat Balza E, Piccioli P, Carta S, Lavieri R, Gattorno M, Semino C, et al. Proton pump inhibitors protect mice from acute systemic inflammation and induce long-term cross-tolerance. Cell Death Dis. 2016;21(7):e2304.CrossRef Balza E, Piccioli P, Carta S, Lavieri R, Gattorno M, Semino C, et al. Proton pump inhibitors protect mice from acute systemic inflammation and induce long-term cross-tolerance. Cell Death Dis. 2016;21(7):e2304.CrossRef
371.
Zurück zum Zitat Hsu WH, Kuo CH, Wang SS, Lu CY, Liu CJ, Chuah SK, et al. Acid suppressive agents and risk of Mycobacterium tuberculosis: case–control study. BMC Gastroenterol. 2014;14:91.PubMedPubMedCentralCrossRef Hsu WH, Kuo CH, Wang SS, Lu CY, Liu CJ, Chuah SK, et al. Acid suppressive agents and risk of Mycobacterium tuberculosis: case–control study. BMC Gastroenterol. 2014;14:91.PubMedPubMedCentralCrossRef
372.
Zurück zum Zitat Hong KS, Kang SJ, Choi JK, Kim JH, Seo H, Lee S, et al. Gastrointestinal tuberculosis is not associated with proton pump inhibitors: a retrospective cohort study. World J Gastroenterol. 2013;19(2):258–64.PubMedPubMedCentralCrossRef Hong KS, Kang SJ, Choi JK, Kim JH, Seo H, Lee S, et al. Gastrointestinal tuberculosis is not associated with proton pump inhibitors: a retrospective cohort study. World J Gastroenterol. 2013;19(2):258–64.PubMedPubMedCentralCrossRef
373.
Zurück zum Zitat West BC, Agastya G, Sodeman W, Callahan J. Furunculosis associated with repeated courses of omeprazole therapy. Clin Infect Dis. 1998;26(5):1234–5.PubMedCrossRef West BC, Agastya G, Sodeman W, Callahan J. Furunculosis associated with repeated courses of omeprazole therapy. Clin Infect Dis. 1998;26(5):1234–5.PubMedCrossRef
375.
Zurück zum Zitat Zwolinska-Wcislo M, Budak A, Bogdal J, Trojanowska D, Stachura J. Fungal colonization of gastric mucosa and its clinical relevance. Med Sci Monit. 2001;7(5):982–8.PubMed Zwolinska-Wcislo M, Budak A, Bogdal J, Trojanowska D, Stachura J. Fungal colonization of gastric mucosa and its clinical relevance. Med Sci Monit. 2001;7(5):982–8.PubMed
376.
Zurück zum Zitat Puig-Asensio M, Padilla B, Garnacho-Montero J, Zaragoza O, Aguado JM, Zaragoza R, et al. Epidemiology and predictive factors for early and late mortality in Candida bloodstream infections: a population-based surveillance in Spain. Clin Microbiol Infect. 2014;20(4):O245–54.PubMedCrossRef Puig-Asensio M, Padilla B, Garnacho-Montero J, Zaragoza O, Aguado JM, Zaragoza R, et al. Epidemiology and predictive factors for early and late mortality in Candida bloodstream infections: a population-based surveillance in Spain. Clin Microbiol Infect. 2014;20(4):O245–54.PubMedCrossRef
377.
Zurück zum Zitat Paiva JA, Pereira JM, Tabah A, Mikstacki A, de Carvalho FB, Koulenti D, et al. Characteristics and risk factors for 28-day mortality of hospital acquired fungemias in ICUs: data from the EUROBACT study. Crit Care. 2016;20(1):53.PubMedPubMedCentralCrossRef Paiva JA, Pereira JM, Tabah A, Mikstacki A, de Carvalho FB, Koulenti D, et al. Characteristics and risk factors for 28-day mortality of hospital acquired fungemias in ICUs: data from the EUROBACT study. Crit Care. 2016;20(1):53.PubMedPubMedCentralCrossRef
378.
Zurück zum Zitat Hofer U. Fungal pathogenesis: Candida’s toxic relationship with its host. Nat Rev Microbiol. 2016;14(5):268.PubMedCrossRef Hofer U. Fungal pathogenesis: Candida’s toxic relationship with its host. Nat Rev Microbiol. 2016;14(5):268.PubMedCrossRef
379.
Zurück zum Zitat Zwolinska-Wcislo M, Budak A, Bogdal J, Trojanowska D, Stachura J. Effect of fungal colonization of gastric mucosa on the course of gastric ulcers healing. Med Sci Monit. 2001;7(2):266–75.PubMed Zwolinska-Wcislo M, Budak A, Bogdal J, Trojanowska D, Stachura J. Effect of fungal colonization of gastric mucosa on the course of gastric ulcers healing. Med Sci Monit. 2001;7(2):266–75.PubMed
380.
Zurück zum Zitat Zwolinska-Wcislo M, Brzozowski T, Budak A, Kwiecien S, Sliwowski Z, Drozdowicz D, et al. Effect of Candida colonization on human ulcerative colitis and the healing of inflammatory changes of the colon in the experimental model of colitis ulcerosa. J Physiol Pharmacol. 2009;60(1):107–18.PubMed Zwolinska-Wcislo M, Brzozowski T, Budak A, Kwiecien S, Sliwowski Z, Drozdowicz D, et al. Effect of Candida colonization on human ulcerative colitis and the healing of inflammatory changes of the colon in the experimental model of colitis ulcerosa. J Physiol Pharmacol. 2009;60(1):107–18.PubMed
381.
Zurück zum Zitat Standaert-Vitse A, Sendid B, Joossens M, Francois N, Vandewalle-El Khoury P, Branche J, et al. Candida albicans colonization and ASCA in familial Crohn’s disease. Am J Gastroenterol. 2009;104(7):1745–53.PubMedCrossRef Standaert-Vitse A, Sendid B, Joossens M, Francois N, Vandewalle-El Khoury P, Branche J, et al. Candida albicans colonization and ASCA in familial Crohn’s disease. Am J Gastroenterol. 2009;104(7):1745–53.PubMedCrossRef
382.
Zurück zum Zitat Singh S, Singh N, Kochhar R, Talwar P, Mehta SK. Cimetidine therapy and duodenal candidiasis: role in healing process. Indian J Gastroenterol. 1992;11(1):21–2.PubMed Singh S, Singh N, Kochhar R, Talwar P, Mehta SK. Cimetidine therapy and duodenal candidiasis: role in healing process. Indian J Gastroenterol. 1992;11(1):21–2.PubMed
383.
Zurück zum Zitat Boero M, Pera A, Andriulli A, Ponti V, Canepa G, Palmas F, et al. Candida overgrowth in gastric juice of peptic ulcer subjects on short- and long-term treatment with H2-receptor antagonists. Digestion. 1983;28(3):158–63.PubMedCrossRef Boero M, Pera A, Andriulli A, Ponti V, Canepa G, Palmas F, et al. Candida overgrowth in gastric juice of peptic ulcer subjects on short- and long-term treatment with H2-receptor antagonists. Digestion. 1983;28(3):158–63.PubMedCrossRef
384.
Zurück zum Zitat Goenka MK, Kochhar R, Chakrabarti A, Kumar A, Gupta O, Talwar P, et al. Candida overgrowth after treatment of duodenal ulcer. A comparison of cimetidine, famotidine, and omeprazole. J Clin Gastroenterol. 1996;23(1):7–10.PubMedCrossRef Goenka MK, Kochhar R, Chakrabarti A, Kumar A, Gupta O, Talwar P, et al. Candida overgrowth after treatment of duodenal ulcer. A comparison of cimetidine, famotidine, and omeprazole. J Clin Gastroenterol. 1996;23(1):7–10.PubMedCrossRef
385.
Zurück zum Zitat Cipollini F, Altilia F. Candidiasis of the small intestine. Gastroenterology. 1981;81(4):825–6.PubMed Cipollini F, Altilia F. Candidiasis of the small intestine. Gastroenterology. 1981;81(4):825–6.PubMed
387.
Zurück zum Zitat Brooks JR, Smith HF, Pease FB Jr. Bacteriology of the stomach immediately following vagotomy: the growth of Candida albicans. Ann Surg. 1974;179(6):859–62.PubMedPubMedCentralCrossRef Brooks JR, Smith HF, Pease FB Jr. Bacteriology of the stomach immediately following vagotomy: the growth of Candida albicans. Ann Surg. 1974;179(6):859–62.PubMedPubMedCentralCrossRef
389.
Zurück zum Zitat Di Febo G, Miglioli M, Calo G, Biasco G, Luzza F, Gizzi G, et al. Candida albicans infection of gastric ulcer frequency and correlation with medical treatment. Results of a multicenter study. Dig Dis Sci. 1985;30(2):178–81.PubMedCrossRef Di Febo G, Miglioli M, Calo G, Biasco G, Luzza F, Gizzi G, et al. Candida albicans infection of gastric ulcer frequency and correlation with medical treatment. Results of a multicenter study. Dig Dis Sci. 1985;30(2):178–81.PubMedCrossRef
390.
Zurück zum Zitat Brzozowski T, Zwolinska-Wcislo M, Konturek PC, Kwiecien S, Drozdowicz D, Konturek SJ, et al. Influence of gastric colonization with Candida albicans on ulcer healing in rats: effect of ranitidine, aspirin and probiotic therapy. Scand J Gastroenterol. 2005;40(3):286–96.PubMedCrossRef Brzozowski T, Zwolinska-Wcislo M, Konturek PC, Kwiecien S, Drozdowicz D, Konturek SJ, et al. Influence of gastric colonization with Candida albicans on ulcer healing in rats: effect of ranitidine, aspirin and probiotic therapy. Scand J Gastroenterol. 2005;40(3):286–96.PubMedCrossRef
391.
Zurück zum Zitat Triger DR, Goepel JR, Slater DN, Underwood JC. Systemic candidiasis complicating acute hepatic failure in patients treated with cimetidine. Lancet. 1981;2(8251):837–8.PubMedCrossRef Triger DR, Goepel JR, Slater DN, Underwood JC. Systemic candidiasis complicating acute hepatic failure in patients treated with cimetidine. Lancet. 1981;2(8251):837–8.PubMedCrossRef
392.
Zurück zum Zitat Kochar DK, Saini G, Kochar SK, Sirohi P, Bumb RA, Mehta RD, et al. A double blind, randomised placebo controlled trial of rifampicin with omeprazole in the treatment of human cutaneous leishmaniasis. J Vector Borne Dis. 2006;43(4):161–7.PubMed Kochar DK, Saini G, Kochar SK, Sirohi P, Bumb RA, Mehta RD, et al. A double blind, randomised placebo controlled trial of rifampicin with omeprazole in the treatment of human cutaneous leishmaniasis. J Vector Borne Dis. 2006;43(4):161–7.PubMed
393.
Zurück zum Zitat Hendel L, Svejgaard E, Walsoe I, Kieffer M, Stenderup A. Esophageal candidosis in progressive systemic sclerosis: occurrence, significance, and treatment with fluconazole. Scand J Gastroenterol. 1988;23(10):1182–6.PubMedCrossRef Hendel L, Svejgaard E, Walsoe I, Kieffer M, Stenderup A. Esophageal candidosis in progressive systemic sclerosis: occurrence, significance, and treatment with fluconazole. Scand J Gastroenterol. 1988;23(10):1182–6.PubMedCrossRef
395.
Zurück zum Zitat Mosimann F. Esophageal candidiasis, omeprazole therapy, and organ transplantation—a word of caution. Transplantation. 1993;56(2):492–3.PubMedCrossRef Mosimann F. Esophageal candidiasis, omeprazole therapy, and organ transplantation—a word of caution. Transplantation. 1993;56(2):492–3.PubMedCrossRef
396.
Zurück zum Zitat Sood A, Sharma M, Jain NP, Chawla LS, Kumar R. Esophageal candidiasis following omeprazole therapy: a report of two cases. Indian J Gastroenterol. 1995;14(2):71–2.PubMed Sood A, Sharma M, Jain NP, Chawla LS, Kumar R. Esophageal candidiasis following omeprazole therapy: a report of two cases. Indian J Gastroenterol. 1995;14(2):71–2.PubMed
397.
Zurück zum Zitat Chocarro Martinez A, Galindo Tobal F, Ruiz-Irastorza G, Gonzalez Lopez A, Alvarez Navia F, Ochoa Sangrador C, et al. Risk factors for esophageal candidiasis. Eur J Clin Microbiol Infect Dis. 2000;19(2):96–100.PubMedCrossRef Chocarro Martinez A, Galindo Tobal F, Ruiz-Irastorza G, Gonzalez Lopez A, Alvarez Navia F, Ochoa Sangrador C, et al. Risk factors for esophageal candidiasis. Eur J Clin Microbiol Infect Dis. 2000;19(2):96–100.PubMedCrossRef
398.
Zurück zum Zitat Takahashi Y, Nagata N, Shimbo T, Nishijima T, Watanabe K, Aoki T, et al. Long-term trends in esophageal candidiasis prevalence and associated risk factors with or without HIV infection: lessons from an endoscopic study of 80,219 patients. PLoS One. 2015;10(7):e0133589.PubMedPubMedCentralCrossRef Takahashi Y, Nagata N, Shimbo T, Nishijima T, Watanabe K, Aoki T, et al. Long-term trends in esophageal candidiasis prevalence and associated risk factors with or without HIV infection: lessons from an endoscopic study of 80,219 patients. PLoS One. 2015;10(7):e0133589.PubMedPubMedCentralCrossRef
399.
Zurück zum Zitat Cat TB, Charash W, Hebert J, Marden BT, Corbett SM, Ahern J, et al. Potential influence of antisecretory therapy on the development of Candida-associated intraabdominal infection. Ann Pharmacother. 2008;42(2):185–91.PubMedCrossRef Cat TB, Charash W, Hebert J, Marden BT, Corbett SM, Ahern J, et al. Potential influence of antisecretory therapy on the development of Candida-associated intraabdominal infection. Ann Pharmacother. 2008;42(2):185–91.PubMedCrossRef
400.
Zurück zum Zitat Liu NN, Kohler JR. Antagonism of fluconazole and a proton pump inhibitor against Candida albicans. Antimicrob Agents Chemother. 2016;60(2):1145–7.PubMedPubMedCentralCrossRef Liu NN, Kohler JR. Antagonism of fluconazole and a proton pump inhibitor against Candida albicans. Antimicrob Agents Chemother. 2016;60(2):1145–7.PubMedPubMedCentralCrossRef
401.
Zurück zum Zitat Cojutti P, Candoni A, Simeone E, Franceschi L, Fanin R, Pea F. Antifungal prophylaxis with posaconazole in patients with acute myeloid leukemia: dose intensification coupled with avoidance of proton pump inhibitors is beneficial in shortening time to effective concentrations. Antimicrob Agents Chemother. 2013;57(12):6081–4.PubMedPubMedCentralCrossRef Cojutti P, Candoni A, Simeone E, Franceschi L, Fanin R, Pea F. Antifungal prophylaxis with posaconazole in patients with acute myeloid leukemia: dose intensification coupled with avoidance of proton pump inhibitors is beneficial in shortening time to effective concentrations. Antimicrob Agents Chemother. 2013;57(12):6081–4.PubMedPubMedCentralCrossRef
402.
Zurück zum Zitat Boyd NK, Zoellner CL, Swancutt MA, Bhavan KP. Utilization of omeprazole to augment subtherapeutic voriconazole concentrations for treatment of Aspergillus infections. Antimicrob Agents Chemother. 2012;56(11):6001–2.PubMedPubMedCentralCrossRef Boyd NK, Zoellner CL, Swancutt MA, Bhavan KP. Utilization of omeprazole to augment subtherapeutic voriconazole concentrations for treatment of Aspergillus infections. Antimicrob Agents Chemother. 2012;56(11):6001–2.PubMedPubMedCentralCrossRef
403.
Zurück zum Zitat Niece KL, Boyd NK, Akers KS. In vitro study of the variable effects of proton pump inhibitors on voriconazole. Antimicrob Agents Chemother. 2015;59(9):5548–54.PubMedPubMedCentralCrossRef Niece KL, Boyd NK, Akers KS. In vitro study of the variable effects of proton pump inhibitors on voriconazole. Antimicrob Agents Chemother. 2015;59(9):5548–54.PubMedPubMedCentralCrossRef
404.
Zurück zum Zitat Chong CR, Chen X, Shi L, Liu JO, Sullivan DJ Jr. A clinical drug library screen identifies astemizole as an antimalarial agent. Nat Chem Biol. 2006;2(8):415–6.PubMedCrossRef Chong CR, Chen X, Shi L, Liu JO, Sullivan DJ Jr. A clinical drug library screen identifies astemizole as an antimalarial agent. Nat Chem Biol. 2006;2(8):415–6.PubMedCrossRef
405.
Zurück zum Zitat Skinner-Adams TS, Davis TM, Manning LS, Johnston WA. The efficacy of benzimidazole drugs against Plasmodium falciparum in vitro. Trans R Soc Trop Med Hyg. 1997;91(5):580–4.PubMedCrossRef Skinner-Adams TS, Davis TM, Manning LS, Johnston WA. The efficacy of benzimidazole drugs against Plasmodium falciparum in vitro. Trans R Soc Trop Med Hyg. 1997;91(5):580–4.PubMedCrossRef
406.
Zurück zum Zitat Skinner-Adams T, Davis TM. Synergistic in vitro antimalarial activity of omeprazole and quinine. Antimicrob Agents Chemother. 1999;43(5):1304–6.PubMedPubMedCentral Skinner-Adams T, Davis TM. Synergistic in vitro antimalarial activity of omeprazole and quinine. Antimicrob Agents Chemother. 1999;43(5):1304–6.PubMedPubMedCentral
407.
Zurück zum Zitat Shanehsaz SM, Ishkhanian S. A comparative study between the efficacy of oral cimetidine and low-dose systemic meglumine antimoniate (MA) with a standard dose of systemic MA in the treatment of cutaneous leishmaniasis. Int J Dermatol. 2015;54(7):834–8.PubMedCrossRef Shanehsaz SM, Ishkhanian S. A comparative study between the efficacy of oral cimetidine and low-dose systemic meglumine antimoniate (MA) with a standard dose of systemic MA in the treatment of cutaneous leishmaniasis. Int J Dermatol. 2015;54(7):834–8.PubMedCrossRef
408.
Zurück zum Zitat Nilforoushzadeh MA, Jaffary F, Ansari N, Siadat AH, Nilforoushan Z, Firouz A. A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasis. J Vector Borne Dis. 2008;45(4):287–91.PubMed Nilforoushzadeh MA, Jaffary F, Ansari N, Siadat AH, Nilforoushan Z, Firouz A. A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasis. J Vector Borne Dis. 2008;45(4):287–91.PubMed
409.
Zurück zum Zitat Li MJ, Lei JH, Wang T, Lu SJ, Guan F, Liu WQ, et al. Cimetidine enhances the protective effect of GST DNA vaccine against Schistosoma japonicum. Exp Parasitol. 2011;128(4):427–32.PubMedCrossRef Li MJ, Lei JH, Wang T, Lu SJ, Guan F, Liu WQ, et al. Cimetidine enhances the protective effect of GST DNA vaccine against Schistosoma japonicum. Exp Parasitol. 2011;128(4):427–32.PubMedCrossRef
410.
Zurück zum Zitat Almeida GT, Lage RC, Anderson L, Venancio TM, Nakaya HI, Miyasato PA, et al. Synergy of omeprazole and praziquantel in vitro treatment against schistosoma mansoni adult Worms. PLoS Negl Trop Dis. 2015;9(9):e0004086.PubMedPubMedCentralCrossRef Almeida GT, Lage RC, Anderson L, Venancio TM, Nakaya HI, Miyasato PA, et al. Synergy of omeprazole and praziquantel in vitro treatment against schistosoma mansoni adult Worms. PLoS Negl Trop Dis. 2015;9(9):e0004086.PubMedPubMedCentralCrossRef
411.
Zurück zum Zitat Weiss C, Clark HF. Rapid inactivation of rotaviruses by exposure to acid buffer or acidic gastric juice. J Gen Virol. 1985;66(Pt 12):2725–30.PubMedCrossRef Weiss C, Clark HF. Rapid inactivation of rotaviruses by exposure to acid buffer or acidic gastric juice. J Gen Virol. 1985;66(Pt 12):2725–30.PubMedCrossRef
412.
Zurück zum Zitat Waldum HL, Brenna E, Sandvik AK. Long-term safety of proton pump inhibitors: risks of gastric neoplasia and infections. Expert Opin Drug Saf. 2002;1(1):29–38.PubMedCrossRef Waldum HL, Brenna E, Sandvik AK. Long-term safety of proton pump inhibitors: risks of gastric neoplasia and infections. Expert Opin Drug Saf. 2002;1(1):29–38.PubMedCrossRef
413.
Zurück zum Zitat Hayase Y, Tobita K, Sato H. Detection of type B influenza virus genes from biopsied gastric mucosa. J Gastroenterol. 2002;37(2):101–5.PubMedCrossRef Hayase Y, Tobita K, Sato H. Detection of type B influenza virus genes from biopsied gastric mucosa. J Gastroenterol. 2002;37(2):101–5.PubMedCrossRef
414.
Zurück zum Zitat Minodier L, Charrel RN, Ceccaldi PE, van der Werf S, Blanchon T, Hanslik T, et al. Prevalence of gastrointestinal symptoms in patients with influenza, clinical significance, and pathophysiology of human influenza viruses in faecal samples: what do we know? Virol J. 2015;12:215.PubMedPubMedCentralCrossRef Minodier L, Charrel RN, Ceccaldi PE, van der Werf S, Blanchon T, Hanslik T, et al. Prevalence of gastrointestinal symptoms in patients with influenza, clinical significance, and pathophysiology of human influenza viruses in faecal samples: what do we know? Virol J. 2015;12:215.PubMedPubMedCentralCrossRef
415.
Zurück zum Zitat Martinsen TC, Taylor DM, Johnsen R, Waldum HL. Gastric acidity protects mice against prion infection? Scand J Gastroenterol. 2002;37(5):497–500.PubMedCrossRef Martinsen TC, Taylor DM, Johnsen R, Waldum HL. Gastric acidity protects mice against prion infection? Scand J Gastroenterol. 2002;37(5):497–500.PubMedCrossRef
416.
Zurück zum Zitat Martinsen TC, Benestad SL, Moldal T, Waldum HL. Inhibitors of gastric acid secretion increase the risk of prion infection in mice. Scand J Gastroenterol. 2011;46(12):1418–22.PubMedCrossRef Martinsen TC, Benestad SL, Moldal T, Waldum HL. Inhibitors of gastric acid secretion increase the risk of prion infection in mice. Scand J Gastroenterol. 2011;46(12):1418–22.PubMedCrossRef
417.
Zurück zum Zitat Safdar N, Maki DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med. 2002;136(11):834–44.PubMedCrossRef Safdar N, Maki DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med. 2002;136(11):834–44.PubMedCrossRef
418.
Zurück zum Zitat Mody L, Maheshwari S, Galecki A, Kauffman CA, Bradley SF. Indwelling device use and antibiotic resistance in nursing homes: identifying a high-risk group. J Am Geriatr Soc. 2007;55(12):1921–6.PubMedPubMedCentralCrossRef Mody L, Maheshwari S, Galecki A, Kauffman CA, Bradley SF. Indwelling device use and antibiotic resistance in nursing homes: identifying a high-risk group. J Am Geriatr Soc. 2007;55(12):1921–6.PubMedPubMedCentralCrossRef
419.
Zurück zum Zitat Tong SY, Chen LF, Fowler VG Jr. Colonization, pathogenicity, host susceptibility, and therapeutics for Staphylococcus aureus: what is the clinical relevance? Semin Immunopathol. 2012;34(2):185–200.PubMedCrossRef Tong SY, Chen LF, Fowler VG Jr. Colonization, pathogenicity, host susceptibility, and therapeutics for Staphylococcus aureus: what is the clinical relevance? Semin Immunopathol. 2012;34(2):185–200.PubMedCrossRef
420.
Zurück zum Zitat McKinnell JA, Miller LG, Eells SJ, Cui E, Huang SS. A systematic literature review and meta-analysis of factors associated with methicillin-resistant Staphylococcus aureus colonization at time of hospital or intensive care unit admission. Infect Control Hosp Epidemiol. 2013;34(10):1077–86.PubMedCrossRef McKinnell JA, Miller LG, Eells SJ, Cui E, Huang SS. A systematic literature review and meta-analysis of factors associated with methicillin-resistant Staphylococcus aureus colonization at time of hospital or intensive care unit admission. Infect Control Hosp Epidemiol. 2013;34(10):1077–86.PubMedCrossRef
421.
Zurück zum Zitat Pogorzelska-Maziarz M, Furuya EY, Larson EL. Risk factors for methicillin-resistant Staphylococcus aureus bacteraemia differ depending on the control group chosen. Epidemiol Infect. 2013;141(11):2376–83.PubMedPubMedCentralCrossRef Pogorzelska-Maziarz M, Furuya EY, Larson EL. Risk factors for methicillin-resistant Staphylococcus aureus bacteraemia differ depending on the control group chosen. Epidemiol Infect. 2013;141(11):2376–83.PubMedPubMedCentralCrossRef
422.
Zurück zum Zitat Forster AJ, Oake N, Roth V, Suh KN, Majewski J, Leeder C, et al. Patient-level factors associated with methicillin-resistant Staphylococcus aureus carriage at hospital admission: a systematic review. Am J Infect Control. 2013;41(3):214–20.PubMedCrossRef Forster AJ, Oake N, Roth V, Suh KN, Majewski J, Leeder C, et al. Patient-level factors associated with methicillin-resistant Staphylococcus aureus carriage at hospital admission: a systematic review. Am J Infect Control. 2013;41(3):214–20.PubMedCrossRef
423.
Zurück zum Zitat Tang SS, Apisarnthanarak A, Hsu LY. Mechanisms of beta-lactam antimicrobial resistance and epidemiology of major community- and healthcare-associated multidrug-resistant bacteria. Adv Drug Deliv Rev. 2014;30(78):3–13.CrossRef Tang SS, Apisarnthanarak A, Hsu LY. Mechanisms of beta-lactam antimicrobial resistance and epidemiology of major community- and healthcare-associated multidrug-resistant bacteria. Adv Drug Deliv Rev. 2014;30(78):3–13.CrossRef
424.
Zurück zum Zitat Furuya EY, Lowy FD. Antimicrobial-resistant bacteria in the community setting. Nat Rev Microbiol. 2006;4(1):36–45.PubMedCrossRef Furuya EY, Lowy FD. Antimicrobial-resistant bacteria in the community setting. Nat Rev Microbiol. 2006;4(1):36–45.PubMedCrossRef
426.
Zurück zum Zitat Terpenning MS, Bradley SF, Wan JY, Chenoweth CE, Jorgensen KA, Kauffman CA. Colonization and infection with antibiotic-resistant bacteria in a long-term care facility. J Am Geriatr Soc. 1994;42(10):1062–9.PubMedCrossRef Terpenning MS, Bradley SF, Wan JY, Chenoweth CE, Jorgensen KA, Kauffman CA. Colonization and infection with antibiotic-resistant bacteria in a long-term care facility. J Am Geriatr Soc. 1994;42(10):1062–9.PubMedCrossRef
427.
Zurück zum Zitat Bradley SF. Methicillin-resistant Staphylococcus aureus in nursing homes. Epidemiology, prevention and management. Drugs Aging. 1997;10(3):185–98.PubMedCrossRef Bradley SF. Methicillin-resistant Staphylococcus aureus in nursing homes. Epidemiology, prevention and management. Drugs Aging. 1997;10(3):185–98.PubMedCrossRef
428.
Zurück zum Zitat Trick WE, Weinstein RA, DeMarais PL, Kuehnert MJ, Tomaska W, Nathan C, et al. Colonization of skilled-care facility residents with antimicrobial-resistant pathogens. J Am Geriatr Soc. 2001;49(3):270–6.PubMedCrossRef Trick WE, Weinstein RA, DeMarais PL, Kuehnert MJ, Tomaska W, Nathan C, et al. Colonization of skilled-care facility residents with antimicrobial-resistant pathogens. J Am Geriatr Soc. 2001;49(3):270–6.PubMedCrossRef
429.
Zurück zum Zitat Strausbaugh LJ, Sukumar SR, Joseph CL. Infectious disease outbreaks in nursing homes: an unappreciated hazard for frail elderly persons. Clin Infect Dis. 2003;36(7):870–6.PubMedCrossRef Strausbaugh LJ, Sukumar SR, Joseph CL. Infectious disease outbreaks in nursing homes: an unappreciated hazard for frail elderly persons. Clin Infect Dis. 2003;36(7):870–6.PubMedCrossRef
430.
Zurück zum Zitat Esposito S, Leone S, Noviello S, Lanniello F, Fiore M. Antibiotic resistance in long-term care facilities. New Microbiol. 2007;30(3):326–31.PubMed Esposito S, Leone S, Noviello S, Lanniello F, Fiore M. Antibiotic resistance in long-term care facilities. New Microbiol. 2007;30(3):326–31.PubMed
431.
Zurück zum Zitat Manzur A, Gudiol F. Methicillin-resistant Staphylococcus aureus in long-term-care facilities. Clin Microbiol Infect. 2009;15(Suppl 7):26–30.PubMedCrossRef Manzur A, Gudiol F. Methicillin-resistant Staphylococcus aureus in long-term-care facilities. Clin Microbiol Infect. 2009;15(Suppl 7):26–30.PubMedCrossRef
432.
Zurück zum Zitat Fisch J, Lansing B, Wang L, Symons K, Cherian K, McNamara S, et al. New acquisition of antibiotic-resistant organisms in skilled nursing facilities. J Clin Microbiol. 2012;50(5):1698–703.PubMedPubMedCentralCrossRef Fisch J, Lansing B, Wang L, Symons K, Cherian K, McNamara S, et al. New acquisition of antibiotic-resistant organisms in skilled nursing facilities. J Clin Microbiol. 2012;50(5):1698–703.PubMedPubMedCentralCrossRef
433.
Zurück zum Zitat Banerjee R, Johnston B, Lohse C, Porter SB, Clabots C, Johnson JR. Escherichia coli sequence type 131 is a dominant, antimicrobial-resistant clonal group associated with healthcare and elderly hosts. Infect Control Hosp Epidemiol. 2013;34(4):361–9.PubMedPubMedCentralCrossRef Banerjee R, Johnston B, Lohse C, Porter SB, Clabots C, Johnson JR. Escherichia coli sequence type 131 is a dominant, antimicrobial-resistant clonal group associated with healthcare and elderly hosts. Infect Control Hosp Epidemiol. 2013;34(4):361–9.PubMedPubMedCentralCrossRef
434.
Zurück zum Zitat Han JH, Maslow J, Han X, Xie SX, Tolomeo P, Santana E, et al. Risk factors for the development of gastrointestinal colonization with fluoroquinolone-resistant Escherichia coli in residents of long-term care facilities. J Infect Dis. 2014;209(3):420–5.PubMedCrossRef Han JH, Maslow J, Han X, Xie SX, Tolomeo P, Santana E, et al. Risk factors for the development of gastrointestinal colonization with fluoroquinolone-resistant Escherichia coli in residents of long-term care facilities. J Infect Dis. 2014;209(3):420–5.PubMedCrossRef
435.
Zurück zum Zitat Fagan M, Lindbaek M, Grude N, Reiso H, Romoren M, Skaare D, et al. Antibiotic resistance patterns of bacteria causing urinary tract infections in the elderly living in nursing homes versus the elderly living at home: an observational study. BMC Geriatr. 2015;15:98.PubMedPubMedCentralCrossRef Fagan M, Lindbaek M, Grude N, Reiso H, Romoren M, Skaare D, et al. Antibiotic resistance patterns of bacteria causing urinary tract infections in the elderly living in nursing homes versus the elderly living at home: an observational study. BMC Geriatr. 2015;15:98.PubMedPubMedCentralCrossRef
436.
Zurück zum Zitat Stine OC, Burrowes S, David S, Johnson JK, Roghmann MC. Transmission clusters of methicillin-resistant Staphylococcus Aureus in long-term care facilities based on whole-genome sequencing. Infect Control Hosp Epidemiol. 2016;37(6):685–91.PubMedCrossRef Stine OC, Burrowes S, David S, Johnson JK, Roghmann MC. Transmission clusters of methicillin-resistant Staphylococcus Aureus in long-term care facilities based on whole-genome sequencing. Infect Control Hosp Epidemiol. 2016;37(6):685–91.PubMedCrossRef
437.
Zurück zum Zitat Richards CL Jr. Preventing antimicrobial-resistant bacterial infections among older adults in long-term care facilities. J Am Med Dir Assoc. 2005;6(2):144–51.PubMedCrossRef Richards CL Jr. Preventing antimicrobial-resistant bacterial infections among older adults in long-term care facilities. J Am Med Dir Assoc. 2005;6(2):144–51.PubMedCrossRef
438.
Zurück zum Zitat van der Waaij D. Colonization pattern of the digestive tract by potentially pathogenic microorganisms: colonization-controlling mechanisms and consequences for antibiotic treatment. Infection. 1983;11(Suppl 2):S90–2.PubMedCrossRef van der Waaij D. Colonization pattern of the digestive tract by potentially pathogenic microorganisms: colonization-controlling mechanisms and consequences for antibiotic treatment. Infection. 1983;11(Suppl 2):S90–2.PubMedCrossRef
439.
Zurück zum Zitat Yoshida Y. Methicillin-resistant Staphylococcus aureus proliferation in the rat gut is influenced by gastric acid inhibition and the administration of antibiotics. Surg Today. 1999;29(4):327–37.PubMedCrossRef Yoshida Y. Methicillin-resistant Staphylococcus aureus proliferation in the rat gut is influenced by gastric acid inhibition and the administration of antibiotics. Surg Today. 1999;29(4):327–37.PubMedCrossRef
440.
Zurück zum Zitat Stiefel U, Rao A, Pultz MJ, Jump RL, Aron DC, Donskey CJ. Suppression of gastric acid production by proton pump inhibitor treatment facilitates colonization of the large intestine by vancomycin-resistant Enterococcus spp. and Klebsiella pneumoniae in clindamycin-treated mice. Antimicrob Agents Chemother. 2006;50(11):3905–7.PubMedPubMedCentralCrossRef Stiefel U, Rao A, Pultz MJ, Jump RL, Aron DC, Donskey CJ. Suppression of gastric acid production by proton pump inhibitor treatment facilitates colonization of the large intestine by vancomycin-resistant Enterococcus spp. and Klebsiella pneumoniae in clindamycin-treated mice. Antimicrob Agents Chemother. 2006;50(11):3905–7.PubMedPubMedCentralCrossRef
441.
Zurück zum Zitat Leung W, Malhi G, Willey BM, McGeer AJ, Borgundvaag B, Thanabalan R, et al. Prevalence and predictors of MRSA, ESBL, and VRE colonization in the ambulatory IBD population. J Crohns Colitis. 2012;6(7):743–9.PubMedCrossRef Leung W, Malhi G, Willey BM, McGeer AJ, Borgundvaag B, Thanabalan R, et al. Prevalence and predictors of MRSA, ESBL, and VRE colonization in the ambulatory IBD population. J Crohns Colitis. 2012;6(7):743–9.PubMedCrossRef
442.
Zurück zum Zitat Falk PS, Winnike J, Woodmansee C, Desai M, Mayhall CG. Outbreak of vancomycin-resistant enterococci in a burn unit. Infect Control Hosp Epidemiol. 2000;21(9):575–82.PubMedCrossRef Falk PS, Winnike J, Woodmansee C, Desai M, Mayhall CG. Outbreak of vancomycin-resistant enterococci in a burn unit. Infect Control Hosp Epidemiol. 2000;21(9):575–82.PubMedCrossRef
443.
Zurück zum Zitat Cetinkaya Y, Falk PS, Mayhall CG. Effect of gastrointestinal bleeding and oral medications on acquisition of vancomycin-resistant Enterococcus faecium in hospitalized patients. Clin Infect Dis. 2002;35(8):935–42.PubMedCrossRef Cetinkaya Y, Falk PS, Mayhall CG. Effect of gastrointestinal bleeding and oral medications on acquisition of vancomycin-resistant Enterococcus faecium in hospitalized patients. Clin Infect Dis. 2002;35(8):935–42.PubMedCrossRef
444.
Zurück zum Zitat McNeil SA, Malani PN, Chenoweth CE, Fontana RJ, Magee JC, Punch JD, et al. Vancomycin-resistant enterococcal colonization and infection in liver transplant candidates and recipients: a prospective surveillance study. Clin Infect Dis. 2006;42(2):195–203.PubMedCrossRef McNeil SA, Malani PN, Chenoweth CE, Fontana RJ, Magee JC, Punch JD, et al. Vancomycin-resistant enterococcal colonization and infection in liver transplant candidates and recipients: a prospective surveillance study. Clin Infect Dis. 2006;42(2):195–203.PubMedCrossRef
445.
Zurück zum Zitat Ben-Ami R, Schwaber MJ, Navon-Venezia S, Schwartz D, Giladi M, Chmelnitsky I, et al. Influx of extended-spectrum beta-lactamase-producing enterobacteriaceae into the hospital. Clin Infect Dis. 2006;42(7):925–34.PubMedCrossRef Ben-Ami R, Schwaber MJ, Navon-Venezia S, Schwartz D, Giladi M, Chmelnitsky I, et al. Influx of extended-spectrum beta-lactamase-producing enterobacteriaceae into the hospital. Clin Infect Dis. 2006;42(7):925–34.PubMedCrossRef
446.
Zurück zum Zitat Sanaka M, Yamamoto T, Kuyama Y. Effects of proton pump inhibitors on gastric emptying: a systematic review. Dig Dis Sci. 2010;55(9):2431–40.PubMedCrossRef Sanaka M, Yamamoto T, Kuyama Y. Effects of proton pump inhibitors on gastric emptying: a systematic review. Dig Dis Sci. 2010;55(9):2431–40.PubMedCrossRef
447.
Zurück zum Zitat Lichtenberger LM, Bhattarai D, Phan TM, Dial EJ, Uray K. Suppression of contractile activity in the small intestine by indomethacin and omeprazole. Am J Physiol Gastrointest Liver Physiol. 2015;308(9):G785–93.PubMedPubMedCentralCrossRef Lichtenberger LM, Bhattarai D, Phan TM, Dial EJ, Uray K. Suppression of contractile activity in the small intestine by indomethacin and omeprazole. Am J Physiol Gastrointest Liver Physiol. 2015;308(9):G785–93.PubMedPubMedCentralCrossRef
448.
Zurück zum Zitat Parkman HP, Urbain JL, Knight LC, Brown KL, Trate DM, Miller MA, et al. Effect of gastric acid suppressants on human gastric motility. Gut. 1998;42(2):243–50.PubMedPubMedCentralCrossRef Parkman HP, Urbain JL, Knight LC, Brown KL, Trate DM, Miller MA, et al. Effect of gastric acid suppressants on human gastric motility. Gut. 1998;42(2):243–50.PubMedPubMedCentralCrossRef
449.
Zurück zum Zitat Zedtwitz-Liebenstein K, Wenisch C, Patruta S, Parschalk B, Daxbock F, Graninger W. Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity. Crit Care Med. 2002;30(5):1118–22.PubMedCrossRef Zedtwitz-Liebenstein K, Wenisch C, Patruta S, Parschalk B, Daxbock F, Graninger W. Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity. Crit Care Med. 2002;30(5):1118–22.PubMedCrossRef
450.
Zurück zum Zitat Kedika RR, Souza RF, Spechler SJ. Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications. Dig Dis Sci. 2009;54(11):2312–7.PubMedPubMedCentralCrossRef Kedika RR, Souza RF, Spechler SJ. Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications. Dig Dis Sci. 2009;54(11):2312–7.PubMedPubMedCentralCrossRef
451.
Zurück zum Zitat Henry EB, Carswell A, Wirz A, Fyffe V, McColl KE. Proton pump inhibitors reduce the bioavailability of dietary vitamin C. Aliment Pharmacol Ther. 2005;22(6):539–45.PubMedCrossRef Henry EB, Carswell A, Wirz A, Fyffe V, McColl KE. Proton pump inhibitors reduce the bioavailability of dietary vitamin C. Aliment Pharmacol Ther. 2005;22(6):539–45.PubMedCrossRef
452.
Zurück zum Zitat McColl KE. Effect of proton pump inhibitors on vitamins and iron. Am J Gastroenterol. 2009;104(Suppl 2):S5–9.PubMedCrossRef McColl KE. Effect of proton pump inhibitors on vitamins and iron. Am J Gastroenterol. 2009;104(Suppl 2):S5–9.PubMedCrossRef
453.
Zurück zum Zitat Ito T, Jensen RT. Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium. Curr Gastroenterol Rep. 2010;12(6):448–57.PubMedPubMedCentralCrossRef Ito T, Jensen RT. Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium. Curr Gastroenterol Rep. 2010;12(6):448–57.PubMedPubMedCentralCrossRef
454.
Zurück zum Zitat Mullin JM, Valenzano MC, Whitby M, Lurie D, Schmidt JD, Jain V, et al. Esomeprazole induces upper gastrointestinal tract transmucosal permeability increase. Aliment Pharmacol Ther. 2008;28(11–12):1317–25.PubMedCrossRef Mullin JM, Valenzano MC, Whitby M, Lurie D, Schmidt JD, Jain V, et al. Esomeprazole induces upper gastrointestinal tract transmucosal permeability increase. Aliment Pharmacol Ther. 2008;28(11–12):1317–25.PubMedCrossRef
455.
Zurück zum Zitat Farrell C, Morgan M, Tully O, Wolov K, Kearney K, Ngo B, et al. Transepithelial leak in Barrett’s esophagus patients: the role of proton pump inhibitors. World J Gastroenterol. 2012;18(22):2793–7.PubMedPubMedCentralCrossRef Farrell C, Morgan M, Tully O, Wolov K, Kearney K, Ngo B, et al. Transepithelial leak in Barrett’s esophagus patients: the role of proton pump inhibitors. World J Gastroenterol. 2012;18(22):2793–7.PubMedPubMedCentralCrossRef
456.
Zurück zum Zitat Tsiaoussis GI, Assimakopoulos SF, Tsamandas AC, Triantos CK, Thomopoulos KC. Intestinal barrier dysfunction in cirrhosis: current concepts in pathophysiology and clinical implications. World J Hepatol. 2015;7(17):2058–68.PubMedPubMedCentralCrossRef Tsiaoussis GI, Assimakopoulos SF, Tsamandas AC, Triantos CK, Thomopoulos KC. Intestinal barrier dysfunction in cirrhosis: current concepts in pathophysiology and clinical implications. World J Hepatol. 2015;7(17):2058–68.PubMedPubMedCentralCrossRef
457.
Zurück zum Zitat Franceschi C, Capri M, Monti D, Giunta S, Olivieri F, Sevini F, et al. Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev. 2007;128(1):92–105.PubMedCrossRef Franceschi C, Capri M, Monti D, Giunta S, Olivieri F, Sevini F, et al. Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev. 2007;128(1):92–105.PubMedCrossRef
458.
Zurück zum Zitat Ostan R, Bucci L, Capri M, Salvioli S, Scurti M, Pini E, et al. Immunosenescence and immunogenetics of human longevity. Neuroimmunomodulation. 2008;15(4–6):224–40.PubMedCrossRef Ostan R, Bucci L, Capri M, Salvioli S, Scurti M, Pini E, et al. Immunosenescence and immunogenetics of human longevity. Neuroimmunomodulation. 2008;15(4–6):224–40.PubMedCrossRef
459.
Zurück zum Zitat Fulop T, Dupuis G, Witkowski JM, Larbi A. The role of immunosenescence in the development of age-related diseases. Rev Invest Clin. 2016;68(2):84–91.PubMed Fulop T, Dupuis G, Witkowski JM, Larbi A. The role of immunosenescence in the development of age-related diseases. Rev Invest Clin. 2016;68(2):84–91.PubMed
460.
461.
Zurück zum Zitat Castle SC. Clinical relevance of age-related immune dysfunction. Clin Infect Dis. 2000;31(2):578–85.PubMedCrossRef Castle SC. Clinical relevance of age-related immune dysfunction. Clin Infect Dis. 2000;31(2):578–85.PubMedCrossRef
462.
465.
Zurück zum Zitat Pelaseyed T, Bergstrom JH, Gustafsson JK, Ermund A, Birchenough GM, Schutte A, et al. The mucus and mucins of the goblet cells and enterocytes provide the first defence line of the gastrointestinal tract and interact with the immune system. Immunol Rev. 2014;260(1):8–20.PubMedPubMedCentralCrossRef Pelaseyed T, Bergstrom JH, Gustafsson JK, Ermund A, Birchenough GM, Schutte A, et al. The mucus and mucins of the goblet cells and enterocytes provide the first defence line of the gastrointestinal tract and interact with the immune system. Immunol Rev. 2014;260(1):8–20.PubMedPubMedCentralCrossRef
466.
Zurück zum Zitat Waldum HL, Hauso O, Fossmark R. The regulation of gastric acid secretion—clinical perspectives. Acta Physiol (Oxf). 2014;210(2):239–56.CrossRef Waldum HL, Hauso O, Fossmark R. The regulation of gastric acid secretion—clinical perspectives. Acta Physiol (Oxf). 2014;210(2):239–56.CrossRef
467.
468.
Zurück zum Zitat Johansson ME, Sjovall H, Hansson GC. The gastrointestinal mucus system in health and disease. Nat Rev Gastroenterol Hepatol. 2013;10(6):352–61.PubMedPubMedCentralCrossRef Johansson ME, Sjovall H, Hansson GC. The gastrointestinal mucus system in health and disease. Nat Rev Gastroenterol Hepatol. 2013;10(6):352–61.PubMedPubMedCentralCrossRef
471.
472.
Zurück zum Zitat Beasley DE, Koltz AM, Lambert JE, Fierer N, Dunn RR. The evolution of stomach acidity and its relevance to the human microbiome. PLoS One. 2015;10(7):e0134116.PubMedPubMedCentralCrossRef Beasley DE, Koltz AM, Lambert JE, Fierer N, Dunn RR. The evolution of stomach acidity and its relevance to the human microbiome. PLoS One. 2015;10(7):e0134116.PubMedPubMedCentralCrossRef
473.
Zurück zum Zitat Smith JL. The role of gastric acid in preventing foodborne disease and how bacteria overcome acid conditions. J Food Prot. 2003;66(7):1292–303.PubMedCrossRef Smith JL. The role of gastric acid in preventing foodborne disease and how bacteria overcome acid conditions. J Food Prot. 2003;66(7):1292–303.PubMedCrossRef
474.
Zurück zum Zitat Hornick RB, Music SI, Wenzel R, Cash R, Libonati JP, Snyder MJ, et al. The Broad Street pump revisited: response of volunteers to ingested cholera vibrios. Bull N Y Acad Med. 1971;47(10):1181–91.PubMedPubMedCentral Hornick RB, Music SI, Wenzel R, Cash R, Libonati JP, Snyder MJ, et al. The Broad Street pump revisited: response of volunteers to ingested cholera vibrios. Bull N Y Acad Med. 1971;47(10):1181–91.PubMedPubMedCentral
475.
Zurück zum Zitat Tennant SM, Hartland EL, Phumoonna T, Lyras D, Rood JI, Robins-Browne RM, et al. Influence of gastric acid on susceptibility to infection with ingested bacterial pathogens. Infect Immun. 2008;76(2):639–45.PubMedCrossRef Tennant SM, Hartland EL, Phumoonna T, Lyras D, Rood JI, Robins-Browne RM, et al. Influence of gastric acid on susceptibility to infection with ingested bacterial pathogens. Infect Immun. 2008;76(2):639–45.PubMedCrossRef
476.
Zurück zum Zitat Monk BC, Mason AB, Abramochkin G, Haber JE, Seto-Young D, Perlin DS. The yeast plasma membrane proton pumping ATPase is a viable antifungal target. I. Effects of the cysteine-modifying reagent omeprazole. Biochim Biophys Acta. 1995;1239(1):81–90.PubMedCrossRef Monk BC, Mason AB, Abramochkin G, Haber JE, Seto-Young D, Perlin DS. The yeast plasma membrane proton pumping ATPase is a viable antifungal target. I. Effects of the cysteine-modifying reagent omeprazole. Biochim Biophys Acta. 1995;1239(1):81–90.PubMedCrossRef
477.
Zurück zum Zitat Perlin DS, Seto-Young D, Monk BC. The plasma membrane H(+)-ATPase of fungi. A candidate drug target? Ann N Y Acad Sci. 1997;3(834):609–17.CrossRef Perlin DS, Seto-Young D, Monk BC. The plasma membrane H(+)-ATPase of fungi. A candidate drug target? Ann N Y Acad Sci. 1997;3(834):609–17.CrossRef
478.
Zurück zum Zitat Vesper BJ, Jawdi A, Altman KW, Haines GK 3rd, Tao L, Radosevich JA. The effect of proton pump inhibitors on the human microbiota. Curr Drug Metab. 2009;10(1):84–9.PubMedCrossRef Vesper BJ, Jawdi A, Altman KW, Haines GK 3rd, Tao L, Radosevich JA. The effect of proton pump inhibitors on the human microbiota. Curr Drug Metab. 2009;10(1):84–9.PubMedCrossRef
479.
Zurück zum Zitat Nagata K, Satoh H, Iwahi T, Shimoyama T, Tamura T. Potent inhibitory action of the gastric proton pump inhibitor lansoprazole against urease activity of Helicobacter pylori: unique action selective for H. pylori cells. Antimicrob Agents Chemother. 1993;37(4):769–74.PubMedPubMedCentralCrossRef Nagata K, Satoh H, Iwahi T, Shimoyama T, Tamura T. Potent inhibitory action of the gastric proton pump inhibitor lansoprazole against urease activity of Helicobacter pylori: unique action selective for H. pylori cells. Antimicrob Agents Chemother. 1993;37(4):769–74.PubMedPubMedCentralCrossRef
480.
Zurück zum Zitat Hirai M, Azuma T, Ito S, Kato T, Kohli Y. A proton pump inhibitor, E3810, has antibacterial activity through binding to Helicobacter pylori. J Gastroenterol. 1995;30(4):461–4.PubMedCrossRef Hirai M, Azuma T, Ito S, Kato T, Kohli Y. A proton pump inhibitor, E3810, has antibacterial activity through binding to Helicobacter pylori. J Gastroenterol. 1995;30(4):461–4.PubMedCrossRef
481.
Zurück zum Zitat Ajdic D, McShan WM, McLaughlin RE, Savic G, Chang J, Carson MB, et al. Genome sequence of Streptococcus mutans UA159, a cariogenic dental pathogen. Proc Natl Acad Sci USA. 2002;99(22):14434–9.PubMedPubMedCentralCrossRef Ajdic D, McShan WM, McLaughlin RE, Savic G, Chang J, Carson MB, et al. Genome sequence of Streptococcus mutans UA159, a cariogenic dental pathogen. Proc Natl Acad Sci USA. 2002;99(22):14434–9.PubMedPubMedCentralCrossRef
482.
Zurück zum Zitat Monk BC, Mason AB, Kardos TB, Perlin DS. Targeting the fungal plasma membrane proton pump. Acta Biochim Pol. 1995;42(4):481–96.PubMed Monk BC, Mason AB, Kardos TB, Perlin DS. Targeting the fungal plasma membrane proton pump. Acta Biochim Pol. 1995;42(4):481–96.PubMed
483.
Zurück zum Zitat Wandall JH. Effects of omeprazole on neutrophil chemotaxis, super oxide production, degranulation, and translocation of cytochrome b-245. Gut. 1992;33(5):617–21.PubMedPubMedCentralCrossRef Wandall JH. Effects of omeprazole on neutrophil chemotaxis, super oxide production, degranulation, and translocation of cytochrome b-245. Gut. 1992;33(5):617–21.PubMedPubMedCentralCrossRef
484.
Zurück zum Zitat Ritter M, Schratzberger P, Rossmann H, Woll E, Seiler K, Seidler U, et al. Effect of inhibitors of Na+/H+exchange and gastric H+/K+ ATPase on cell volume, intracellular pH and migration of human polymorphonuclear leucocytes. Br J Pharmacol. 1998;124(4):627–38.PubMedPubMedCentralCrossRef Ritter M, Schratzberger P, Rossmann H, Woll E, Seiler K, Seidler U, et al. Effect of inhibitors of Na+/H+exchange and gastric H+/K+ ATPase on cell volume, intracellular pH and migration of human polymorphonuclear leucocytes. Br J Pharmacol. 1998;124(4):627–38.PubMedPubMedCentralCrossRef
485.
Zurück zum Zitat Capodicasa E, De Bellis F, Pelli MA. Effect of lansoprazole on human leukocyte function. Immunopharmacol Immunotoxicol. 1999;21(2):357–77.PubMedCrossRef Capodicasa E, De Bellis F, Pelli MA. Effect of lansoprazole on human leukocyte function. Immunopharmacol Immunotoxicol. 1999;21(2):357–77.PubMedCrossRef
486.
Zurück zum Zitat Martins de Oliveira R, Antunes E, Pedrazzoli J Jr, Gambero A. The inhibitory effects of H+ K+ ATPase inhibitors on human neutrophils in vitro: restoration by a K+ ionophore. Inflamm Res. 2007;56(3):105–11.PubMedCrossRef Martins de Oliveira R, Antunes E, Pedrazzoli J Jr, Gambero A. The inhibitory effects of H+ K+ ATPase inhibitors on human neutrophils in vitro: restoration by a K+ ionophore. Inflamm Res. 2007;56(3):105–11.PubMedCrossRef
487.
Zurück zum Zitat Agastya G, West BC, Callahan JM. Omeprazole inhibits phagocytosis and acidification of phagolysosomes of normal human neutrophils in vitro. Immunopharmacol Immunotoxicol. 2000;22(2):357–72.PubMedCrossRef Agastya G, West BC, Callahan JM. Omeprazole inhibits phagocytosis and acidification of phagolysosomes of normal human neutrophils in vitro. Immunopharmacol Immunotoxicol. 2000;22(2):357–72.PubMedCrossRef
488.
Zurück zum Zitat Yoshida N, Yoshikawa T, Tanaka Y, Fujita N, Kassai K, Naito Y, et al. A new mechanism for anti-inflammatory actions of proton pump inhibitors—inhibitory effects on neutrophil-endothelial cell interactions. Aliment Pharmacol Ther. 2000;14(Suppl 1):74–81.PubMedCrossRef Yoshida N, Yoshikawa T, Tanaka Y, Fujita N, Kassai K, Naito Y, et al. A new mechanism for anti-inflammatory actions of proton pump inhibitors—inhibitory effects on neutrophil-endothelial cell interactions. Aliment Pharmacol Ther. 2000;14(Suppl 1):74–81.PubMedCrossRef
489.
Zurück zum Zitat Suzuki M, Mori M, Fukumura D, Suzuki H, Miura S, Ishii H. Omeprazole attenuates neutrophil-endothelial cell adhesive interaction induced by extracts of Helicobacter pylori. J Gastroenterol Hepatol. 1999;14(1):27–31.PubMedCrossRef Suzuki M, Mori M, Fukumura D, Suzuki H, Miura S, Ishii H. Omeprazole attenuates neutrophil-endothelial cell adhesive interaction induced by extracts of Helicobacter pylori. J Gastroenterol Hepatol. 1999;14(1):27–31.PubMedCrossRef
490.
Zurück zum Zitat Lapenna D, de Gioia S, Ciofani G, Festi D, Cuccurullo F. Antioxidant properties of omeprazole. FEBS Lett. 1996;382(1–2):189–92.PubMedCrossRef Lapenna D, de Gioia S, Ciofani G, Festi D, Cuccurullo F. Antioxidant properties of omeprazole. FEBS Lett. 1996;382(1–2):189–92.PubMedCrossRef
491.
Zurück zum Zitat Suzuki M, Mori M, Miura S, Suematsu M, Fukumura D, Kimura H, et al. Omeprazole attenuates oxygen-derived free radical production from human neutrophils. Free Radic Biol Med. 1996;21(5):727–31.PubMedCrossRef Suzuki M, Mori M, Miura S, Suematsu M, Fukumura D, Kimura H, et al. Omeprazole attenuates oxygen-derived free radical production from human neutrophils. Free Radic Biol Med. 1996;21(5):727–31.PubMedCrossRef
492.
Zurück zum Zitat Blandizzi C, Fornai M, Colucci R, Natale G, Lubrano V, Vassalle C, et al. Lansoprazole prevents experimental gastric injury induced by non-steroidal anti-inflammatory drugs through a reduction of mucosal oxidative damage. World J Gastroenterol. 2005;11(26):4052–60.PubMedPubMedCentralCrossRef Blandizzi C, Fornai M, Colucci R, Natale G, Lubrano V, Vassalle C, et al. Lansoprazole prevents experimental gastric injury induced by non-steroidal anti-inflammatory drugs through a reduction of mucosal oxidative damage. World J Gastroenterol. 2005;11(26):4052–60.PubMedPubMedCentralCrossRef
493.
Zurück zum Zitat Fornai M, Natale G, Colucci R, Tuccori M, Carazzina G, Antonioli L, et al. Mechanisms of protection by pantoprazole against NSAID-induced gastric mucosal damage. Naunyn Schmiedebergs Arch Pharmacol. 2005;372(1):79–87.PubMedCrossRef Fornai M, Natale G, Colucci R, Tuccori M, Carazzina G, Antonioli L, et al. Mechanisms of protection by pantoprazole against NSAID-induced gastric mucosal damage. Naunyn Schmiedebergs Arch Pharmacol. 2005;372(1):79–87.PubMedCrossRef
494.
Zurück zum Zitat Simon WA, Sturm E, Hartmann HJ, Weser U. Hydroxyl radical scavenging reactivity of proton pump inhibitors. Biochem Pharmacol. 2006;71(9):1337–41.PubMedCrossRef Simon WA, Sturm E, Hartmann HJ, Weser U. Hydroxyl radical scavenging reactivity of proton pump inhibitors. Biochem Pharmacol. 2006;71(9):1337–41.PubMedCrossRef
495.
Zurück zum Zitat Pastoris O, Verri M, Boschi F, Kastsiuchenka O, Balestra B, Pace F, et al. Effects of esomeprazole on glutathione levels and mitochondrial oxidative phosphorylation in the gastric mucosa of rats treated with indomethacin. Naunyn Schmiedebergs Arch Pharmacol. 2008;378(4):421–9.PubMedCrossRef Pastoris O, Verri M, Boschi F, Kastsiuchenka O, Balestra B, Pace F, et al. Effects of esomeprazole on glutathione levels and mitochondrial oxidative phosphorylation in the gastric mucosa of rats treated with indomethacin. Naunyn Schmiedebergs Arch Pharmacol. 2008;378(4):421–9.PubMedCrossRef
496.
Zurück zum Zitat Biswas K, Bandyopadhyay U, Chattopadhyay I, Varadaraj A, Ali E, Banerjee RK. A novel antioxidant and antiapoptotic role of omeprazole to block gastric ulcer through scavenging of hydroxyl radical. J Biol Chem. 2003;278(13):10993–1001.PubMedCrossRef Biswas K, Bandyopadhyay U, Chattopadhyay I, Varadaraj A, Ali E, Banerjee RK. A novel antioxidant and antiapoptotic role of omeprazole to block gastric ulcer through scavenging of hydroxyl radical. J Biol Chem. 2003;278(13):10993–1001.PubMedCrossRef
497.
Zurück zum Zitat Becker JC, Grosser N, Waltke C, Schulz S, Erdmann K, Domschke W, et al. Beyond gastric acid reduction: proton pump inhibitors induce heme oxygenase-1 in gastric and endothelial cells. Biochem Biophys Res Commun. 2006;345(3):1014–21.PubMedCrossRef Becker JC, Grosser N, Waltke C, Schulz S, Erdmann K, Domschke W, et al. Beyond gastric acid reduction: proton pump inhibitors induce heme oxygenase-1 in gastric and endothelial cells. Biochem Biophys Res Commun. 2006;345(3):1014–21.PubMedCrossRef
498.
Zurück zum Zitat Ohara T, Arakawa T. Lansoprazole decreases peripheral blood monocytes and intercellular adhesion molecule-1-positive mononuclear cells. Dig Dis Sci. 1999;44(8):1710–5.PubMedCrossRef Ohara T, Arakawa T. Lansoprazole decreases peripheral blood monocytes and intercellular adhesion molecule-1-positive mononuclear cells. Dig Dis Sci. 1999;44(8):1710–5.PubMedCrossRef
499.
Zurück zum Zitat Handa O, Yoshida N, Fujita N, Tanaka Y, Ueda M, Takagi T, et al. Molecular mechanisms involved in anti-inflammatory effects of proton pump inhibitors. Inflamm Res. 2006;55(11):476–80.PubMedCrossRef Handa O, Yoshida N, Fujita N, Tanaka Y, Ueda M, Takagi T, et al. Molecular mechanisms involved in anti-inflammatory effects of proton pump inhibitors. Inflamm Res. 2006;55(11):476–80.PubMedCrossRef
500.
Zurück zum Zitat Namazi MR, Jowkar F. A succinct review of the general and immunological pharmacologic effects of proton pump inhibitors. J Clin Pharm Ther. 2008;33(3):215–7.PubMedCrossRef Namazi MR, Jowkar F. A succinct review of the general and immunological pharmacologic effects of proton pump inhibitors. J Clin Pharm Ther. 2008;33(3):215–7.PubMedCrossRef
501.
Zurück zum Zitat Ghebremariam YT, Cooke JP, Gerhart W, Griego C, Brower JB, Doyle-Eisele M, et al. Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis. J Transl Med. 2015;13:249.PubMedPubMedCentralCrossRef Ghebremariam YT, Cooke JP, Gerhart W, Griego C, Brower JB, Doyle-Eisele M, et al. Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis. J Transl Med. 2015;13:249.PubMedPubMedCentralCrossRef
502.
Zurück zum Zitat Ghebremariam YT, LePendu P, Lee JC, Erlanson DA, Slaviero A, Shah NH, et al. Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation. 2013;128(8):845–53.PubMedCrossRef Ghebremariam YT, LePendu P, Lee JC, Erlanson DA, Slaviero A, Shah NH, et al. Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation. 2013;128(8):845–53.PubMedCrossRef
503.
Zurück zum Zitat Liu W, Baker SS, Trinidad J, Burlingame AL, Baker RD, Forte JG, et al. Inhibition of lysosomal enzyme activities by proton pump inhibitors. J Gastroenterol. 2013;48(12):1343–52.PubMedCrossRef Liu W, Baker SS, Trinidad J, Burlingame AL, Baker RD, Forte JG, et al. Inhibition of lysosomal enzyme activities by proton pump inhibitors. J Gastroenterol. 2013;48(12):1343–52.PubMedCrossRef
504.
Zurück zum Zitat Sasaki T, Yamaya M, Yasuda H, Inoue D, Yamada M, Kubo H, et al. The proton pump inhibitor lansoprazole inhibits rhinovirus infection in cultured human tracheal epithelial cells. Eur J Pharmacol. 2005;509(2–3):201–10.PubMedCrossRef Sasaki T, Yamaya M, Yasuda H, Inoue D, Yamada M, Kubo H, et al. The proton pump inhibitor lansoprazole inhibits rhinovirus infection in cultured human tracheal epithelial cells. Eur J Pharmacol. 2005;509(2–3):201–10.PubMedCrossRef
505.
Zurück zum Zitat Kuroda M, Yoshida N, Ichikawa H, Takagi T, Okuda T, Naito Y, et al. Lansoprazole, a proton pump inhibitor, reduces the severity of indomethacin-induced rat enteritis. Int J Mol Med. 2006;17(1):89–93.PubMed Kuroda M, Yoshida N, Ichikawa H, Takagi T, Okuda T, Naito Y, et al. Lansoprazole, a proton pump inhibitor, reduces the severity of indomethacin-induced rat enteritis. Int J Mol Med. 2006;17(1):89–93.PubMed
506.
Zurück zum Zitat Aybay C, Imir T, Okur H. The effect of omeprazole on human natural killer cell activity. Gen Pharmacol. 1995;26(6):1413–8.PubMedCrossRef Aybay C, Imir T, Okur H. The effect of omeprazole on human natural killer cell activity. Gen Pharmacol. 1995;26(6):1413–8.PubMedCrossRef
507.
Zurück zum Zitat Shamburek RD, Ruddy S, Schubert ML. Omeprazole and neutrophil function. Gastroenterology. 1993;104(3):938–40.PubMedCrossRef Shamburek RD, Ruddy S, Schubert ML. Omeprazole and neutrophil function. Gastroenterology. 1993;104(3):938–40.PubMedCrossRef
508.
Zurück zum Zitat Jiang S, Meadows J, Anderson SA, Mukkada AJ. Antileishmanial activity of the antiulcer agent omeprazole. Antimicrob Agents Chemother. 2002;46(8):2569–74.PubMedPubMedCentralCrossRef Jiang S, Meadows J, Anderson SA, Mukkada AJ. Antileishmanial activity of the antiulcer agent omeprazole. Antimicrob Agents Chemother. 2002;46(8):2569–74.PubMedPubMedCentralCrossRef
509.
Zurück zum Zitat Vishvakarma NK, Singh SM. Immunopotentiating effect of proton pump inhibitor pantoprazole in a lymphoma-bearing murine host: implication in antitumor activation of tumor-associated macrophages. Immunol Lett. 2010;134(1):83–92.PubMedCrossRef Vishvakarma NK, Singh SM. Immunopotentiating effect of proton pump inhibitor pantoprazole in a lymphoma-bearing murine host: implication in antitumor activation of tumor-associated macrophages. Immunol Lett. 2010;134(1):83–92.PubMedCrossRef
510.
Zurück zum Zitat Vishvakarma NK, Singh SM. Augmentation of myelopoiesis in a murine host bearing a T cell lymphoma following in vivo administration of proton pump inhibitor pantoprazole. Biochimie. 2011;93(10):1786–96.PubMedCrossRef Vishvakarma NK, Singh SM. Augmentation of myelopoiesis in a murine host bearing a T cell lymphoma following in vivo administration of proton pump inhibitor pantoprazole. Biochimie. 2011;93(10):1786–96.PubMedCrossRef
511.
Zurück zum Zitat De Milito A, Fais S. Tumor acidity, chemoresistance and proton pump inhibitors. Future Oncol. 2005;1(6):779–86.PubMedCrossRef De Milito A, Fais S. Tumor acidity, chemoresistance and proton pump inhibitors. Future Oncol. 2005;1(6):779–86.PubMedCrossRef
512.
Zurück zum Zitat Fais S. A nonmainstream approach against cancer. J Enzyme Inhib Med Chem. 2016;14:1–8. Fais S. A nonmainstream approach against cancer. J Enzyme Inhib Med Chem. 2016;14:1–8.
513.
Zurück zum Zitat Mehta J, Powles RL, Treleaven J, Shields M, Agrawal S, Rege K, et al. Cimetidine-induced myelosuppression after bone marrow transplantation. Leuk Lymphoma. 1994;13(1–2):179–81.PubMedCrossRef Mehta J, Powles RL, Treleaven J, Shields M, Agrawal S, Rege K, et al. Cimetidine-induced myelosuppression after bone marrow transplantation. Leuk Lymphoma. 1994;13(1–2):179–81.PubMedCrossRef
514.
Zurück zum Zitat Ching TL, Koelemij JG, Bast A. The effect of histamine on the oxidative burst of HL60 cells before and after exposure to reactive oxygen species. Inflamm Res. 1995;44(3):99–104.PubMedCrossRef Ching TL, Koelemij JG, Bast A. The effect of histamine on the oxidative burst of HL60 cells before and after exposure to reactive oxygen species. Inflamm Res. 1995;44(3):99–104.PubMedCrossRef
515.
Zurück zum Zitat Ching TL, de Jong J, Bast A. Structural characteristics of histamine H2 receptor antagonists that scavenge hypochlorous acid. Eur J Pharmacol. 1994;268(1):89–93.PubMedCrossRef Ching TL, de Jong J, Bast A. Structural characteristics of histamine H2 receptor antagonists that scavenge hypochlorous acid. Eur J Pharmacol. 1994;268(1):89–93.PubMedCrossRef
516.
Zurück zum Zitat Mikawa K, Akamatsu H, Nishina K, Shiga M, Maekawa N, Obara H, et al. The effects of cimetidine, ranitidine, and famotidine on human neutrophil functions. Anesth Analg. 1999;89(1):218–24.PubMed Mikawa K, Akamatsu H, Nishina K, Shiga M, Maekawa N, Obara H, et al. The effects of cimetidine, ranitidine, and famotidine on human neutrophil functions. Anesth Analg. 1999;89(1):218–24.PubMed
518.
Zurück zum Zitat Werner K, Neumann D, Seifert R. Analysis of the histamine H2-receptor in human monocytes. Biochem Pharmacol. 2014;92(2):369–79.PubMedCrossRef Werner K, Neumann D, Seifert R. Analysis of the histamine H2-receptor in human monocytes. Biochem Pharmacol. 2014;92(2):369–79.PubMedCrossRef
519.
Zurück zum Zitat Burde R, Seifert R. Stimulation of histamine H2- (and H1)-receptors activates Ca2+ influx in all-trans-retinoic acid-differentiated HL-60 cells independently of phospholipase C or adenylyl cyclase. Naunyn Schmiedebergs Arch Pharmacol. 1996;353(2):123–9.PubMedCrossRef Burde R, Seifert R. Stimulation of histamine H2- (and H1)-receptors activates Ca2+ influx in all-trans-retinoic acid-differentiated HL-60 cells independently of phospholipase C or adenylyl cyclase. Naunyn Schmiedebergs Arch Pharmacol. 1996;353(2):123–9.PubMedCrossRef
520.
Zurück zum Zitat Akdis CA, Simons FE. Histamine receptors are hot in immunopharmacology. Eur J Pharmacol. 2006;533(1–3):69–76.PubMedCrossRef Akdis CA, Simons FE. Histamine receptors are hot in immunopharmacology. Eur J Pharmacol. 2006;533(1–3):69–76.PubMedCrossRef
521.
Zurück zum Zitat Reher TM, Brunskole I, Neumann D, Seifert R. Evidence for ligand-specific conformations of the histamine H(2)-receptor in human eosinophils and neutrophils. Biochem Pharmacol. 2012;84(9):1174–85.PubMedCrossRef Reher TM, Brunskole I, Neumann D, Seifert R. Evidence for ligand-specific conformations of the histamine H(2)-receptor in human eosinophils and neutrophils. Biochem Pharmacol. 2012;84(9):1174–85.PubMedCrossRef
522.
Zurück zum Zitat Nielsen HJ, Nielsen H, Moesgaard F, Tvede N, Klarlund K, Mansa B, et al. The effect of ranitidine on cellular immunity in patients with multiple myeloma. Cancer Immunol Immunother. 1990;32(3):201–5.PubMedCrossRef Nielsen HJ, Nielsen H, Moesgaard F, Tvede N, Klarlund K, Mansa B, et al. The effect of ranitidine on cellular immunity in patients with multiple myeloma. Cancer Immunol Immunother. 1990;32(3):201–5.PubMedCrossRef
523.
Zurück zum Zitat Nielsen HJ, Nielsen H, Jensen S, Moesgaard F. Ranitidine improves postoperative monocyte and neutrophil function. Arch Surg. 1994;129(3):309–15.PubMedCrossRef Nielsen HJ, Nielsen H, Jensen S, Moesgaard F. Ranitidine improves postoperative monocyte and neutrophil function. Arch Surg. 1994;129(3):309–15.PubMedCrossRef
524.
Zurück zum Zitat Neugebauer E, Lorenz W, Beckurts T, Maroske D, Merte H. Significance of histamine formation and release in the development of endotoxic shock: proof of current concepts by randomized controlled studies in rats. Rev Infect Dis. 1987;9 Suppl 5:S585–93. Neugebauer E, Lorenz W, Beckurts T, Maroske D, Merte H. Significance of histamine formation and release in the development of endotoxic shock: proof of current concepts by randomized controlled studies in rats. Rev Infect Dis. 1987;9 Suppl 5:S585–93.
525.
Zurück zum Zitat Rixen D, Neugebauer E, Lechleuthner A, Buschauer A, Nagelschmidt M, Thoma S, et al. Beneficial effect of H2-agonism and H1-antagonism in rat endotoxic shock. Shock. 1994;2(1):47–52.PubMedCrossRef Rixen D, Neugebauer E, Lechleuthner A, Buschauer A, Nagelschmidt M, Thoma S, et al. Beneficial effect of H2-agonism and H1-antagonism in rat endotoxic shock. Shock. 1994;2(1):47–52.PubMedCrossRef
526.
Zurück zum Zitat Hahm KB, Kim WH, Lee SI, Kang JK, Park IS. Comparison of immunomodulative effects of the histamine-2 receptor antagonists cimetidine, ranitidine, and famotidine on peripheral blood mononuclear cells in gastric cancer patients. Scand J Gastroenterol. 1995;30(3):265–71.PubMedCrossRef Hahm KB, Kim WH, Lee SI, Kang JK, Park IS. Comparison of immunomodulative effects of the histamine-2 receptor antagonists cimetidine, ranitidine, and famotidine on peripheral blood mononuclear cells in gastric cancer patients. Scand J Gastroenterol. 1995;30(3):265–71.PubMedCrossRef
527.
Zurück zum Zitat Nielsen HJ, Nielsen HI, Jensen S, Moesgaard FA. The effect of ranitidine on postoperative monocyte and neutrophil granulocyte function. Ugeskr Laeger. 1995;157(44):6119–24.PubMed Nielsen HJ, Nielsen HI, Jensen S, Moesgaard FA. The effect of ranitidine on postoperative monocyte and neutrophil granulocyte function. Ugeskr Laeger. 1995;157(44):6119–24.PubMed
528.
Zurück zum Zitat Rasmussen LA, Nielsen HJ, Sorensen S, Sorensen C, Rasmussen R, Sorensen S, et al. Ranitidine reduces postoperative interleukin-6 induced C-reactive protein synthesis. J Am Coll Surg. 1995;181(2):138–44.PubMed Rasmussen LA, Nielsen HJ, Sorensen S, Sorensen C, Rasmussen R, Sorensen S, et al. Ranitidine reduces postoperative interleukin-6 induced C-reactive protein synthesis. J Am Coll Surg. 1995;181(2):138–44.PubMed
529.
Zurück zum Zitat Siegers CP, Andresen S, Keogh JP. Does cimetidine improve prospects for cancer patients?. A reappraisal of the evidence to date. Digestion. 1999;60(5):415–21.PubMedCrossRef Siegers CP, Andresen S, Keogh JP. Does cimetidine improve prospects for cancer patients?. A reappraisal of the evidence to date. Digestion. 1999;60(5):415–21.PubMedCrossRef
531.
Zurück zum Zitat Rao A, Jump RL, Pultz NJ, Pultz MJ, Donskey CJ. In vitro killing of nosocomial pathogens by acid and acidified nitrite. Antimicrob Agents Chemother. 2006;50(11):3901–4.PubMedPubMedCentralCrossRef Rao A, Jump RL, Pultz NJ, Pultz MJ, Donskey CJ. In vitro killing of nosocomial pathogens by acid and acidified nitrite. Antimicrob Agents Chemother. 2006;50(11):3901–4.PubMedPubMedCentralCrossRef
532.
Zurück zum Zitat Jump RL, Pultz MJ, Donskey CJ. Vegetative Clostridium difficile survives in room air on moist surfaces and in gastric contents with reduced acidity: a potential mechanism to explain the association between proton pump inhibitors and C. difficile-associated diarrhea? Antimicrob Agents Chemother. 2007;51(8):2883–7.PubMedPubMedCentralCrossRef Jump RL, Pultz MJ, Donskey CJ. Vegetative Clostridium difficile survives in room air on moist surfaces and in gastric contents with reduced acidity: a potential mechanism to explain the association between proton pump inhibitors and C. difficile-associated diarrhea? Antimicrob Agents Chemother. 2007;51(8):2883–7.PubMedPubMedCentralCrossRef
533.
Zurück zum Zitat Wilson KH. Efficiency of various bile salt preparations for stimulation of Clostridium difficile spore germination. J Clin Microbiol. 1983;18(4):1017–9.PubMedPubMedCentral Wilson KH. Efficiency of various bile salt preparations for stimulation of Clostridium difficile spore germination. J Clin Microbiol. 1983;18(4):1017–9.PubMedPubMedCentral
534.
Zurück zum Zitat Dial S, Delaney JA, Schneider V, Suissa S. Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy. CMAJ. 2006;175(7):745–8.PubMedPubMedCentralCrossRef Dial S, Delaney JA, Schneider V, Suissa S. Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy. CMAJ. 2006;175(7):745–8.PubMedPubMedCentralCrossRef
535.
Zurück zum Zitat Imhann F, Bonder MJ, Vich Vila A, Fu J, Mujagic Z, Vork L, et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016;65(5):740–8.PubMedCrossRef Imhann F, Bonder MJ, Vich Vila A, Fu J, Mujagic Z, Vork L, et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016;65(5):740–8.PubMedCrossRef
536.
Zurück zum Zitat Seto CT, Jeraldo P, Orenstein R, Chia N, DiBaise JK. Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility. Microbiome. 2014;2:42.PubMedPubMedCentralCrossRef Seto CT, Jeraldo P, Orenstein R, Chia N, DiBaise JK. Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility. Microbiome. 2014;2:42.PubMedPubMedCentralCrossRef
537.
Zurück zum Zitat Jackson MA, Goodrich JK, Maxan ME, Freedberg DE, Abrams JA, Poole AC, et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut. 2016;65(5):749–56.PubMedCrossRef Jackson MA, Goodrich JK, Maxan ME, Freedberg DE, Abrams JA, Poole AC, et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut. 2016;65(5):749–56.PubMedCrossRef
538.
Zurück zum Zitat Buffie CG, Bucci V, Stein RR, McKenney PT, Ling L, Gobourne A, et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature. 2015;517(7533):205–8.PubMedCrossRef Buffie CG, Bucci V, Stein RR, McKenney PT, Ling L, Gobourne A, et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature. 2015;517(7533):205–8.PubMedCrossRef
539.
Zurück zum Zitat Allegretti JR, Kearney S, Li N, Bogart E, Bullock K, Gerber GK, et al. Recurrent Clostridium difficile infection associates with distinct bile acid and microbiome profiles. Aliment Pharmacol Ther. 2016;43(11):1142–53.PubMedPubMedCentralCrossRef Allegretti JR, Kearney S, Li N, Bogart E, Bullock K, Gerber GK, et al. Recurrent Clostridium difficile infection associates with distinct bile acid and microbiome profiles. Aliment Pharmacol Ther. 2016;43(11):1142–53.PubMedPubMedCentralCrossRef
540.
Zurück zum Zitat Clooney AG, Bernstein CN, Leslie WD, Vagianos K, Sargent M, Laserna-Mendieta EJ, et al. A comparison of the gut microbiome between long-term users and non-users of proton pump inhibitors. Aliment Pharmacol Ther. 2016;43(9):974–84.PubMedCrossRef Clooney AG, Bernstein CN, Leslie WD, Vagianos K, Sargent M, Laserna-Mendieta EJ, et al. A comparison of the gut microbiome between long-term users and non-users of proton pump inhibitors. Aliment Pharmacol Ther. 2016;43(9):974–84.PubMedCrossRef
541.
Zurück zum Zitat Melgar S, Nieuwdorp M. Are proton pump inhibitors affecting intestinal microbiota health? Gastroenterology. 2015;149(4):848–50.PubMedCrossRef Melgar S, Nieuwdorp M. Are proton pump inhibitors affecting intestinal microbiota health? Gastroenterology. 2015;149(4):848–50.PubMedCrossRef
542.
Zurück zum Zitat Stewart DB, Hegarty JP. Correlation between virulence gene expression and proton pump inhibitors and ambient pH in Clostridium difficile: results of an in vitro study. J Med Microbiol. 2013;62(Pt 10):1517–23.PubMedCrossRef Stewart DB, Hegarty JP. Correlation between virulence gene expression and proton pump inhibitors and ambient pH in Clostridium difficile: results of an in vitro study. J Med Microbiol. 2013;62(Pt 10):1517–23.PubMedCrossRef
543.
Zurück zum Zitat Hegarty JP, Sangster W, Harris LR 3rd, Stewart DB. Proton pump inhibitors induce changes in colonocyte gene expression that may affect Clostridium difficile infection. Surgery. 2014;156(4):972–8.PubMedCrossRef Hegarty JP, Sangster W, Harris LR 3rd, Stewart DB. Proton pump inhibitors induce changes in colonocyte gene expression that may affect Clostridium difficile infection. Surgery. 2014;156(4):972–8.PubMedCrossRef
544.
Zurück zum Zitat Craven DE, Driks MR. Nosocomial pneumonia in the intubated patient. Semin Respir Infect. 1987;2(1):20–33.PubMed Craven DE, Driks MR. Nosocomial pneumonia in the intubated patient. Semin Respir Infect. 1987;2(1):20–33.PubMed
545.
Zurück zum Zitat Atherton ST, White DJ. Stomach as source of bacteria colonising respiratory tract during artificial ventilation. Lancet. 1978;2(8097):968–9.PubMedCrossRef Atherton ST, White DJ. Stomach as source of bacteria colonising respiratory tract during artificial ventilation. Lancet. 1978;2(8097):968–9.PubMedCrossRef
546.
Zurück zum Zitat du Moulin GC, Paterson DG, Hedley-Whyte J, Lisbon A. Aspiration of gastric bacteria in antacid-treated patients: a frequent cause of postoperative colonisation of the airway. Lancet. 1982;1(8266):242–5.PubMed du Moulin GC, Paterson DG, Hedley-Whyte J, Lisbon A. Aspiration of gastric bacteria in antacid-treated patients: a frequent cause of postoperative colonisation of the airway. Lancet. 1982;1(8266):242–5.PubMed
547.
Zurück zum Zitat Rosen R, Hu L, Amirault J, Khatwa U, Ward DV, Onderdonk A. 16S community profiling identifies proton pump inhibitor related differences in gastric, lung, and oropharyngeal microflora. J Pediatr. 2015;166(4):917–23.PubMedPubMedCentralCrossRef Rosen R, Hu L, Amirault J, Khatwa U, Ward DV, Onderdonk A. 16S community profiling identifies proton pump inhibitor related differences in gastric, lung, and oropharyngeal microflora. J Pediatr. 2015;166(4):917–23.PubMedPubMedCentralCrossRef
548.
Zurück zum Zitat de Jager CP, Wever PC, Gemen EF, van Oijen MG, van Gageldonk-Lafeber AB, Siersema PD, et al. Proton pump inhibitor therapy predisposes to community-acquired Streptococcus pneumoniae pneumonia. Aliment Pharmacol Ther. 2012;36(10):941–9.PubMedCrossRef de Jager CP, Wever PC, Gemen EF, van Oijen MG, van Gageldonk-Lafeber AB, Siersema PD, et al. Proton pump inhibitor therapy predisposes to community-acquired Streptococcus pneumoniae pneumonia. Aliment Pharmacol Ther. 2012;36(10):941–9.PubMedCrossRef
549.
Zurück zum Zitat Schuijt TJ, Lankelma JM, Scicluna BP, de Sousa e Melo F, Roelofs JJ, de Boer JD, et al. The gut microbiota plays a protective role in the host defence against pneumococcal pneumonia. Gut. 2016;65(4):575–83.PubMedCrossRef Schuijt TJ, Lankelma JM, Scicluna BP, de Sousa e Melo F, Roelofs JJ, de Boer JD, et al. The gut microbiota plays a protective role in the host defence against pneumococcal pneumonia. Gut. 2016;65(4):575–83.PubMedCrossRef
550.
Zurück zum Zitat Lauderdale TL, Chang FY, Ben RJ, Yin HC, Ni YH, Tsai JW, et al. Etiology of community acquired pneumonia among adult patients requiring hospitalization in Taiwan. Respir Med. 2005;99(9):1079–86.PubMedCrossRef Lauderdale TL, Chang FY, Ben RJ, Yin HC, Ni YH, Tsai JW, et al. Etiology of community acquired pneumonia among adult patients requiring hospitalization in Taiwan. Respir Med. 2005;99(9):1079–86.PubMedCrossRef
551.
Zurück zum Zitat Apisarnthanarak A, Mundy LM. Etiology of community-acquired pneumonia. Clin Chest Med. 2005;26(1):47–55.PubMedCrossRef Apisarnthanarak A, Mundy LM. Etiology of community-acquired pneumonia. Clin Chest Med. 2005;26(1):47–55.PubMedCrossRef
552.
Zurück zum Zitat Garcia-Martinez I, Frances R, Zapater P, Gimenez P, Gomez-Hurtado I, Moratalla A, et al. Use of proton pump inhibitors decrease cellular oxidative burst in patients with decompensated cirrhosis. J Gastroenterol Hepatol. 2015;30(1):147–54.PubMedCrossRef Garcia-Martinez I, Frances R, Zapater P, Gimenez P, Gomez-Hurtado I, Moratalla A, et al. Use of proton pump inhibitors decrease cellular oxidative burst in patients with decompensated cirrhosis. J Gastroenterol Hepatol. 2015;30(1):147–54.PubMedCrossRef
554.
Zurück zum Zitat Charlot M, Ahlehoff O, Norgaard ML, Jorgensen CH, Sorensen R, Abildstrom SZ, et al. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med. 2010;153(6):378–86.PubMedCrossRef Charlot M, Ahlehoff O, Norgaard ML, Jorgensen CH, Sorensen R, Abildstrom SZ, et al. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med. 2010;153(6):378–86.PubMedCrossRef
555.
Zurück zum Zitat Lazarus B, Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016;176(2):238–46.PubMedPubMedCentralCrossRef Lazarus B, Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016;176(2):238–46.PubMedPubMedCentralCrossRef
556.
Zurück zum Zitat Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296(24):2947–53.PubMedCrossRef Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296(24):2947–53.PubMedCrossRef
557.
Zurück zum Zitat Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008;179(4):319–26.PubMedPubMedCentralCrossRef Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008;179(4):319–26.PubMedPubMedCentralCrossRef
558.
Zurück zum Zitat Fournier MR, Targownik LE, Leslie WD. Proton pump inhibitors, osteoporosis, and osteoporosis-related fractures. Maturitas. 2009;64(1):9–13.PubMedCrossRef Fournier MR, Targownik LE, Leslie WD. Proton pump inhibitors, osteoporosis, and osteoporosis-related fractures. Maturitas. 2009;64(1):9–13.PubMedCrossRef
559.
Zurück zum Zitat de Vries F, Cooper AL, Cockle SM, van Staa TP, Cooper C. Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteoporos Int. 2009;20(12):1989–98.PubMedCrossRef de Vries F, Cooper AL, Cockle SM, van Staa TP, Cooper C. Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteoporos Int. 2009;20(12):1989–98.PubMedCrossRef
560.
Zurück zum Zitat McCarthy DM. Adverse effects of proton pump inhibitor drugs: clues and conclusions. Curr Opin Gastroenterol. 2010;26(6):624–31.PubMedCrossRef McCarthy DM. Adverse effects of proton pump inhibitor drugs: clues and conclusions. Curr Opin Gastroenterol. 2010;26(6):624–31.PubMedCrossRef
561.
Zurück zum Zitat Ye X, Liu H, Wu C, Qin Y, Zang J, Gao Q, et al. Proton pump inhibitors therapy and risk of hip fracture: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2011;23(9):794–800.PubMedCrossRef Ye X, Liu H, Wu C, Qin Y, Zang J, Gao Q, et al. Proton pump inhibitors therapy and risk of hip fracture: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2011;23(9):794–800.PubMedCrossRef
562.
Zurück zum Zitat Ngamruengphong S, Leontiadis GI, Radhi S, Dentino A, Nugent K. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2011;106(7):1209–18 (quiz 19). Ngamruengphong S, Leontiadis GI, Radhi S, Dentino A, Nugent K. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2011;106(7):1209–18 (quiz 19).
563.
Zurück zum Zitat Lau YT, Ahmed NN. Fracture risk and bone mineral density reduction associated with proton pump inhibitors. Pharmacotherapy. 2012;32(1):67–79.PubMedCrossRef Lau YT, Ahmed NN. Fracture risk and bone mineral density reduction associated with proton pump inhibitors. Pharmacotherapy. 2012;32(1):67–79.PubMedCrossRef
564.
Zurück zum Zitat Fraser LA, Leslie WD, Targownik LE, Papaioannou A, Adachi JD, CaMos Research Group. The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study. Osteoporos Int. 2013;24(4):1161–8. Fraser LA, Leslie WD, Targownik LE, Papaioannou A, Adachi JD, CaMos Research Group. The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study. Osteoporos Int. 2013;24(4):1161–8.
565.
Zurück zum Zitat Prieto-Alhambra D, Pages-Castella A, Wallace G, Javaid MK, Judge A, Nogues X, et al. Predictors of fracture while on treatment with oral bisphosphonates: a population-based cohort study. J Bone Miner Res. 2014;29(1):268–74.PubMedCrossRef Prieto-Alhambra D, Pages-Castella A, Wallace G, Javaid MK, Judge A, Nogues X, et al. Predictors of fracture while on treatment with oral bisphosphonates: a population-based cohort study. J Bone Miner Res. 2014;29(1):268–74.PubMedCrossRef
566.
Zurück zum Zitat Panday K, Gona A, Humphrey MB. Medication-induced osteoporosis: screening and treatment strategies. Ther Adv Musculoskelet Dis. 2014;6(5):185–202.PubMedPubMedCentralCrossRef Panday K, Gona A, Humphrey MB. Medication-induced osteoporosis: screening and treatment strategies. Ther Adv Musculoskelet Dis. 2014;6(5):185–202.PubMedPubMedCentralCrossRef
567.
Zurück zum Zitat Cai D, Feng W, Jiang Q. Acid-suppressive medications and risk of fracture: an updated meta-analysis. Int J Clin Exp Med. 2015;8(6):8893–904.PubMedPubMedCentral Cai D, Feng W, Jiang Q. Acid-suppressive medications and risk of fracture: an updated meta-analysis. Int J Clin Exp Med. 2015;8(6):8893–904.PubMedPubMedCentral
568.
Zurück zum Zitat Yang SD, Chen Q, Wei HK, Zhang F, Yang DL, Shen Y, et al. Bone fracture and the interaction between bisphosphonates and proton pump inhibitors: a meta-analysis. Int J Clin Exp Med. 2015;8(4):4899–910.PubMedPubMedCentral Yang SD, Chen Q, Wei HK, Zhang F, Yang DL, Shen Y, et al. Bone fracture and the interaction between bisphosphonates and proton pump inhibitors: a meta-analysis. Int J Clin Exp Med. 2015;8(4):4899–910.PubMedPubMedCentral
569.
Zurück zum Zitat Zhou B, Huang Y, Li H, Sun W, Liu J. Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporos Int. 2016;27(1):339–47.PubMedCrossRef Zhou B, Huang Y, Li H, Sun W, Liu J. Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporos Int. 2016;27(1):339–47.PubMedCrossRef
570.
Zurück zum Zitat Andersen BN, Johansen PB, Abrahamsen B. Proton pump inhibitors and osteoporosis. Curr Opin Rheumatol. 2016;28(4):420–5.PubMedCrossRef Andersen BN, Johansen PB, Abrahamsen B. Proton pump inhibitors and osteoporosis. Curr Opin Rheumatol. 2016;28(4):420–5.PubMedCrossRef
571.
Zurück zum Zitat Geller JL, Adams JS. Proton pump inhibitor therapy and hip fracture risk. JAMA. 2007;297(13):1429 (author reply 30). Geller JL, Adams JS. Proton pump inhibitor therapy and hip fracture risk. JAMA. 2007;297(13):1429 (author reply 30).
573.
Zurück zum Zitat Abrahamsen B, Eiken P, Eastell R. Proton pump inhibitor use and the antifracture efficacy of alendronate. Arch Intern Med. 2011;171(11):998–1004.PubMed Abrahamsen B, Eiken P, Eastell R. Proton pump inhibitor use and the antifracture efficacy of alendronate. Arch Intern Med. 2011;171(11):998–1004.PubMed
574.
Zurück zum Zitat O’Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med. 2005;118(7):778–81.PubMedCrossRef O’Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med. 2005;118(7):778–81.PubMedCrossRef
575.
Zurück zum Zitat Insogna KL. The effect of proton pump-inhibiting drugs on mineral metabolism. Am J Gastroenterol. 2009;104(Suppl 2):S2–4.PubMedCrossRef Insogna KL. The effect of proton pump-inhibiting drugs on mineral metabolism. Am J Gastroenterol. 2009;104(Suppl 2):S2–4.PubMedCrossRef
576.
Zurück zum Zitat Wright MJ, Proctor DD, Insogna KL, Kerstetter JE. Proton pump-inhibiting drugs, calcium homeostasis, and bone health. Nutr Rev. 2008;66(2):103–8.PubMedCrossRef Wright MJ, Proctor DD, Insogna KL, Kerstetter JE. Proton pump-inhibiting drugs, calcium homeostasis, and bone health. Nutr Rev. 2008;66(2):103–8.PubMedCrossRef
577.
Zurück zum Zitat Tawadrous D, Dixon S, Shariff SZ, Fleet J, Gandhi S, Jain AK, et al. Altered mental status in older adults with histamine2-receptor antagonists: a population-based study. Eur J Intern Med. 2014;25(8):701–9.PubMedCrossRef Tawadrous D, Dixon S, Shariff SZ, Fleet J, Gandhi S, Jain AK, et al. Altered mental status in older adults with histamine2-receptor antagonists: a population-based study. Eur J Intern Med. 2014;25(8):701–9.PubMedCrossRef
578.
Zurück zum Zitat Otremba I, Wilczynski K, Szewieczek J. Delirium in the geriatric unit: proton-pump inhibitors and other risk factors. Clin Interv Aging. 2016;11:397–405.PubMedPubMedCentral Otremba I, Wilczynski K, Szewieczek J. Delirium in the geriatric unit: proton-pump inhibitors and other risk factors. Clin Interv Aging. 2016;11:397–405.PubMedPubMedCentral
579.
Zurück zum Zitat Lundell L, Vieth M, Gibson F, Nagy P, Kahrilas PJ. Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. Aliment Pharmacol Ther. 2015;42(6):649–63.PubMedCrossRef Lundell L, Vieth M, Gibson F, Nagy P, Kahrilas PJ. Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. Aliment Pharmacol Ther. 2015;42(6):649–63.PubMedCrossRef
580.
Zurück zum Zitat Ko Y, Tang J, Sanagapalli S, Kim BS, Leong RW. Safety of proton pump inhibitors and risk of gastric cancers: review of literature and pathophysiological mechanisms. Expert Opin Drug Saf. 2016;15(1):53–63.PubMedCrossRef Ko Y, Tang J, Sanagapalli S, Kim BS, Leong RW. Safety of proton pump inhibitors and risk of gastric cancers: review of literature and pathophysiological mechanisms. Expert Opin Drug Saf. 2016;15(1):53–63.PubMedCrossRef
581.
Zurück zum Zitat Tran-Duy A, Spaetgens B, Hoes AW, de Wit NJ, Stehouwer CD. Use of proton pump inhibitors and risks of fundic gland polyps and gastric cancer: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14(12):1706–19 e5. Tran-Duy A, Spaetgens B, Hoes AW, de Wit NJ, Stehouwer CD. Use of proton pump inhibitors and risks of fundic gland polyps and gastric cancer: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14(12):1706–19 e5.
582.
Zurück zum Zitat Carnovale C, Gentili M, Fortino I, Merlino L, Clementi E, Radice S, et al. The importance of monitoring adverse drug reactions in elderly patients: the results of a long-term pharmacovigilance programme. Expert Opin Drug Saf. 2016;15(2):131–9.PubMedCrossRef Carnovale C, Gentili M, Fortino I, Merlino L, Clementi E, Radice S, et al. The importance of monitoring adverse drug reactions in elderly patients: the results of a long-term pharmacovigilance programme. Expert Opin Drug Saf. 2016;15(2):131–9.PubMedCrossRef
583.
584.
Zurück zum Zitat Andersson T, Nagy P, Niazi M, Nylander S, Galbraith H, Ranjan S, et al. Effect of esomeprazole with/without acetylsalicylic acid, omeprazole and lansoprazole on pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. Am J Cardiovasc Drugs. 2014;14(3):217–27.PubMedCrossRef Andersson T, Nagy P, Niazi M, Nylander S, Galbraith H, Ranjan S, et al. Effect of esomeprazole with/without acetylsalicylic acid, omeprazole and lansoprazole on pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. Am J Cardiovasc Drugs. 2014;14(3):217–27.PubMedCrossRef
585.
Zurück zum Zitat Hariharan S, Southworth MR, Madabushi R. Clopidogrel, CYP2C19 and proton pump inhibitors: what we know and what it means. J Clin Pharmacol. 2014;54(8):884–8.PubMedCrossRef Hariharan S, Southworth MR, Madabushi R. Clopidogrel, CYP2C19 and proton pump inhibitors: what we know and what it means. J Clin Pharmacol. 2014;54(8):884–8.PubMedCrossRef
586.
Zurück zum Zitat Harvey A, Modak A, Dery U, Roy M, Rinfret S, Bertrand OF, et al. Changes in CYP2C19 enzyme activity evaluated by the [(13)C]-pantoprazole breath test after co-administration of clopidogrel and proton pump inhibitors following percutaneous coronary intervention and correlation to platelet reactivity. J Breath Res. 2016;10(1):017104.PubMedCrossRef Harvey A, Modak A, Dery U, Roy M, Rinfret S, Bertrand OF, et al. Changes in CYP2C19 enzyme activity evaluated by the [(13)C]-pantoprazole breath test after co-administration of clopidogrel and proton pump inhibitors following percutaneous coronary intervention and correlation to platelet reactivity. J Breath Res. 2016;10(1):017104.PubMedCrossRef
587.
Zurück zum Zitat Stangier J, Eriksson BI, Dahl OE, Ahnfelt L, Nehmiz G, Stahle H, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol. 2005;45(5):555–63.PubMedCrossRef Stangier J, Eriksson BI, Dahl OE, Ahnfelt L, Nehmiz G, Stahle H, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol. 2005;45(5):555–63.PubMedCrossRef
588.
Zurück zum Zitat Kim A, Chung I, Yoon SH, Yu KS, Lim KS, Cho JY, et al. Effects of proton pump inhibitors on metformin pharmacokinetics and pharmacodynamics. Drug Metab Dispos. 2014;42(7):1174–9.PubMedCrossRef Kim A, Chung I, Yoon SH, Yu KS, Lim KS, Cho JY, et al. Effects of proton pump inhibitors on metformin pharmacokinetics and pharmacodynamics. Drug Metab Dispos. 2014;42(7):1174–9.PubMedCrossRef
589.
Zurück zum Zitat Ding Y, Jia Y, Song Y, Lu C, Li Y, Chen M, et al. The effect of lansoprazole, an OCT inhibitor, on metformin pharmacokinetics in healthy subjects. Eur J Clin Pharmacol. 2014;70(2):141–6.PubMedCrossRef Ding Y, Jia Y, Song Y, Lu C, Li Y, Chen M, et al. The effect of lansoprazole, an OCT inhibitor, on metformin pharmacokinetics in healthy subjects. Eur J Clin Pharmacol. 2014;70(2):141–6.PubMedCrossRef
590.
591.
Zurück zum Zitat Santucci R, Leveque D, Lescoute A, Kemmel V, Herbrecht R. Delayed elimination of methotrexate associated with co-administration of proton pump inhibitors. Anticancer Res. 2010;30(9):3807–10.PubMed Santucci R, Leveque D, Lescoute A, Kemmel V, Herbrecht R. Delayed elimination of methotrexate associated with co-administration of proton pump inhibitors. Anticancer Res. 2010;30(9):3807–10.PubMed
592.
Zurück zum Zitat Reeves DJ, Moore ES, Bascom D, Rensing B. Retrospective evaluation of methotrexate elimination when co-administered with proton pump inhibitors. Br J Clin Pharmacol. 2014;78(3):565–71.PubMedPubMedCentralCrossRef Reeves DJ, Moore ES, Bascom D, Rensing B. Retrospective evaluation of methotrexate elimination when co-administered with proton pump inhibitors. Br J Clin Pharmacol. 2014;78(3):565–71.PubMedPubMedCentralCrossRef
593.
Zurück zum Zitat Suzuki K, Doki K, Homma M, Tamaki H, Hori S, Ohtani H, et al. Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol. 2009;67(1):44–9.PubMedPubMedCentralCrossRef Suzuki K, Doki K, Homma M, Tamaki H, Hori S, Ohtani H, et al. Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol. 2009;67(1):44–9.PubMedPubMedCentralCrossRef
594.
Zurück zum Zitat Urai M, Kaneko Y, Niki M, Inoue M, Tanabe K, Umeyama T, et al. Potent drugs that attenuate anti-Candida albicans activity of fluconazole and their possible mechanisms of action. J Infect Chemother. 2014;20(10):612–5.PubMedCrossRef Urai M, Kaneko Y, Niki M, Inoue M, Tanabe K, Umeyama T, et al. Potent drugs that attenuate anti-Candida albicans activity of fluconazole and their possible mechanisms of action. J Infect Chemother. 2014;20(10):612–5.PubMedCrossRef
595.
Zurück zum Zitat Knorr JP, Sjeime M, Braitman LE, Jawa P, Zaki R, Ortiz J. Concomitant proton pump inhibitors with mycophenolate mofetil and the risk of rejection in kidney transplant recipients. Transplantation. 2014;97(5):518–24.PubMedCrossRef Knorr JP, Sjeime M, Braitman LE, Jawa P, Zaki R, Ortiz J. Concomitant proton pump inhibitors with mycophenolate mofetil and the risk of rejection in kidney transplant recipients. Transplantation. 2014;97(5):518–24.PubMedCrossRef
596.
Zurück zum Zitat Kees MG, Steinke T, Moritz S, Rupprecht K, Paulus EM, Kees F, et al. Omeprazole impairs the absorption of mycophenolate mofetil but not of enteric-coated mycophenolate sodium in healthy volunteers. J Clin Pharmacol. 2012;52(8):1265–72.PubMedCrossRef Kees MG, Steinke T, Moritz S, Rupprecht K, Paulus EM, Kees F, et al. Omeprazole impairs the absorption of mycophenolate mofetil but not of enteric-coated mycophenolate sodium in healthy volunteers. J Clin Pharmacol. 2012;52(8):1265–72.PubMedCrossRef
597.
Zurück zum Zitat Kofler S, Wolf C, Shvets N, Sisic Z, Muller T, Behr J, et al. The proton pump inhibitor pantoprazole and its interaction with enteric-coated mycophenolate sodium in transplant recipients. J Heart Lung Transplant. 2011;30(5):565–71.PubMedCrossRef Kofler S, Wolf C, Shvets N, Sisic Z, Muller T, Behr J, et al. The proton pump inhibitor pantoprazole and its interaction with enteric-coated mycophenolate sodium in transplant recipients. J Heart Lung Transplant. 2011;30(5):565–71.PubMedCrossRef
598.
Zurück zum Zitat Yamasaki M, Funakoshi S, Matsuda S, Imazu T, Takeda Y, Murakami T, et al. Interaction of magnesium oxide with gastric acid secretion inhibitors in clinical pharmacotherapy. Eur J Clin Pharmacol. 2014;70(8):921–4.PubMedCrossRef Yamasaki M, Funakoshi S, Matsuda S, Imazu T, Takeda Y, Murakami T, et al. Interaction of magnesium oxide with gastric acid secretion inhibitors in clinical pharmacotherapy. Eur J Clin Pharmacol. 2014;70(8):921–4.PubMedCrossRef
599.
Zurück zum Zitat van Leeuwen RW, Jansman FG, van den Bemt PM, de Man F, Piran F, Vincenten I, et al. Drug-drug interactions in patients treated for cancer: a prospective study on clinical interventions. Ann Oncol. 2015;26(5):992–7.PubMedCrossRef van Leeuwen RW, Jansman FG, van den Bemt PM, de Man F, Piran F, Vincenten I, et al. Drug-drug interactions in patients treated for cancer: a prospective study on clinical interventions. Ann Oncol. 2015;26(5):992–7.PubMedCrossRef
600.
Zurück zum Zitat Yucel E, Sancar M, Yucel A, Okuyan B. Adverse drug reactions due to drug-drug interactions with proton pump inhibitors: assessment of systematic reviews with AMSTAR method. Expert Opin Drug Saf. 2016;15(2):223–36.PubMedCrossRef Yucel E, Sancar M, Yucel A, Okuyan B. Adverse drug reactions due to drug-drug interactions with proton pump inhibitors: assessment of systematic reviews with AMSTAR method. Expert Opin Drug Saf. 2016;15(2):223–36.PubMedCrossRef
601.
Zurück zum Zitat Matsuoka A, Takahashi N, Miura M, Niioka T, Kawakami K, Matsunaga T, et al. H2-receptor antagonist influences dasatinib pharmacokinetics in a patient with Philadelphia-positive acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2012;70(2):351–2.PubMedCrossRef Matsuoka A, Takahashi N, Miura M, Niioka T, Kawakami K, Matsunaga T, et al. H2-receptor antagonist influences dasatinib pharmacokinetics in a patient with Philadelphia-positive acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2012;70(2):351–2.PubMedCrossRef
602.
Zurück zum Zitat Takahashi N, Miura M, Niioka T, Sawada K. Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients. Cancer Chemother Pharmacol. 2012;69(4):999–1004.PubMedCrossRef Takahashi N, Miura M, Niioka T, Sawada K. Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients. Cancer Chemother Pharmacol. 2012;69(4):999–1004.PubMedCrossRef
603.
Zurück zum Zitat Corley DA, Kubo A, Zhao W, Quesenberry C. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology. 2010;139(1):93–101.PubMedPubMedCentralCrossRef Corley DA, Kubo A, Zhao W, Quesenberry C. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology. 2010;139(1):93–101.PubMedPubMedCentralCrossRef
604.
Zurück zum Zitat Asaoka D, Nagahara A, Shimada Y, Matsumoto K, Ueyama H, Matsumoto K, et al. Risk factors for osteoporosis in Japan: is it associated with Helicobacter pylori? Ther Clin Risk Manag. 2015;11:381–91.PubMedPubMedCentralCrossRef Asaoka D, Nagahara A, Shimada Y, Matsumoto K, Ueyama H, Matsumoto K, et al. Risk factors for osteoporosis in Japan: is it associated with Helicobacter pylori? Ther Clin Risk Manag. 2015;11:381–91.PubMedPubMedCentralCrossRef
605.
Zurück zum Zitat Mullin JM, Gabello M, Murray LJ, Farrell CP, Bellows J, Wolov KR, et al. Proton pump inhibitors: actions and reactions. Drug Discov Today. 2009;14(13–14):647–60.PubMedCrossRef Mullin JM, Gabello M, Murray LJ, Farrell CP, Bellows J, Wolov KR, et al. Proton pump inhibitors: actions and reactions. Drug Discov Today. 2009;14(13–14):647–60.PubMedCrossRef
606.
Zurück zum Zitat Olbe L, Carlsson E, Lindberg P. A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole. Nat Rev Drug Discov. 2003;2(2):132–9.PubMedCrossRef Olbe L, Carlsson E, Lindberg P. A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole. Nat Rev Drug Discov. 2003;2(2):132–9.PubMedCrossRef
607.
Zurück zum Zitat Gregoire JP, Moisan J, Chabot I, Gaudet M. Appropriateness of omeprazole prescribing in Quebec’s senior population. Can J Gastroenterol. 2000;14(8):676–80.PubMedCrossRef Gregoire JP, Moisan J, Chabot I, Gaudet M. Appropriateness of omeprazole prescribing in Quebec’s senior population. Can J Gastroenterol. 2000;14(8):676–80.PubMedCrossRef
608.
Zurück zum Zitat Jacobson BC, Ferris TG, Shea TL, Mahlis EM, Lee TH, Wang TC. Who is using chronic acid suppression therapy and why? Am J Gastroenterol. 2003;98(1):51–8.PubMedCrossRef Jacobson BC, Ferris TG, Shea TL, Mahlis EM, Lee TH, Wang TC. Who is using chronic acid suppression therapy and why? Am J Gastroenterol. 2003;98(1):51–8.PubMedCrossRef
609.
Zurück zum Zitat van Vliet EP, Otten HJ, Rudolphus A, Knoester PD, Hoogsteden HC, Kuipers EJ, et al. Inappropriate prescription of proton pump inhibitors on two pulmonary medicine wards. Eur J Gastroenterol Hepatol. 2008;20(7):608–12.PubMedCrossRef van Vliet EP, Otten HJ, Rudolphus A, Knoester PD, Hoogsteden HC, Kuipers EJ, et al. Inappropriate prescription of proton pump inhibitors on two pulmonary medicine wards. Eur J Gastroenterol Hepatol. 2008;20(7):608–12.PubMedCrossRef
610.
Zurück zum Zitat Choudhry MN, Soran H, Ziglam HM. Overuse and inappropriate prescribing of proton pump inhibitors in patients with Clostridium difficile-associated disease. QJM. 2008;101(6):445–8.PubMedCrossRef Choudhry MN, Soran H, Ziglam HM. Overuse and inappropriate prescribing of proton pump inhibitors in patients with Clostridium difficile-associated disease. QJM. 2008;101(6):445–8.PubMedCrossRef
611.
Zurück zum Zitat van Boxel OS, Hagenaars MP, Smout AJ, Siersema PD. Socio-demographic factors influence chronic proton pump inhibitor use by a large population in the Netherlands. Aliment Pharmacol Ther. 2009;29(5):571–9.PubMedCrossRef van Boxel OS, Hagenaars MP, Smout AJ, Siersema PD. Socio-demographic factors influence chronic proton pump inhibitor use by a large population in the Netherlands. Aliment Pharmacol Ther. 2009;29(5):571–9.PubMedCrossRef
612.
Zurück zum Zitat Rakesh TP. Proton pump inhibitors: use, misuse and concerns about long-term therapy. Clin J Gastroenterol. 2011;4(2):53–9.PubMedCrossRef Rakesh TP. Proton pump inhibitors: use, misuse and concerns about long-term therapy. Clin J Gastroenterol. 2011;4(2):53–9.PubMedCrossRef
613.
Zurück zum Zitat Gawron AJ, Rothe J, Fought AJ, Fareeduddin A, Toto E, Boris L, et al. Many patients continue using proton pump inhibitors after negative results from tests for reflux disease. Clin Gastroenterol Hepatol. 2012;10(6):620–5 (quiz e57). Gawron AJ, Rothe J, Fought AJ, Fareeduddin A, Toto E, Boris L, et al. Many patients continue using proton pump inhibitors after negative results from tests for reflux disease. Clin Gastroenterol Hepatol. 2012;10(6):620–5 (quiz e57).
614.
Zurück zum Zitat Haastrup PF, Rasmussen S, Hansen JM, Christensen RD, Sondergaard J, Jarbol DE. General practice variation when initiating long-term prescribing of proton pump inhibitors: a nationwide cohort study. BMC Fam Pract. 2016;17(1):57.PubMedPubMedCentralCrossRef Haastrup PF, Rasmussen S, Hansen JM, Christensen RD, Sondergaard J, Jarbol DE. General practice variation when initiating long-term prescribing of proton pump inhibitors: a nationwide cohort study. BMC Fam Pract. 2016;17(1):57.PubMedPubMedCentralCrossRef
615.
Zurück zum Zitat Nardino RJ, Vender RJ, Herbert PN. Overuse of acid-suppressive therapy in hospitalized patients. Am J Gastroenterol. 2000;95(11):3118–22.PubMed Nardino RJ, Vender RJ, Herbert PN. Overuse of acid-suppressive therapy in hospitalized patients. Am J Gastroenterol. 2000;95(11):3118–22.PubMed
616.
Zurück zum Zitat Scagliarini R, Magnani E, Pratico A, Bocchini R, Sambo P, Pazzi P. Inadequate use of acid-suppressive therapy in hospitalized patients and its implications for general practice. Dig Dis Sci. 2005;50(12):2307–11.PubMedCrossRef Scagliarini R, Magnani E, Pratico A, Bocchini R, Sambo P, Pazzi P. Inadequate use of acid-suppressive therapy in hospitalized patients and its implications for general practice. Dig Dis Sci. 2005;50(12):2307–11.PubMedCrossRef
617.
Zurück zum Zitat Targownik LE, Metge C, Roos L, Leung S. The prevalence of and the clinical and demographic characteristics associated with high-intensity proton pump inhibitor use. Am J Gastroenterol. 2007;102(5):942–50.PubMedCrossRef Targownik LE, Metge C, Roos L, Leung S. The prevalence of and the clinical and demographic characteristics associated with high-intensity proton pump inhibitor use. Am J Gastroenterol. 2007;102(5):942–50.PubMedCrossRef
618.
Zurück zum Zitat Thomas L, Culley EJ, Gladowski P, Goff V, Fong J, Marche SM. Longitudinal analysis of the costs associated with inpatient initiation and subsequent outpatient continuation of proton pump inhibitor therapy for stress ulcer prophylaxis in a large managed care organization. J Manag Care Pharm. 2010;16(2):122–9.PubMed Thomas L, Culley EJ, Gladowski P, Goff V, Fong J, Marche SM. Longitudinal analysis of the costs associated with inpatient initiation and subsequent outpatient continuation of proton pump inhibitor therapy for stress ulcer prophylaxis in a large managed care organization. J Manag Care Pharm. 2010;16(2):122–9.PubMed
619.
Zurück zum Zitat Ramirez E, Lei SH, Borobia AM, Pinana E, Fudio S, Munoz R, et al. Overuse of PPIs in patients at admission, during treatment, and at discharge in a tertiary Spanish hospital. Curr Clin Pharmacol. 2010;5(4):288–97.PubMedCrossRef Ramirez E, Lei SH, Borobia AM, Pinana E, Fudio S, Munoz R, et al. Overuse of PPIs in patients at admission, during treatment, and at discharge in a tertiary Spanish hospital. Curr Clin Pharmacol. 2010;5(4):288–97.PubMedCrossRef
620.
Zurück zum Zitat Sheikh-Taha M, Alaeddine S, Nassif J. Use of acid suppressive therapy in hospitalized non-critically ill patients. World J Gastrointest Pharmacol Ther. 2012;3(6):93–6.PubMedPubMedCentral Sheikh-Taha M, Alaeddine S, Nassif J. Use of acid suppressive therapy in hospitalized non-critically ill patients. World J Gastrointest Pharmacol Ther. 2012;3(6):93–6.PubMedPubMedCentral
621.
Zurück zum Zitat Patel HR, Dhande P. Imprudent gastro-protective approach in majority of specialists’ clinics of a tertiary hospital. J Clin Diagn Res. 2016;10(3):FC12–5. Patel HR, Dhande P. Imprudent gastro-protective approach in majority of specialists’ clinics of a tertiary hospital. J Clin Diagn Res. 2016;10(3):FC12–5.
622.
Zurück zum Zitat Gupta R, Garg P, Kottoor R, Munoz JC, Jamal MM, Lambiase LR, et al. Overuse of acid suppression therapy in hospitalized patients. South Med J. 2010;103(3):207–11.PubMedCrossRef Gupta R, Garg P, Kottoor R, Munoz JC, Jamal MM, Lambiase LR, et al. Overuse of acid suppression therapy in hospitalized patients. South Med J. 2010;103(3):207–11.PubMedCrossRef
623.
Zurück zum Zitat Shin S. Evaluation of costs accrued through inadvertent continuation of hospital-initiated proton pump inhibitor therapy for stress ulcer prophylaxis beyond hospital discharge: a retrospective chart review. Ther Clin Risk Manag. 2015;11:649–57.PubMedPubMedCentralCrossRef Shin S. Evaluation of costs accrued through inadvertent continuation of hospital-initiated proton pump inhibitor therapy for stress ulcer prophylaxis beyond hospital discharge: a retrospective chart review. Ther Clin Risk Manag. 2015;11:649–57.PubMedPubMedCentralCrossRef
624.
Zurück zum Zitat Heidelbaugh JJ, Inadomi JM. Magnitude and economic impact of inappropriate use of stress ulcer prophylaxis in non-ICU hospitalized patients. Am J Gastroenterol. 2006;101(10):2200–5.PubMedCrossRef Heidelbaugh JJ, Inadomi JM. Magnitude and economic impact of inappropriate use of stress ulcer prophylaxis in non-ICU hospitalized patients. Am J Gastroenterol. 2006;101(10):2200–5.PubMedCrossRef
625.
Zurück zum Zitat Grant K, Al-Adhami N, Tordoff J, Livesey J, Barbezat G, Reith D. Continuation of proton pump inhibitors from hospital to community. Pharm World Sci. 2006;28(4):189–93.PubMedCrossRef Grant K, Al-Adhami N, Tordoff J, Livesey J, Barbezat G, Reith D. Continuation of proton pump inhibitors from hospital to community. Pharm World Sci. 2006;28(4):189–93.PubMedCrossRef
626.
Zurück zum Zitat Teramura-Gronblad M, Hosia-Randell H, Muurinen S, Pitkala K. Use of proton-pump inhibitors and their associated risks among frail elderly nursing home residents. Scand J Prim Health Care. 2010;28(3):154–9.PubMedPubMedCentralCrossRef Teramura-Gronblad M, Hosia-Randell H, Muurinen S, Pitkala K. Use of proton-pump inhibitors and their associated risks among frail elderly nursing home residents. Scand J Prim Health Care. 2010;28(3):154–9.PubMedPubMedCentralCrossRef
627.
Zurück zum Zitat Patterson Burdsall D, Flores HC, Krueger J, Garretson S, Gorbien MJ, Iacch A, et al. Use of proton pump inhibitors with lack of diagnostic indications in 22 Midwestern US skilled nursing facilities. J Am Med Dir Assoc. 2013;14(6):429–32.PubMedCrossRef Patterson Burdsall D, Flores HC, Krueger J, Garretson S, Gorbien MJ, Iacch A, et al. Use of proton pump inhibitors with lack of diagnostic indications in 22 Midwestern US skilled nursing facilities. J Am Med Dir Assoc. 2013;14(6):429–32.PubMedCrossRef
628.
Zurück zum Zitat de Souto Barreto P, Lapeyre-Mestre M, Mathieu C, Piau C, Bouget C, Cayla F, et al. Prevalence and associations of the use of proton-pump inhibitors in nursing homes: a cross-sectional study. J Am Med Dir Assoc. 2013;14(4):265–9.PubMedCrossRef de Souto Barreto P, Lapeyre-Mestre M, Mathieu C, Piau C, Bouget C, Cayla F, et al. Prevalence and associations of the use of proton-pump inhibitors in nursing homes: a cross-sectional study. J Am Med Dir Assoc. 2013;14(4):265–9.PubMedCrossRef
629.
Zurück zum Zitat Rane PP, Guha S, Chatterjee S, Aparasu RR. Prevalence and predictors of non-evidence based proton pump inhibitor use among elderly nursing home residents in the US. Res Social Adm Pharm. 2017;13(2):358–63.PubMedCrossRef Rane PP, Guha S, Chatterjee S, Aparasu RR. Prevalence and predictors of non-evidence based proton pump inhibitor use among elderly nursing home residents in the US. Res Social Adm Pharm. 2017;13(2):358–63.PubMedCrossRef
630.
Zurück zum Zitat Rababa M, Al-Ghassani AA, Kovach CR, Dyer EM. Proton pump inhibitors and the prescribing cascade. J Gerontol Nurs. 2016;42(4):23–31.PubMedCrossRef Rababa M, Al-Ghassani AA, Kovach CR, Dyer EM. Proton pump inhibitors and the prescribing cascade. J Gerontol Nurs. 2016;42(4):23–31.PubMedCrossRef
631.
Zurück zum Zitat Haastrup PF, Paulsen MS, Christensen RD, Sondergaard J, Hansen JM, Jarbol DE. Medical and non-medical predictors of initiating long-term use of proton pump inhibitors: a nationwide cohort study of first-time users during a 10-year period. Aliment Pharmacol Ther. 2016;44(1):78–87.PubMedCrossRef Haastrup PF, Paulsen MS, Christensen RD, Sondergaard J, Hansen JM, Jarbol DE. Medical and non-medical predictors of initiating long-term use of proton pump inhibitors: a nationwide cohort study of first-time users during a 10-year period. Aliment Pharmacol Ther. 2016;44(1):78–87.PubMedCrossRef
632.
Zurück zum Zitat El-Serag HB, Fitzgerald S, Richardson P. The extent and determinants of prescribing and adherence with acid-reducing medications: a national claims database study. Am J Gastroenterol. 2009;104(9):2161–7.PubMedCrossRef El-Serag HB, Fitzgerald S, Richardson P. The extent and determinants of prescribing and adherence with acid-reducing medications: a national claims database study. Am J Gastroenterol. 2009;104(9):2161–7.PubMedCrossRef
633.
Zurück zum Zitat van Boxel OS, Hagenaars MP, Smout AJ, Siersema PD. Sociodemographic factors influence use of proton pump inhibitors among users of nonsteroidal anti-inflammatory drugs. Clin Gastroenterol Hepatol. 2009;7(8):855–61.PubMedCrossRef van Boxel OS, Hagenaars MP, Smout AJ, Siersema PD. Sociodemographic factors influence use of proton pump inhibitors among users of nonsteroidal anti-inflammatory drugs. Clin Gastroenterol Hepatol. 2009;7(8):855–61.PubMedCrossRef
634.
Zurück zum Zitat Zhu LL, Xu LC, Chen Y, Zhou Q, Zeng S. Poor awareness of preventing aspirin-induced gastrointestinal injury with combined protective medications. World J Gastroenterol. 2012;18(24):3167–72.PubMedPubMedCentralCrossRef Zhu LL, Xu LC, Chen Y, Zhou Q, Zeng S. Poor awareness of preventing aspirin-induced gastrointestinal injury with combined protective medications. World J Gastroenterol. 2012;18(24):3167–72.PubMedPubMedCentralCrossRef
635.
Zurück zum Zitat Schiff M, Peura D. HZT-501 (DUEXIS((R)); ibuprofen 800 mg/famotidine 26.6 mg) gastrointestinal protection in the treatment of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Expert Rev Gastroenterol Hepatol. 2012;6(1):25–35.PubMedCrossRef Schiff M, Peura D. HZT-501 (DUEXIS((R)); ibuprofen 800 mg/famotidine 26.6 mg) gastrointestinal protection in the treatment of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Expert Rev Gastroenterol Hepatol. 2012;6(1):25–35.PubMedCrossRef
636.
Zurück zum Zitat Fujita T, Kutsumi H, Sanuki T, Hayakumo T, Azuma T. Adherence to the preventive strategies for nonsteroidal anti-inflammatory drug- or low-dose aspirin-induced gastrointestinal injuries. J Gastroenterol. 2013;48(5):559–73.PubMedPubMedCentralCrossRef Fujita T, Kutsumi H, Sanuki T, Hayakumo T, Azuma T. Adherence to the preventive strategies for nonsteroidal anti-inflammatory drug- or low-dose aspirin-induced gastrointestinal injuries. J Gastroenterol. 2013;48(5):559–73.PubMedPubMedCentralCrossRef
637.
Zurück zum Zitat Schjerning Olsen AM, Gislason GH, McGettigan P, Fosbol E, Sorensen R, Hansen ML, et al. Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction. JAMA. 2015;313(8):805–14.PubMedCrossRef Schjerning Olsen AM, Gislason GH, McGettigan P, Fosbol E, Sorensen R, Hansen ML, et al. Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction. JAMA. 2015;313(8):805–14.PubMedCrossRef
638.
Zurück zum Zitat Kim J, Lee J, Shin CM, Lee DH, Park BJ. Risk of gastrointestinal bleeding and cardiovascular events due to NSAIDs in the diabetic elderly population. BMJ Open Diabetes Res Care. 2015;3(1):e000133.PubMedPubMedCentralCrossRef Kim J, Lee J, Shin CM, Lee DH, Park BJ. Risk of gastrointestinal bleeding and cardiovascular events due to NSAIDs in the diabetic elderly population. BMJ Open Diabetes Res Care. 2015;3(1):e000133.PubMedPubMedCentralCrossRef
639.
Zurück zum Zitat Yuan JQ, Tsoi KK, Yang M, Wang JY, Threapleton DE, Yang ZY, et al. Systematic review with network meta-analysis: comparative effectiveness and safety of strategies for preventing NSAID-associated gastrointestinal toxicity. Aliment Pharmacol Ther. 2016;43(12):1262–75.PubMedCrossRef Yuan JQ, Tsoi KK, Yang M, Wang JY, Threapleton DE, Yang ZY, et al. Systematic review with network meta-analysis: comparative effectiveness and safety of strategies for preventing NSAID-associated gastrointestinal toxicity. Aliment Pharmacol Ther. 2016;43(12):1262–75.PubMedCrossRef
640.
Zurück zum Zitat Yang M, He M, Zhao M, Zou B, Liu J, Luo LM, et al. Proton pump inhibitors for preventing non-steroidal anti-inflammatory drug induced gastrointestinal toxicity: a systematic review. Curr Med Res Opin. 2017;25:1–8. Yang M, He M, Zhao M, Zou B, Liu J, Luo LM, et al. Proton pump inhibitors for preventing non-steroidal anti-inflammatory drug induced gastrointestinal toxicity: a systematic review. Curr Med Res Opin. 2017;25:1–8.
641.
Zurück zum Zitat McRorie JW, Kirby JA, Miner PB. Histamine2-receptor antagonists: rapid development of tachyphylaxis with repeat dosing. World J Gastrointest Pharmacol Ther. 2014;5(2):57–62.PubMedPubMedCentral McRorie JW, Kirby JA, Miner PB. Histamine2-receptor antagonists: rapid development of tachyphylaxis with repeat dosing. World J Gastrointest Pharmacol Ther. 2014;5(2):57–62.PubMedPubMedCentral
642.
Zurück zum Zitat Wilder-Smith CH, Ernst T, Gennoni M, Zeyen B, Halter F, Merki HS. Tolerance to oral H2-receptor antagonists. Dig Dis Sci. 1990;35(8):976–83.PubMedCrossRef Wilder-Smith CH, Ernst T, Gennoni M, Zeyen B, Halter F, Merki HS. Tolerance to oral H2-receptor antagonists. Dig Dis Sci. 1990;35(8):976–83.PubMedCrossRef
643.
Zurück zum Zitat Welage LS. Overview of pharmacologic agents for acid suppression in critically ill patients. Am J Health Syst Pharm. 2005;62(10 Suppl 2):S4–10.PubMed Welage LS. Overview of pharmacologic agents for acid suppression in critically ill patients. Am J Health Syst Pharm. 2005;62(10 Suppl 2):S4–10.PubMed
644.
Zurück zum Zitat Kurosawa S. What is important in treating elderly with H2 receptor antagonists. Nihon Rinsho. 2002;60(8):1613–7.PubMed Kurosawa S. What is important in treating elderly with H2 receptor antagonists. Nihon Rinsho. 2002;60(8):1613–7.PubMed
645.
Zurück zum Zitat Lackner TE, Heard T, Glunz S, Gann N, Babington M, Malone DC. Gastrointestinal disease control after histamine2-receptor antagonist dose modification for renal impairment in frail chronically ill elderly patients. J Am Geriatr Soc. 2003;51(5):650–6.PubMedCrossRef Lackner TE, Heard T, Glunz S, Gann N, Babington M, Malone DC. Gastrointestinal disease control after histamine2-receptor antagonist dose modification for renal impairment in frail chronically ill elderly patients. J Am Geriatr Soc. 2003;51(5):650–6.PubMedCrossRef
646.
Zurück zum Zitat Manlucu J, Tonelli M, Ray JG, Papaioannou A, Youssef G, Thiessen-Philbrook HR, et al. Dose-reducing H2 receptor antagonists in the presence of low glomerular filtration rate: a systematic review of the evidence. Nephrol Dial Transplant. 2005;20(11):2376–84.PubMedCrossRef Manlucu J, Tonelli M, Ray JG, Papaioannou A, Youssef G, Thiessen-Philbrook HR, et al. Dose-reducing H2 receptor antagonists in the presence of low glomerular filtration rate: a systematic review of the evidence. Nephrol Dial Transplant. 2005;20(11):2376–84.PubMedCrossRef
647.
Zurück zum Zitat Boudville N. The predictable effect that renal failure has on H2 receptor antagonists–increasing the half-life along with increasing prescribing errors. Nephrol Dial Transplant. 2005;20(11):2315–7.PubMedCrossRef Boudville N. The predictable effect that renal failure has on H2 receptor antagonists–increasing the half-life along with increasing prescribing errors. Nephrol Dial Transplant. 2005;20(11):2315–7.PubMedCrossRef
648.
Zurück zum Zitat Matzke GR. Doses of histamine-2-receptor antagonists should be reduced in patients with low glomerular filtration rate. Nat Clin Pract Nephrol. 2006;2(6):298–9.PubMedCrossRef Matzke GR. Doses of histamine-2-receptor antagonists should be reduced in patients with low glomerular filtration rate. Nat Clin Pract Nephrol. 2006;2(6):298–9.PubMedCrossRef
649.
Zurück zum Zitat Juurlink DN. Proton pump inhibitors and clopidogrel: putting the interaction in perspective. Circulation. 2009;120(23):2310–2.PubMedCrossRef Juurlink DN. Proton pump inhibitors and clopidogrel: putting the interaction in perspective. Circulation. 2009;120(23):2310–2.PubMedCrossRef
650.
Zurück zum Zitat Dunn SP, Steinhubl SR, Bauer D, Charnigo RJ, Berger PB, Topol EJ. Impact of proton pump inhibitor therapy on the efficacy of clopidogrel in the CAPRIE and CREDO trials. J Am Heart Assoc. 2013;2(1):e004564.PubMedPubMedCentralCrossRef Dunn SP, Steinhubl SR, Bauer D, Charnigo RJ, Berger PB, Topol EJ. Impact of proton pump inhibitor therapy on the efficacy of clopidogrel in the CAPRIE and CREDO trials. J Am Heart Assoc. 2013;2(1):e004564.PubMedPubMedCentralCrossRef
651.
Zurück zum Zitat O’Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009;374(9694):989–97.PubMedCrossRef O’Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009;374(9694):989–97.PubMedCrossRef
652.
Zurück zum Zitat Siller-Matula JM, Jilma B, Schror K, Christ G, Huber K. Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis. J Thromb Haemost. 2010;8(12):2624–41.PubMedCrossRef Siller-Matula JM, Jilma B, Schror K, Christ G, Huber K. Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis. J Thromb Haemost. 2010;8(12):2624–41.PubMedCrossRef
653.
Zurück zum Zitat Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB, et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol. 2010;105(12):2533–49.PubMedCrossRef Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB, et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol. 2010;105(12):2533–49.PubMedCrossRef
654.
Zurück zum Zitat Yamane K, Kato Y, Tazaki J, Tada T, Makiyama T, Imai M, et al. Effects of PPIs and an H2 blocker on the antiplatelet function of clopidogrel in Japanese patients under dual antiplatelet therapy. J Atheroscler Thromb. 2012;19(6):559–69.PubMedCrossRef Yamane K, Kato Y, Tazaki J, Tada T, Makiyama T, Imai M, et al. Effects of PPIs and an H2 blocker on the antiplatelet function of clopidogrel in Japanese patients under dual antiplatelet therapy. J Atheroscler Thromb. 2012;19(6):559–69.PubMedCrossRef
655.
Zurück zum Zitat Sherwood MW, Melloni C, Jones WS, Washam JB, Hasselblad V, Dolor RJ. Individual proton pump inhibitors and outcomes in patients with coronary artery disease on dual antiplatelet therapy: a systematic review. J Am Heart Assoc. 2015;4(11). Sherwood MW, Melloni C, Jones WS, Washam JB, Hasselblad V, Dolor RJ. Individual proton pump inhibitors and outcomes in patients with coronary artery disease on dual antiplatelet therapy: a systematic review. J Am Heart Assoc. 2015;4(11).
656.
Zurück zum Zitat Wallace J, Paauw DS. Appropriate prescribing and important drug interactions in older adults. Med Clin N Am. 2015;99(2):295–310.PubMedCrossRef Wallace J, Paauw DS. Appropriate prescribing and important drug interactions in older adults. Med Clin N Am. 2015;99(2):295–310.PubMedCrossRef
657.
Zurück zum Zitat Jarchow-Macdonald AA, Mangoni AA. Prescribing patterns of proton pump inhibitors in older hospitalized patients in a Scottish health board. Geriatr Gerontol Int. 2013;13(4):1002–9.PubMedCrossRef Jarchow-Macdonald AA, Mangoni AA. Prescribing patterns of proton pump inhibitors in older hospitalized patients in a Scottish health board. Geriatr Gerontol Int. 2013;13(4):1002–9.PubMedCrossRef
658.
Zurück zum Zitat Hershcovici T, Fass R. Gastro-oesophageal reflux disease: beyond proton pump inhibitor therapy. Drugs. 2011;71(18):2381–9.PubMedCrossRef Hershcovici T, Fass R. Gastro-oesophageal reflux disease: beyond proton pump inhibitor therapy. Drugs. 2011;71(18):2381–9.PubMedCrossRef
659.
Zurück zum Zitat Huang J, Cao Y, Liao C, Wu L, Gao F. Effect of histamine-2-receptor antagonists versus sucralfate on stress ulcer prophylaxis in mechanically ventilated patients: a meta-analysis of 10 randomized controlled trials. Crit Care. 2010;14(5):R194.PubMedPubMedCentralCrossRef Huang J, Cao Y, Liao C, Wu L, Gao F. Effect of histamine-2-receptor antagonists versus sucralfate on stress ulcer prophylaxis in mechanically ventilated patients: a meta-analysis of 10 randomized controlled trials. Crit Care. 2010;14(5):R194.PubMedPubMedCentralCrossRef
660.
Zurück zum Zitat Liu B, Liu S, Yin A, Siddiqi J. Risks and benefits of stress ulcer prophylaxis in adult neurocritical care patients: a systematic review and meta-analysis of randomized controlled trials. Crit Care. 2015;19:409.PubMedPubMedCentralCrossRef Liu B, Liu S, Yin A, Siddiqi J. Risks and benefits of stress ulcer prophylaxis in adult neurocritical care patients: a systematic review and meta-analysis of randomized controlled trials. Crit Care. 2015;19:409.PubMedPubMedCentralCrossRef
661.
Zurück zum Zitat Krag M, Perner A, Wetterslev J, Moller MH. Stress ulcer prophylaxis in adult neurocritical care patients–no firm evidence for benefit or harm. Crit Care. 2016;20:22.PubMedPubMedCentralCrossRef Krag M, Perner A, Wetterslev J, Moller MH. Stress ulcer prophylaxis in adult neurocritical care patients–no firm evidence for benefit or harm. Crit Care. 2016;20:22.PubMedPubMedCentralCrossRef
662.
Zurück zum Zitat Ben-Menachem T, Fogel R, Patel RV, Touchette M, Zarowitz BJ, Hadzijahic N, et al. Prophylaxis for stress-related gastric hemorrhage in the medical intensive care unit. A randomized, controlled, single-blind study. Ann Intern Med. 1994;121(8):568–75.PubMedCrossRef Ben-Menachem T, Fogel R, Patel RV, Touchette M, Zarowitz BJ, Hadzijahic N, et al. Prophylaxis for stress-related gastric hemorrhage in the medical intensive care unit. A randomized, controlled, single-blind study. Ann Intern Med. 1994;121(8):568–75.PubMedCrossRef
663.
Zurück zum Zitat Cook DJ, Reeve BK, Scholes LC. Histamine-2-receptor antagonists and antacids in the critically ill population: stress ulceration versus nosocomial pneumonia. Infect Control Hosp Epidemiol. 1994;15(7):437–42.PubMedCrossRef Cook DJ, Reeve BK, Scholes LC. Histamine-2-receptor antagonists and antacids in the critically ill population: stress ulceration versus nosocomial pneumonia. Infect Control Hosp Epidemiol. 1994;15(7):437–42.PubMedCrossRef
664.
Zurück zum Zitat Patel AJ, Som R. What is the optimum prophylaxis against gastrointestinal haemorrhage for patients undergoing adult cardiac surgery: histamine receptor antagonists, or proton-pump inhibitors? Interact Cardiovasc Thorac Surg. 2013;16(3):356–60.PubMedCrossRef Patel AJ, Som R. What is the optimum prophylaxis against gastrointestinal haemorrhage for patients undergoing adult cardiac surgery: histamine receptor antagonists, or proton-pump inhibitors? Interact Cardiovasc Thorac Surg. 2013;16(3):356–60.PubMedCrossRef
665.
Zurück zum Zitat Krag M, Perner A, Wetterslev J, Wise MP, Hylander Moller M. Stress ulcer prophylaxis versus placebo or no prophylaxis in critically ill patients. A systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. Intensive Care Med. 2014;40(1):11–22.PubMedCrossRef Krag M, Perner A, Wetterslev J, Wise MP, Hylander Moller M. Stress ulcer prophylaxis versus placebo or no prophylaxis in critically ill patients. A systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. Intensive Care Med. 2014;40(1):11–22.PubMedCrossRef
666.
Zurück zum Zitat Krag M, Perner A, Moller MH. Stress ulcer prophylaxis in the intensive care unit. Curr Opin Crit Care. 2016;22(2):186–90.PubMed Krag M, Perner A, Moller MH. Stress ulcer prophylaxis in the intensive care unit. Curr Opin Crit Care. 2016;22(2):186–90.PubMed
667.
Zurück zum Zitat Buendgens L, Koch A, Tacke F. Prevention of stress-related ulcer bleeding at the intensive care unit: risks and benefits of stress ulcer prophylaxis. World J Crit Care Med. 2016;5(1):57–64.PubMedPubMedCentralCrossRef Buendgens L, Koch A, Tacke F. Prevention of stress-related ulcer bleeding at the intensive care unit: risks and benefits of stress ulcer prophylaxis. World J Crit Care Med. 2016;5(1):57–64.PubMedPubMedCentralCrossRef
668.
Zurück zum Zitat Martinez RC, Bedani R, Saad SM. Scientific evidence for health effects attributed to the consumption of probiotics and prebiotics: an update for current perspectives and future challenges. Br J Nutr. 2015;114(12):1993–2015.PubMedCrossRef Martinez RC, Bedani R, Saad SM. Scientific evidence for health effects attributed to the consumption of probiotics and prebiotics: an update for current perspectives and future challenges. Br J Nutr. 2015;114(12):1993–2015.PubMedCrossRef
669.
Zurück zum Zitat Szajewska H, Konarska Z, Kolodziej M. probiotic bacterial and fungal strains: claims with evidence. Dig Dis. 2016;34(3):251–9.PubMedCrossRef Szajewska H, Konarska Z, Kolodziej M. probiotic bacterial and fungal strains: claims with evidence. Dig Dis. 2016;34(3):251–9.PubMedCrossRef
671.
Zurück zum Zitat Islam J, Cohen J, Rajkumar C, Llewelyn MJ. Probiotics for the prevention and treatment of Clostridium difficile in older patients. Age Ageing. 2012;41(6):706–11.PubMedCrossRef Islam J, Cohen J, Rajkumar C, Llewelyn MJ. Probiotics for the prevention and treatment of Clostridium difficile in older patients. Age Ageing. 2012;41(6):706–11.PubMedCrossRef
672.
Zurück zum Zitat Allen SJ. The potential of probiotics to prevent Clostridium difficile infection. Infect Dis Clin N Am. 2015;29(1):135–44.CrossRef Allen SJ. The potential of probiotics to prevent Clostridium difficile infection. Infect Dis Clin N Am. 2015;29(1):135–44.CrossRef
673.
Zurück zum Zitat Maziade PJ, Pereira P, Goldstein EJ. A decade of experience in primary prevention of Clostridium difficile infection at a community hospital using the probiotic combination Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+). Clin Infect Dis. 2015;15(60 Suppl 2):S144–7.CrossRef Maziade PJ, Pereira P, Goldstein EJ. A decade of experience in primary prevention of Clostridium difficile infection at a community hospital using the probiotic combination Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+). Clin Infect Dis. 2015;15(60 Suppl 2):S144–7.CrossRef
674.
Zurück zum Zitat Evans CT, Johnson S. Prevention of Clostridium difficile infection with probiotics. Clin Infect Dis. 2015;15(60 Suppl 2):S122–8.CrossRef Evans CT, Johnson S. Prevention of Clostridium difficile infection with probiotics. Clin Infect Dis. 2015;15(60 Suppl 2):S122–8.CrossRef
675.
Zurück zum Zitat McFarland LV. Probiotics for the primary and secondary prevention of C. difficile infections: a meta-analysis and systematic review. Antibiotics (Basel). 2015;4(2):160–78.CrossRef McFarland LV. Probiotics for the primary and secondary prevention of C. difficile infections: a meta-analysis and systematic review. Antibiotics (Basel). 2015;4(2):160–78.CrossRef
676.
Zurück zum Zitat Auclair J, Frappier M, Millette M. Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+): characterization, manufacture, mechanisms of action, and quality control of a specific probiotic combination for primary prevention of Clostridium difficile infection. Clin Infect Dis. 2015;15(60 Suppl 2):S135–43.CrossRef Auclair J, Frappier M, Millette M. Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+): characterization, manufacture, mechanisms of action, and quality control of a specific probiotic combination for primary prevention of Clostridium difficile infection. Clin Infect Dis. 2015;15(60 Suppl 2):S135–43.CrossRef
677.
Zurück zum Zitat Ollech JE, Shen NT, Crawford CV, Ringel Y. Use of probiotics in prevention and treatment of patients with Clostridium difficile infection. Best Pract Res Clin Gastroenterol. 2016;30(1):111–8.PubMedCrossRef Ollech JE, Shen NT, Crawford CV, Ringel Y. Use of probiotics in prevention and treatment of patients with Clostridium difficile infection. Best Pract Res Clin Gastroenterol. 2016;30(1):111–8.PubMedCrossRef
678.
Zurück zum Zitat Lau CS, Chamberlain RS. Probiotics are effective at preventing Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Int J Gen Med. 2016;9:27–37.PubMedPubMedCentral Lau CS, Chamberlain RS. Probiotics are effective at preventing Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Int J Gen Med. 2016;9:27–37.PubMedPubMedCentral
679.
Zurück zum Zitat Spinler JK, Ross CL, Savidge TC. Probiotics as adjunctive therapy for preventing Clostridium difficile infection—what are we waiting for? Anaerobe. 2016;41:51–7.PubMedCrossRef Spinler JK, Ross CL, Savidge TC. Probiotics as adjunctive therapy for preventing Clostridium difficile infection—what are we waiting for? Anaerobe. 2016;41:51–7.PubMedCrossRef
680.
Zurück zum Zitat Chopra T, Goldstein EJ. Clostridium difficile infection in long-term care facilities: a call to action for antimicrobial stewardship. Clin Infect Dis. 2015;15(60 Suppl 2):S72–6.CrossRef Chopra T, Goldstein EJ. Clostridium difficile infection in long-term care facilities: a call to action for antimicrobial stewardship. Clin Infect Dis. 2015;15(60 Suppl 2):S72–6.CrossRef
681.
Zurück zum Zitat Shen NT, Maw A, Tmanova LL, Pino A, Ancy K, Crawford CV, et al. Timely use of probiotics in hospitalized adults prevents Clostridium difficile infection: a systematic review with meta-regression analysis. Gastroenterology. 2017. Shen NT, Maw A, Tmanova LL, Pino A, Ancy K, Crawford CV, et al. Timely use of probiotics in hospitalized adults prevents Clostridium difficile infection: a systematic review with meta-regression analysis. Gastroenterology. 2017.
682.
Zurück zum Zitat McFarland LV. Meta-analysis of probiotics for the prevention of traveler’s diarrhea. Travel Med Infect Dis. 2007;5(2):97–105.PubMedCrossRef McFarland LV. Meta-analysis of probiotics for the prevention of traveler’s diarrhea. Travel Med Infect Dis. 2007;5(2):97–105.PubMedCrossRef
683.
Zurück zum Zitat Xie C, Li J, Wang K, Li Q, Chen D. Probiotics for the prevention of antibiotic-associated diarrhoea in older patients: a systematic review. Travel Med Infect Dis. 2015;13(2):128–34.PubMedCrossRef Xie C, Li J, Wang K, Li Q, Chen D. Probiotics for the prevention of antibiotic-associated diarrhoea in older patients: a systematic review. Travel Med Infect Dis. 2015;13(2):128–34.PubMedCrossRef
685.
Zurück zum Zitat Compare D, Rocco A, Sgamato C, Coccoli P, Campo SM, Nazionale I, et al. Lactobacillus paracasei F19 versus placebo for the prevention of proton pump inhibitor-induced bowel symptoms: a randomized clinical trial. Dig Liver Dis. 2015;47(4):273–9.PubMedCrossRef Compare D, Rocco A, Sgamato C, Coccoli P, Campo SM, Nazionale I, et al. Lactobacillus paracasei F19 versus placebo for the prevention of proton pump inhibitor-induced bowel symptoms: a randomized clinical trial. Dig Liver Dis. 2015;47(4):273–9.PubMedCrossRef
687.
Zurück zum Zitat Hao Q, Dong BR, Wu T. Probiotics for preventing acute upper respiratory tract infections. Cochrane Database Syst Rev. 2015;2:CD006895. Hao Q, Dong BR, Wu T. Probiotics for preventing acute upper respiratory tract infections. Cochrane Database Syst Rev. 2015;2:CD006895.
688.
Zurück zum Zitat Bo L, Li J, Tao T, Bai Y, Ye X, Hotchkiss RS, et al. Probiotics for preventing ventilator-associated pneumonia. Cochrane Database Syst Rev. 2014;10:CD009066.PubMedCentral Bo L, Li J, Tao T, Bai Y, Ye X, Hotchkiss RS, et al. Probiotics for preventing ventilator-associated pneumonia. Cochrane Database Syst Rev. 2014;10:CD009066.PubMedCentral
689.
Zurück zum Zitat Zeng J, Wang CT, Zhang FS, Qi F, Wang SF, Ma S, et al. Effect of probiotics on the incidence of ventilator-associated pneumonia in critically ill patients: a randomized controlled multicenter trial. Intensive Care Med. 2016;42(6):1018–28.PubMedCrossRef Zeng J, Wang CT, Zhang FS, Qi F, Wang SF, Ma S, et al. Effect of probiotics on the incidence of ventilator-associated pneumonia in critically ill patients: a randomized controlled multicenter trial. Intensive Care Med. 2016;42(6):1018–28.PubMedCrossRef
690.
Zurück zum Zitat Vieira AT, Rocha VM, Tavares L, Garcia CC, Teixeira MM, Oliveira SC, et al. Control of Klebsiella pneumoniae pulmonary infection and immunomodulation by oral treatment with the commensal probiotic Bifidobacterium longum 5(1A). Microbes Infect. 2016;18(3):180–9.PubMedCrossRef Vieira AT, Rocha VM, Tavares L, Garcia CC, Teixeira MM, Oliveira SC, et al. Control of Klebsiella pneumoniae pulmonary infection and immunomodulation by oral treatment with the commensal probiotic Bifidobacterium longum 5(1A). Microbes Infect. 2016;18(3):180–9.PubMedCrossRef
691.
Zurück zum Zitat Hanson L, VandeVusse L, Jerme M, Abad CL, Safdar N. Probiotics for treatment and prevention of urogenital infections in women: a systematic review. J Midwifery Womens Health. 2016;61(3):339–55.PubMedCrossRef Hanson L, VandeVusse L, Jerme M, Abad CL, Safdar N. Probiotics for treatment and prevention of urogenital infections in women: a systematic review. J Midwifery Womens Health. 2016;61(3):339–55.PubMedCrossRef
692.
Zurück zum Zitat Lytvyn L, Quach K, Banfield L, Johnston BC, Mertz D. Probiotics and synbiotics for the prevention of postoperative infections following abdominal surgery: a systematic review and meta-analysis of randomized controlled trials. J Hosp Infect. 2016;92(2):130–9.PubMedCrossRef Lytvyn L, Quach K, Banfield L, Johnston BC, Mertz D. Probiotics and synbiotics for the prevention of postoperative infections following abdominal surgery: a systematic review and meta-analysis of randomized controlled trials. J Hosp Infect. 2016;92(2):130–9.PubMedCrossRef
693.
Zurück zum Zitat Ohshima T, Kojima Y, Seneviratne CJ, Maeda N. Therapeutic application of synbiotics, a fusion of probiotics and prebiotics, and biogenics as a new concept for oral Candida infections: a mini review. Front Microbiol. 2016;7:10.PubMedPubMedCentralCrossRef Ohshima T, Kojima Y, Seneviratne CJ, Maeda N. Therapeutic application of synbiotics, a fusion of probiotics and prebiotics, and biogenics as a new concept for oral Candida infections: a mini review. Front Microbiol. 2016;7:10.PubMedPubMedCentralCrossRef
694.
Zurück zum Zitat O’Connor EM. The role of gut microbiota in nutritional status. Curr Opin Clin Nutr Metab Care. 2013;16(5):509–16.PubMedCrossRef O’Connor EM. The role of gut microbiota in nutritional status. Curr Opin Clin Nutr Metab Care. 2013;16(5):509–16.PubMedCrossRef
695.
Zurück zum Zitat Mondot S, de Wouters T, Dore J, Lepage P. The human gut microbiome and its dysfunctions. Dig Dis. 2013;31(3–4):278–85.PubMedCrossRef Mondot S, de Wouters T, Dore J, Lepage P. The human gut microbiome and its dysfunctions. Dig Dis. 2013;31(3–4):278–85.PubMedCrossRef
696.
Zurück zum Zitat Mondot S, Lepage P. The human gut microbiome and its dysfunctions through the meta-omics prism. Ann N Y Acad Sci. 2016;1372(1):9–19.PubMedCrossRef Mondot S, Lepage P. The human gut microbiome and its dysfunctions through the meta-omics prism. Ann N Y Acad Sci. 2016;1372(1):9–19.PubMedCrossRef
697.
Zurück zum Zitat Lin CS, Chang CJ, Lu CC, Martel J, Ojcius DM, Ko YF, et al. Impact of the gut microbiota, prebiotics, and probiotics on human health and disease. Biomed J. 2014;37(5):259–68.PubMedCrossRef Lin CS, Chang CJ, Lu CC, Martel J, Ojcius DM, Ko YF, et al. Impact of the gut microbiota, prebiotics, and probiotics on human health and disease. Biomed J. 2014;37(5):259–68.PubMedCrossRef
698.
Zurück zum Zitat Tojo R, Suarez A, Clemente MG, de los Reyes-Gavilan CG, Margolles A, Gueimonde M, et al. Intestinal microbiota in health and disease: role of bifidobacteria in gut homeostasis. World J Gastroenterol. 2014;20(41):15163–76. Tojo R, Suarez A, Clemente MG, de los Reyes-Gavilan CG, Margolles A, Gueimonde M, et al. Intestinal microbiota in health and disease: role of bifidobacteria in gut homeostasis. World J Gastroenterol. 2014;20(41):15163–76.
700.
Zurück zum Zitat Peterson CT, Sharma V, Elmen L, Peterson SN. Immune homeostasis, dysbiosis and therapeutic modulation of the gut microbiota. Clin Exp Immunol. 2015;179(3):363–77.PubMedPubMedCentralCrossRef Peterson CT, Sharma V, Elmen L, Peterson SN. Immune homeostasis, dysbiosis and therapeutic modulation of the gut microbiota. Clin Exp Immunol. 2015;179(3):363–77.PubMedPubMedCentralCrossRef
701.
Zurück zum Zitat Spaiser SJ, Culpepper T, Nieves C Jr, Ukhanova M, Mai V, Percival SS, et al. Lactobacillus gasseri KS-13, Bifidobacterium bifidum G9-1, and Bifidobacterium longum MM-2 ingestion induces a less inflammatory cytokine profile and a potentially beneficial shift in gut microbiota in older adults: a randomized, double-blind, placebo-controlled, crossover study. J Am Coll Nutr. 2015;34(6):459–69.PubMedCrossRef Spaiser SJ, Culpepper T, Nieves C Jr, Ukhanova M, Mai V, Percival SS, et al. Lactobacillus gasseri KS-13, Bifidobacterium bifidum G9-1, and Bifidobacterium longum MM-2 ingestion induces a less inflammatory cytokine profile and a potentially beneficial shift in gut microbiota in older adults: a randomized, double-blind, placebo-controlled, crossover study. J Am Coll Nutr. 2015;34(6):459–69.PubMedCrossRef
702.
Zurück zum Zitat DeGruttola AK, Low D, Mizoguchi A, Mizoguchi E. Current understanding of dysbiosis in disease in human and animal models. Inflamm Bowel Dis. 2016;22(5):1137–50.PubMedPubMedCentralCrossRef DeGruttola AK, Low D, Mizoguchi A, Mizoguchi E. Current understanding of dysbiosis in disease in human and animal models. Inflamm Bowel Dis. 2016;22(5):1137–50.PubMedPubMedCentralCrossRef
703.
Zurück zum Zitat Mosca A, Leclerc M, Hugot JP. Gut microbiota diversity and human diseases: should we reintroduce key predators in our ecosystem? Front Microbiol. 2016;7:455.PubMedPubMedCentralCrossRef Mosca A, Leclerc M, Hugot JP. Gut microbiota diversity and human diseases: should we reintroduce key predators in our ecosystem? Front Microbiol. 2016;7:455.PubMedPubMedCentralCrossRef
704.
Zurück zum Zitat Rogers GB, Keating DJ, Young RL, Wong ML, Licinio J, Wesselingh S. From gut dysbiosis to altered brain function and mental illness: mechanisms and pathways. Mol Psychiatry. 2016;21(6):738–48.PubMedPubMedCentralCrossRef Rogers GB, Keating DJ, Young RL, Wong ML, Licinio J, Wesselingh S. From gut dysbiosis to altered brain function and mental illness: mechanisms and pathways. Mol Psychiatry. 2016;21(6):738–48.PubMedPubMedCentralCrossRef
705.
Zurück zum Zitat Di Cerbo A, Palmieri B, Aponte M, Morales-Medina JC, Iannitti T. Mechanisms and therapeutic effectiveness of lactobacilli. J Clin Pathol. 2016;69(3):187–203.PubMedCrossRef Di Cerbo A, Palmieri B, Aponte M, Morales-Medina JC, Iannitti T. Mechanisms and therapeutic effectiveness of lactobacilli. J Clin Pathol. 2016;69(3):187–203.PubMedCrossRef
707.
Zurück zum Zitat Chung H, Kasper DL. Microbiota-stimulated immune mechanisms to maintain gut homeostasis. Curr Opin Immunol. 2010;22(4):455–60.PubMedCrossRef Chung H, Kasper DL. Microbiota-stimulated immune mechanisms to maintain gut homeostasis. Curr Opin Immunol. 2010;22(4):455–60.PubMedCrossRef
708.
Zurück zum Zitat Yu LC, Wang JT, Wei SC, Ni YH. Host-microbial interactions and regulation of intestinal epithelial barrier function: from physiology to pathology. World J Gastrointest Pathophysiol. 2012;3(1):27–43.PubMedPubMedCentralCrossRef Yu LC, Wang JT, Wei SC, Ni YH. Host-microbial interactions and regulation of intestinal epithelial barrier function: from physiology to pathology. World J Gastrointest Pathophysiol. 2012;3(1):27–43.PubMedPubMedCentralCrossRef
709.
Zurück zum Zitat Aziz Q, Dore J, Emmanuel A, Guarner F, Quigley EM. Gut microbiota and gastrointestinal health: current concepts and future directions. Neurogastroenterol Motil. 2013;25(1):4–15.PubMedCrossRef Aziz Q, Dore J, Emmanuel A, Guarner F, Quigley EM. Gut microbiota and gastrointestinal health: current concepts and future directions. Neurogastroenterol Motil. 2013;25(1):4–15.PubMedCrossRef
710.
Zurück zum Zitat Valentini M, Piermattei A, Di Sante G, Migliara G, Delogu G, Ria F. Immunomodulation by gut microbiota: role of Toll-like receptor expressed by T cells. J Immunol Res. 2014;2014:586939.PubMedPubMedCentralCrossRef Valentini M, Piermattei A, Di Sante G, Migliara G, Delogu G, Ria F. Immunomodulation by gut microbiota: role of Toll-like receptor expressed by T cells. J Immunol Res. 2014;2014:586939.PubMedPubMedCentralCrossRef
711.
Zurück zum Zitat Medina M, Izquierdo E, Ennahar S, Sanz Y. Differential immunomodulatory properties of Bifidobacterium logum strains: relevance to probiotic selection and clinical applications. Clin Exp Immunol. 2007;150(3):531–8.PubMedPubMedCentralCrossRef Medina M, Izquierdo E, Ennahar S, Sanz Y. Differential immunomodulatory properties of Bifidobacterium logum strains: relevance to probiotic selection and clinical applications. Clin Exp Immunol. 2007;150(3):531–8.PubMedPubMedCentralCrossRef
712.
Zurück zum Zitat Ashraf R, Shah NP. Immune system stimulation by probiotic microorganisms. Crit Rev Food Sci Nutr. 2014;54(7):938–56.PubMedCrossRef Ashraf R, Shah NP. Immune system stimulation by probiotic microorganisms. Crit Rev Food Sci Nutr. 2014;54(7):938–56.PubMedCrossRef
713.
Zurück zum Zitat Gill HS, Rutherfurd KJ, Cross ML, Gopal PK. Enhancement of immunity in the elderly by dietary supplementation with the probiotic Bifidobacterium lactis HN019. Am J Clin Nutr. 2001;74(6):833–9.PubMed Gill HS, Rutherfurd KJ, Cross ML, Gopal PK. Enhancement of immunity in the elderly by dietary supplementation with the probiotic Bifidobacterium lactis HN019. Am J Clin Nutr. 2001;74(6):833–9.PubMed
714.
715.
Zurück zum Zitat Millette M, Dupont C, Archambault D, Lacroix M. Partial characterization of bacteriocins produced by human Lactococcus lactis and Pediococccus acidilactici isolates. J Appl Microbiol. 2007;102(1):274–82.PubMedCrossRef Millette M, Dupont C, Archambault D, Lacroix M. Partial characterization of bacteriocins produced by human Lactococcus lactis and Pediococccus acidilactici isolates. J Appl Microbiol. 2007;102(1):274–82.PubMedCrossRef
716.
Zurück zum Zitat Zeinhom M, Tellez AM, Delcenserie V, El-Kholy AM, El-Shinawy SH, Griffiths MW. Yogurt containing bioactive molecules produced by Lactobacillus acidophilus La-5 exerts a protective effect against enterohemorrhagic Escherichia coli in mice. J Food Prot. 2012;75(10):1796–805.PubMedCrossRef Zeinhom M, Tellez AM, Delcenserie V, El-Kholy AM, El-Shinawy SH, Griffiths MW. Yogurt containing bioactive molecules produced by Lactobacillus acidophilus La-5 exerts a protective effect against enterohemorrhagic Escherichia coli in mice. J Food Prot. 2012;75(10):1796–805.PubMedCrossRef
717.
Zurück zum Zitat Aoki T, Asahara T, Matsumoto K, Takada T, Chonan O, Nakamori K, et al. Effects of the continuous intake of a milk drink containing Lactobacillus casei strain Shirota on abdominal symptoms, fecal microbiota, and metabolites in gastrectomized subjects. Scand J Gastroenterol. 2014;49(5):552–63.PubMedCrossRef Aoki T, Asahara T, Matsumoto K, Takada T, Chonan O, Nakamori K, et al. Effects of the continuous intake of a milk drink containing Lactobacillus casei strain Shirota on abdominal symptoms, fecal microbiota, and metabolites in gastrectomized subjects. Scand J Gastroenterol. 2014;49(5):552–63.PubMedCrossRef
718.
Zurück zum Zitat Pace F, Pace M, Quartarone G. Probiotics in digestive diseases: focus on Lactobacillus GG. Minerva Gastroenterol Dietol. 2015;61(4):273–92.PubMed Pace F, Pace M, Quartarone G. Probiotics in digestive diseases: focus on Lactobacillus GG. Minerva Gastroenterol Dietol. 2015;61(4):273–92.PubMed
719.
Zurück zum Zitat Sugawara T, Sawada D, Ishida Y, Aihara K, Aoki Y, Takehara I, et al. Regulatory effect of paraprobiotic Lactobacillus gasseri CP2305 on gut environment and function. Microb Ecol Health Dis. 2016;27:30259.PubMed Sugawara T, Sawada D, Ishida Y, Aihara K, Aoki Y, Takehara I, et al. Regulatory effect of paraprobiotic Lactobacillus gasseri CP2305 on gut environment and function. Microb Ecol Health Dis. 2016;27:30259.PubMed
720.
Zurück zum Zitat Vlasova AN, Kandasamy S, Chattha KS, Rajashekara G, Saif LJ. Comparison of probiotic lactobacilli and bifidobacteria effects, immune responses and rotavirus vaccines and infection in different host species. Vet Immunol Immunopathol. 2016;172:72–84.PubMedPubMedCentralCrossRef Vlasova AN, Kandasamy S, Chattha KS, Rajashekara G, Saif LJ. Comparison of probiotic lactobacilli and bifidobacteria effects, immune responses and rotavirus vaccines and infection in different host species. Vet Immunol Immunopathol. 2016;172:72–84.PubMedPubMedCentralCrossRef
721.
Zurück zum Zitat El-Abbadi NH, Dao MC, Meydani SN. Yogurt: role in healthy and active aging. Am J Clin Nutr. 2014;99(5 Suppl):1263S–70S.PubMedCrossRef El-Abbadi NH, Dao MC, Meydani SN. Yogurt: role in healthy and active aging. Am J Clin Nutr. 2014;99(5 Suppl):1263S–70S.PubMedCrossRef
722.
Zurück zum Zitat Manley KJ, Fraenkel MB, Mayall BC, Power DA. Probiotic treatment of vancomycin-resistant enterococci: a randomised controlled trial. Med J Aust. 2007;186(9):454–7.PubMed Manley KJ, Fraenkel MB, Mayall BC, Power DA. Probiotic treatment of vancomycin-resistant enterococci: a randomised controlled trial. Med J Aust. 2007;186(9):454–7.PubMed
723.
Zurück zum Zitat Szachta P, Ignys I, Cichy W. An evaluation of the ability of the probiotic strain Lactobacillus rhamnosus GG to eliminate the gastrointestinal carrier state of vancomycin-resistant enterococci in colonized children. J Clin Gastroenterol. 2011;45(10):872–7.PubMedCrossRef Szachta P, Ignys I, Cichy W. An evaluation of the ability of the probiotic strain Lactobacillus rhamnosus GG to eliminate the gastrointestinal carrier state of vancomycin-resistant enterococci in colonized children. J Clin Gastroenterol. 2011;45(10):872–7.PubMedCrossRef
724.
Zurück zum Zitat O’Connor EM, O’Herlihy EA, O’Toole PW. Gut microbiota in older subjects: variation, health consequences and dietary intervention prospects. Proc Nutr Soc. 2014;73(4):441–51.PubMedCrossRef O’Connor EM, O’Herlihy EA, O’Toole PW. Gut microbiota in older subjects: variation, health consequences and dietary intervention prospects. Proc Nutr Soc. 2014;73(4):441–51.PubMedCrossRef
725.
Zurück zum Zitat Fisher A, Varendran R. Letter: clinical predictors of Clostridium difficile infection - advanced age and residential status are important factors for prediction and prevention. Aliment Pharmacol Ther. 2015;41(2):232–3.PubMedCrossRef Fisher A, Varendran R. Letter: clinical predictors of Clostridium difficile infection - advanced age and residential status are important factors for prediction and prevention. Aliment Pharmacol Ther. 2015;41(2):232–3.PubMedCrossRef
726.
Zurück zum Zitat Boyle RJ, Robins-Browne RM, Tang ML. Probiotic use in clinical practice: what are the risks? Am J Clin Nutr. 2006;83(6):1256–64 (quiz 446–7). Boyle RJ, Robins-Browne RM, Tang ML. Probiotic use in clinical practice: what are the risks? Am J Clin Nutr. 2006;83(6):1256–64 (quiz 446–7).
727.
Zurück zum Zitat Doron S, Snydman DR. Risk and safety of probiotics. Clin Infect Dis. 2015;15(60 Suppl 2):S129–34.CrossRef Doron S, Snydman DR. Risk and safety of probiotics. Clin Infect Dis. 2015;15(60 Suppl 2):S129–34.CrossRef
728.
Zurück zum Zitat Borriello SP, Hammes WP, Holzapfel W, Marteau P, Schrezenmeir J, Vaara M, et al. Safety of probiotics that contain lactobacilli or bifidobacteria. Clin Infect Dis. 2003;36(6):775–80.PubMedCrossRef Borriello SP, Hammes WP, Holzapfel W, Marteau P, Schrezenmeir J, Vaara M, et al. Safety of probiotics that contain lactobacilli or bifidobacteria. Clin Infect Dis. 2003;36(6):775–80.PubMedCrossRef
729.
Zurück zum Zitat Bartley J. Vitamin D: emerging roles in infection and immunity. Expert Rev Anti Infect Ther. 2010;8(12):1359–69.PubMedCrossRef Bartley J. Vitamin D: emerging roles in infection and immunity. Expert Rev Anti Infect Ther. 2010;8(12):1359–69.PubMedCrossRef
730.
731.
Zurück zum Zitat White JH. Vitamin D metabolism and signaling in the immune system. Rev Endocr Metab Disord. 2012;13(1):21–9.PubMedCrossRef White JH. Vitamin D metabolism and signaling in the immune system. Rev Endocr Metab Disord. 2012;13(1):21–9.PubMedCrossRef
732.
Zurück zum Zitat Gunville CF, Mourani PM, Ginde AA. The role of vitamin D in prevention and treatment of infection. Inflamm Allergy Drug Targets. 2013;12(4):239–45.PubMedPubMedCentralCrossRef Gunville CF, Mourani PM, Ginde AA. The role of vitamin D in prevention and treatment of infection. Inflamm Allergy Drug Targets. 2013;12(4):239–45.PubMedPubMedCentralCrossRef
733.
Zurück zum Zitat Quraishi SA, Litonjua AA, Moromizato T, Gibbons FK, Camargo CA Jr, Giovannucci E, et al. Association between prehospital vitamin D status and hospital-acquired bloodstream infections. Am J Clin Nutr. 2013;98(4):952–9.PubMedPubMedCentralCrossRef Quraishi SA, Litonjua AA, Moromizato T, Gibbons FK, Camargo CA Jr, Giovannucci E, et al. Association between prehospital vitamin D status and hospital-acquired bloodstream infections. Am J Clin Nutr. 2013;98(4):952–9.PubMedPubMedCentralCrossRef
734.
Zurück zum Zitat de Haan K, Groeneveld AB, de Geus HR, Egal M, Struijs A. Vitamin D deficiency as a risk factor for infection, sepsis and mortality in the critically ill: systematic review and meta-analysis. Crit Care. 2014;18(6):660.PubMedPubMedCentralCrossRef de Haan K, Groeneveld AB, de Geus HR, Egal M, Struijs A. Vitamin D deficiency as a risk factor for infection, sepsis and mortality in the critically ill: systematic review and meta-analysis. Crit Care. 2014;18(6):660.PubMedPubMedCentralCrossRef
735.
Zurück zum Zitat Bjelakovic G, Gluud LL, Nikolova D, Whitfield K, Krstic G, Wetterslev J, et al. Vitamin D supplementation for prevention of cancer in adults. Cochrane Database Syst Rev. 2014;6:CD007469. Bjelakovic G, Gluud LL, Nikolova D, Whitfield K, Krstic G, Wetterslev J, et al. Vitamin D supplementation for prevention of cancer in adults. Cochrane Database Syst Rev. 2014;6:CD007469.
736.
Zurück zum Zitat Martineau AR, James WY, Hooper RL, Barnes NC, Jolliffe DA, Greiller CL, et al. Vitamin D3 supplementation in patients with chronic obstructive pulmonary disease (ViDiCO): a multicentre, double-blind, randomised controlled trial. Lancet Respir Med. 2015;3(2):120–30.PubMedCrossRef Martineau AR, James WY, Hooper RL, Barnes NC, Jolliffe DA, Greiller CL, et al. Vitamin D3 supplementation in patients with chronic obstructive pulmonary disease (ViDiCO): a multicentre, double-blind, randomised controlled trial. Lancet Respir Med. 2015;3(2):120–30.PubMedCrossRef
737.
Zurück zum Zitat Kempker JA, Magee MJ, Cegielski JP, Martin GS. Associations between vitamin D level and hospitalizations with and without an infection in a national cohort of medicare beneficiaries. Am J Epidemiol. 2016;183(10):920–9.PubMedPubMedCentralCrossRef Kempker JA, Magee MJ, Cegielski JP, Martin GS. Associations between vitamin D level and hospitalizations with and without an infection in a national cohort of medicare beneficiaries. Am J Epidemiol. 2016;183(10):920–9.PubMedPubMedCentralCrossRef
738.
Zurück zum Zitat Sahay T, Ananthakrishnan AN. Vitamin D deficiency is associated with community-acquired clostridium difficile infection: a case–control study. BMC Infect Dis. 2014;14:661.PubMedPubMedCentralCrossRef Sahay T, Ananthakrishnan AN. Vitamin D deficiency is associated with community-acquired clostridium difficile infection: a case–control study. BMC Infect Dis. 2014;14:661.PubMedPubMedCentralCrossRef
739.
Zurück zum Zitat van der Wilden GM, Fagenholz PJ, Velmahos GC, Quraishi SA, Schipper IB, Camargo CA Jr. Vitamin D status and severity of Clostridium difficile infections: a prospective cohort study in hospitalized adults. JPEN J Parenter Enteral Nutr. 2015;39(4):465–70.PubMedCrossRef van der Wilden GM, Fagenholz PJ, Velmahos GC, Quraishi SA, Schipper IB, Camargo CA Jr. Vitamin D status and severity of Clostridium difficile infections: a prospective cohort study in hospitalized adults. JPEN J Parenter Enteral Nutr. 2015;39(4):465–70.PubMedCrossRef
740.
Zurück zum Zitat Abdelfatah M, Nayfe R, Moftakhar B, Nijim A, El Zoghbi M, Donskey CJ, et al. Low vitamin D level and impact on severity and recurrence of Clostridium difficile infections. J Investig Med. 2015;63(1):17–21.PubMedCrossRef Abdelfatah M, Nayfe R, Moftakhar B, Nijim A, El Zoghbi M, Donskey CJ, et al. Low vitamin D level and impact on severity and recurrence of Clostridium difficile infections. J Investig Med. 2015;63(1):17–21.PubMedCrossRef
741.
Zurück zum Zitat Wong KK, Lee R, Watkins RR, Haller N. Prolonged Clostridium difficile infection may be associated with vitamin D deficiency. JPEN J Parenter Enteral Nutr. 2016;40(5):682–7.PubMedCrossRef Wong KK, Lee R, Watkins RR, Haller N. Prolonged Clostridium difficile infection may be associated with vitamin D deficiency. JPEN J Parenter Enteral Nutr. 2016;40(5):682–7.PubMedCrossRef
742.
Zurück zum Zitat Micic D, Rao K, Trindade BC, Walk ST, Chenoweth E, Jain R, et al. Serum 25-hydroxyvitamin D levels are not associated with adverse outcomes in Clostridium difficile infection. Infect Dis Rep. 2015;7(3):5979.PubMedPubMedCentralCrossRef Micic D, Rao K, Trindade BC, Walk ST, Chenoweth E, Jain R, et al. Serum 25-hydroxyvitamin D levels are not associated with adverse outcomes in Clostridium difficile infection. Infect Dis Rep. 2015;7(3):5979.PubMedPubMedCentralCrossRef
743.
Zurück zum Zitat Ryz NR, Lochner A, Bhullar K, Ma C, Huang T, Bhinder G, et al. Dietary vitamin D3 deficiency alters intestinal mucosal defence and increases susceptibility to Citrobacter rodentium-induced colitis. Am J Physiol Gastrointest Liver Physiol. 2015;309(9):G730–42.PubMedPubMedCentralCrossRef Ryz NR, Lochner A, Bhullar K, Ma C, Huang T, Bhinder G, et al. Dietary vitamin D3 deficiency alters intestinal mucosal defence and increases susceptibility to Citrobacter rodentium-induced colitis. Am J Physiol Gastrointest Liver Physiol. 2015;309(9):G730–42.PubMedPubMedCentralCrossRef
744.
Zurück zum Zitat Murdoch DR, Slow S, Chambers ST, Jennings LC, Stewart AW, Priest PC, et al. Effect of vitamin D3 supplementation on upper respiratory tract infections in healthy adults: the VIDARIS randomized controlled trial. JAMA. 2012;308(13):1333–9.PubMedCrossRef Murdoch DR, Slow S, Chambers ST, Jennings LC, Stewart AW, Priest PC, et al. Effect of vitamin D3 supplementation on upper respiratory tract infections in healthy adults: the VIDARIS randomized controlled trial. JAMA. 2012;308(13):1333–9.PubMedCrossRef
745.
Zurück zum Zitat Slow S, Priest PC, Chambers ST, Stewart AW, Jennings LC, Florkowski CM, et al. Effect of vitamin D3 supplementation on Staphylococcus aureus nasal carriage: a randomized, double-blind, placebo-controlled trial in healthy adults. Clin Microbiol Infect. 2014;20(5):453–8.PubMedCrossRef Slow S, Priest PC, Chambers ST, Stewart AW, Jennings LC, Florkowski CM, et al. Effect of vitamin D3 supplementation on Staphylococcus aureus nasal carriage: a randomized, double-blind, placebo-controlled trial in healthy adults. Clin Microbiol Infect. 2014;20(5):453–8.PubMedCrossRef
746.
Zurück zum Zitat de Sa Del Fiol F, Barberato-Filho S, Lopes LC, de Cassia Bergamaschi C. Vitamin D and respiratory infections. J Infect Dev Ctries. 2015;9(4):355–61.PubMedCrossRef de Sa Del Fiol F, Barberato-Filho S, Lopes LC, de Cassia Bergamaschi C. Vitamin D and respiratory infections. J Infect Dev Ctries. 2015;9(4):355–61.PubMedCrossRef
747.
Zurück zum Zitat MacLaren R, Reynolds PM, Allen RR. Histamine-2 receptor antagonists vs proton pump inhibitors on gastrointestinal tract hemorrhage and infectious complications in the intensive care unit. JAMA Intern Med. 2014;174(4):564–74.PubMedCrossRef MacLaren R, Reynolds PM, Allen RR. Histamine-2 receptor antagonists vs proton pump inhibitors on gastrointestinal tract hemorrhage and infectious complications in the intensive care unit. JAMA Intern Med. 2014;174(4):564–74.PubMedCrossRef
748.
Zurück zum Zitat Giuliano C, Wilhelm SM, Kale-Pradhan PB. Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis. Expert Rev Clin Pharmacol. 2012;5(3):337–44.PubMedCrossRef Giuliano C, Wilhelm SM, Kale-Pradhan PB. Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis. Expert Rev Clin Pharmacol. 2012;5(3):337–44.PubMedCrossRef
749.
Zurück zum Zitat Johnstone J, Nerenberg K, Loeb M. Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia. Aliment Pharmacol Ther. 2010;31(11):1165–77.PubMedCrossRef Johnstone J, Nerenberg K, Loeb M. Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia. Aliment Pharmacol Ther. 2010;31(11):1165–77.PubMedCrossRef
Metadaten
Titel
Acid-Suppressive Therapy and Risk of Infections: Pros and Cons
verfasst von
Leon Fisher
Alexander Fisher
Publikationsdatum
01.07.2017
Verlag
Springer International Publishing
Erschienen in
Clinical Drug Investigation / Ausgabe 7/2017
Print ISSN: 1173-2563
Elektronische ISSN: 1179-1918
DOI
https://doi.org/10.1007/s40261-017-0519-y

Weitere Artikel der Ausgabe 7/2017

Clinical Drug Investigation 7/2017 Zur Ausgabe